

**Prevalence of Drugs by Antidiabetic Class, Among Medicare Parts A, B, and D FFS Population With Diabetes, by Age, Gender, and Race, 2006-2009**

Age is calculated as of December 31 of the year.

Note: An asterisk (\*) signifies small cell count (<11).

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Biguanides	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Insulins	Meglitinides	Sulfonylureas	Thiazolidine-diones
Overall	Overall	2006	0.6%	0.1%	33.1%	0.1%	1.1%	24.4%	2.6%	33.0%	22.1%
Overall	Overall	2007	0.5%	0.2%	34.8%	2.7%	1.3%	22.4%	2.2%	32.0%	19.5%
Overall	Overall	2008	0.4%	0.2%	36.0%	4.3%	1.2%	22.8%	2.0%	30.7%	14.6%
Overall	Overall	2009	0.4%	0.1%	37.2%	5.2%	1.0%	23.5%	1.8%	29.4%	13.0%
Age	Under 45	2006	0.4%	0.3%	34.6%	0.1%	1.8%	27.7%	1.3%	20.7%	19.2%
Age	Under 45	2007	0.3%	0.4%	36.1%	2.1%	2.4%	28.2%	1.1%	19.8%	17.2%
Age	Under 45	2008	0.3%	0.4%	36.9%	3.5%	2.1%	28.6%	0.9%	18.8%	13.2%
Age	Under 45	2009	0.3%	0.3%	37.9%	4.3%	1.8%	29.3%	0.8%	17.7%	11.6%
Age	45 to 54	2006	0.5%	0.3%	38.1%	0.2%	2.0%	29.2%	1.8%	27.2%	23.7%
Age	45 to 54	2007	0.4%	0.4%	39.7%	2.5%	2.5%	29.2%	1.5%	26.5%	21.1%
Age	45 to 54	2008	0.4%	0.4%	41.0%	4.1%	2.3%	29.9%	1.3%	25.2%	16.2%
Age	45 to 54	2009	0.4%	0.4%	42.2%	5.1%	1.9%	30.8%	1.1%	23.8%	14.3%
Age	55 to 64	2006	0.6%	0.3%	38.9%	0.1%	2.0%	32.1%	2.3%	32.1%	26.0%
Age	55 to 64	2007	0.5%	0.3%	40.6%	2.7%	2.3%	31.2%	1.9%	31.3%	23.0%
Age	55 to 64	2008	0.5%	0.3%	41.6%	4.4%	2.1%	31.8%	1.7%	29.9%	17.2%
Age	55 to 64	2009	0.4%	0.3%	42.6%	5.4%	1.8%	32.6%	1.4%	28.2%	15.3%
Age	65 to74	2006	0.6%	0.1%	39.6%	0.2%	1.4%	22.9%	2.6%	35.5%	25.4%
Age	65 to74	2007	0.5%	0.2%	41.5%	3.1%	1.6%	20.8%	2.1%	33.7%	22.1%
Age	65 to74	2008	0.5%	0.2%	42.9%	4.9%	1.6%	21.3%	1.9%	32.4%	16.6%
Age	65 to74	2009	0.4%	0.1%	44.0%	5.9%	1.3%	21.9%	1.7%	30.7%	14.8%
Age	75 to 84	2006	0.6%	0.1%	29.1%	0.1%	0.5%	22.2%	2.9%	34.6%	20.3%
Age	75 to 84	2007	0.5%	0.1%	30.8%	2.6%	0.6%	20.0%	2.5%	33.3%	17.9%
Age	75 to 84	2008	0.5%	0.1%	32.1%	4.1%	0.5%	20.3%	2.4%	32.1%	13.4%
Age	75 to 84	2009	0.4%	0.1%	33.5%	5.1%	0.5%	20.8%	2.1%	31.0%	12.1%
Age	85 to 94	2006	0.5%	0.0%	17.8%	0.1%	0.1%	22.9%	2.9%	32.1%	14.4%
Age	85 to 94	2007	0.4%	0.0%	19.3%	1.8%	0.1%	20.5%	2.8%	31.6%	13.1%
Age	85 to 94	2008	0.4%	0.0%	20.2%	3.1%	0.1%	20.6%	2.7%	30.4%	9.7%
Age	85 to 94	2009	0.4%	0.0%	21.4%	4.0%	0.1%	21.0%	2.5%	29.4%	8.6%
Age	95 and over	2006	0.4%	*	9.8%	0.0%	0.0%	21.2%	2.4%	27.0%	9.2%
Age	95 and over	2007	0.3%	*	10.8%	0.9%	0.0%	19.5%	2.5%	26.9%	8.4%
Age	95 and over	2008	0.3%	*	11.7%	1.8%	0.0%	19.7%	2.6%	26.0%	6.3%
Age	95 and over	2009	0.3%	*	12.4%	2.6%	0.0%	20.2%	2.4%	25.4%	5.5%
Gender	Male	2006	0.6%	0.1%	33.4%	0.2%	1.0%	23.4%	2.5%	34.1%	22.8%
Gender	Male	2007	0.5%	0.1%	35.1%	2.7%	1.2%	21.8%	2.2%	33.1%	20.3%
Gender	Male	2008	0.5%	0.1%	36.4%	4.3%	1.1%	22.4%	2.0%	32.0%	15.6%
Gender	Male	2009	0.4%	0.1%	37.8%	5.3%	1.0%	23.1%	1.8%	30.7%	14.0%
Gender	Female	2006	0.6%	0.1%	33.0%	0.1%	1.1%	25.0%	2.6%	32.4%	21.6%

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Biguanides	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Insulins	Meglitinides	Sulfonylureas	Thiazolidine-diones
Gender	Female	2007	0.5%	0.2%	34.7%	2.6%	1.3%	22.8%	2.3%	31.3%	18.9%
Gender	Female	2008	0.4%	0.2%	35.8%	4.2%	1.3%	23.1%	2.1%	29.9%	13.9%
Gender	Female	2009	0.4%	0.2%	36.9%	5.2%	1.1%	23.7%	1.9%	28.5%	12.4%
Race	White	2006	0.5%	0.2%	33.2%	0.2%	1.2%	23.4%	2.5%	33.1%	21.5%
Race	White	2007	0.4%	0.2%	34.9%	2.7%	1.4%	21.3%	2.2%	32.0%	18.8%
Race	White	2008	0.4%	0.2%	36.1%	4.3%	1.3%	21.7%	2.0%	30.7%	14.0%
Race	White	2009	0.4%	0.2%	37.3%	5.2%	1.1%	22.3%	1.7%	29.3%	12.5%
Race	Black	2006	0.5%	0.1%	30.6%	0.1%	0.8%	30.9%	2.4%	31.0%	21.4%
Race	Black	2007	0.4%	0.1%	32.6%	2.0%	0.9%	29.6%	2.1%	30.7%	19.2%
Race	Black	2008	0.4%	0.1%	33.5%	3.5%	0.9%	30.1%	1.9%	29.6%	14.3%
Race	Black	2009	0.4%	0.1%	34.6%	4.4%	0.8%	30.7%	1.7%	28.4%	12.8%
Race	Asian	2006	1.5%	0.0%	37.1%	0.2%	0.3%	13.5%	4.2%	37.8%	27.6%
Race	Asian	2007	1.4%	0.0%	38.1%	4.1%	0.4%	13.8%	3.9%	36.1%	25.7%
Race	Asian	2008	1.4%	0.1%	39.0%	6.9%	0.4%	14.2%	3.8%	34.4%	19.9%
Race	Asian	2009	1.3%	0.1%	40.5%	8.8%	0.4%	14.7%	3.5%	32.9%	18.3%
Race	Hispanic	2006	0.7%	0.1%	37.6%	0.1%	0.6%	24.3%	3.0%	35.4%	27.5%
Race	Hispanic	2007	0.7%	0.1%	39.2%	2.6%	0.8%	24.9%	2.6%	34.4%	25.3%
Race	Hispanic	2008	0.6%	0.1%	40.2%	4.8%	0.8%	25.8%	2.5%	33.0%	19.8%
Race	Hispanic	2009	0.6%	0.1%	41.7%	6.2%	0.7%	26.7%	2.3%	31.5%	18.5%
Race	American Indian/ Alaska Native	2006	0.6%	0.1%	31.9%	0.1%	0.6%	27.6%	1.1%	29.3%	23.6%
Race	American Indian/ Alaska Native	2007	0.5%	0.1%	34.9%	1.5%	0.9%	27.9%	0.9%	30.4%	23.6%
Race	American Indian/ Alaska Native	2008	0.5%	0.1%	36.6%	2.5%	0.9%	28.9%	0.9%	29.9%	20.5%
Race	American Indian/ Alaska Native	2009	0.5%	0.1%	38.4%	3.1%	0.7%	30.8%	0.7%	29.2%	19.3%

**Prevalence of Drugs by Antidiabetic Class, Among Medicare Parts A, B, and D FFS Population With Diabetes and At Least One Antidiabetic Drug Order, by Age, Gender, and Race, 2006-2009**

Age is calculated as of December 31 of the year.

Note: An asterisk (\*) signifies small cell count (<11).

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Biguanides	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Insulins	Meglitinides	Sulfonylureas	Thiazolidine-diones
Overall	Overall	2006	0.9%	0.2%	49.6%	0.2%	1.6%	36.5%	3.8%	49.4%	33.0%
Overall	Overall	2007	0.7%	0.2%	53.2%	4.1%	1.9%	34.2%	3.4%	48.8%	29.7%
Overall	Overall	2008	0.7%	0.2%	55.1%	6.5%	1.8%	34.9%	3.1%	47.0%	22.3%
Overall	Overall	2009	0.6%	0.2%	56.6%	8.0%	1.5%	35.6%	2.8%	44.6%	19.8%
Age	Under 45	2006	0.7%	0.5%	56.5%	0.2%	3.0%	45.1%	2.1%	33.7%	31.2%
Age	Under 45	2007	0.5%	0.6%	58.5%	3.5%	3.9%	45.6%	1.8%	32.1%	27.8%
Age	Under 45	2008	0.5%	0.6%	59.9%	5.6%	3.5%	46.4%	1.5%	30.5%	21.5%
Age	Under 45	2009	0.4%	0.5%	60.9%	6.9%	2.9%	47.2%	1.3%	28.5%	18.7%
Age	45 to 54	2006	0.8%	0.5%	57.1%	0.2%	3.1%	43.8%	2.7%	40.7%	35.4%
Age	45 to 54	2007	0.6%	0.5%	59.5%	3.7%	3.8%	43.7%	2.2%	39.7%	31.6%
Age	45 to 54	2008	0.6%	0.6%	61.3%	6.1%	3.5%	44.7%	1.9%	37.7%	24.2%
Age	45 to 54	2009	0.6%	0.5%	62.6%	7.6%	2.9%	45.7%	1.6%	35.4%	21.2%
Age	55 to 64	2006	0.8%	0.4%	53.9%	0.2%	2.7%	44.5%	3.2%	44.4%	36.1%
Age	55 to 64	2007	0.7%	0.5%	56.8%	3.8%	3.2%	43.6%	2.6%	43.7%	32.1%
Age	55 to 64	2008	0.7%	0.5%	58.3%	6.2%	3.0%	44.5%	2.3%	41.9%	24.2%
Age	55 to 64	2009	0.6%	0.4%	59.5%	7.6%	2.5%	45.6%	2.0%	39.4%	21.3%
Age	65 to74	2006	0.9%	0.2%	56.2%	0.2%	1.9%	32.5%	3.7%	50.4%	36.0%
Age	65 to74	2007	0.7%	0.2%	60.4%	4.5%	2.3%	30.3%	3.1%	49.1%	32.2%
Age	65 to74	2008	0.7%	0.2%	62.4%	7.1%	2.3%	30.9%	2.7%	47.1%	24.1%
Age	65 to74	2009	0.6%	0.2%	63.8%	8.6%	1.9%	31.8%	2.4%	44.6%	21.5%
Age	75 to 84	2006	0.9%	0.1%	44.4%	0.2%	0.7%	33.9%	4.4%	52.8%	31.0%
Age	75 to 84	2007	0.8%	0.1%	48.2%	4.1%	0.9%	31.3%	4.0%	52.2%	28.1%
Age	75 to 84	2008	0.7%	0.1%	50.3%	6.5%	0.8%	31.9%	3.7%	50.4%	21.0%
Age	75 to 84	2009	0.7%	0.1%	52.2%	8.0%	0.8%	32.4%	3.3%	48.2%	18.8%
Age	85 to 94	2006	0.8%	0.0%	30.4%	0.1%	0.2%	39.2%	4.9%	54.9%	24.7%
Age	85 to 94	2007	0.7%	0.0%	33.6%	3.2%	0.2%	35.7%	4.8%	55.1%	22.9%
Age	85 to 94	2008	0.7%	0.0%	35.5%	5.4%	0.2%	36.2%	4.7%	53.3%	16.9%
Age	85 to 94	2009	0.7%	0.0%	37.2%	6.9%	0.2%	36.6%	4.3%	51.3%	15.0%
Age	95 and over	2006	0.8%	*	20.2%	0.1%	0.1%	43.7%	5.0%	55.8%	19.0%
Age	95 and over	2007	0.7%	*	22.6%	1.9%	0.1%	40.7%	5.3%	56.2%	17.5%
Age	95 and over	2008	0.7%	*	24.5%	3.8%	0.1%	41.2%	5.3%	54.4%	13.1%
Age	95 and over	2009	0.7%	*	25.7%	5.4%	0.1%	42.0%	5.0%	52.7%	11.5%
Gender	Male	2006	0.9%	0.2%	50.3%	0.2%	1.5%	35.3%	3.8%	51.4%	34.4%
Gender	Male	2007	0.7%	0.2%	53.6%	4.1%	1.8%	33.3%	3.3%	50.6%	31.1%
Gender	Male	2008	0.7%	0.2%	55.5%	6.5%	1.7%	34.1%	3.0%	48.8%	23.7%
Gender	Male	2009	0.7%	0.2%	57.3%	8.0%	1.4%	35.0%	2.7%	46.5%	21.3%
Gender	Female	2006	0.8%	0.2%	49.2%	0.2%	1.6%	37.3%	3.8%	48.3%	32.2%

<b>Breakdown</b>	<b>Category</b>	<b>Year</b>	<b>Alpha Glucosidase Inhibitors</b>	<b>Amylin Analogs</b>	<b>Biguanides</b>	<b>Dipeptidyl Peptidase-4 Inhibitors</b>	<b>Glucagonlike Peptide 1 Receptor Agonists</b>	<b>Insulins</b>	<b>Meglitinides</b>	<b>Sulfonylureas</b>	<b>Thiazolidine-diones</b>
Gender	Female	2007	0.7%	0.2%	52.9%	4.0%	2.0%	34.8%	3.4%	47.7%	28.8%
Gender	Female	2008	0.6%	0.2%	54.7%	6.5%	1.9%	35.4%	3.2%	45.7%	21.3%
Gender	Female	2009	0.6%	0.2%	56.2%	8.0%	1.6%	36.1%	2.8%	43.4%	18.8%
Race	White	2006	0.8%	0.2%	50.0%	0.2%	1.9%	35.3%	3.7%	49.9%	32.3%
Race	White	2007	0.6%	0.3%	53.7%	4.2%	2.1%	32.7%	3.3%	49.2%	29.0%
Race	White	2008	0.6%	0.3%	55.7%	6.6%	2.0%	33.4%	3.0%	47.3%	21.6%
Race	White	2009	0.6%	0.2%	57.3%	7.9%	1.7%	34.2%	2.7%	45.0%	19.1%
Race	Black	2006	0.7%	0.1%	44.7%	0.1%	1.1%	45.2%	3.4%	45.3%	31.2%
Race	Black	2007	0.7%	0.2%	47.9%	3.0%	1.3%	43.5%	3.0%	45.2%	28.3%
Race	Black	2008	0.6%	0.2%	49.2%	5.1%	1.3%	44.3%	2.8%	43.5%	21.1%
Race	Black	2009	0.6%	0.2%	50.5%	6.4%	1.1%	44.9%	2.5%	41.5%	18.7%
Race	Asian	2006	2.4%	0.1%	56.7%	0.3%	0.4%	20.7%	6.5%	57.9%	42.3%
Race	Asian	2007	2.2%	0.1%	59.0%	6.4%	0.6%	21.4%	6.0%	55.9%	39.7%
Race	Asian	2008	2.1%	0.1%	60.8%	10.7%	0.6%	22.1%	5.9%	53.6%	31.0%
Race	Asian	2009	2.0%	0.1%	62.5%	13.5%	0.5%	22.7%	5.4%	50.8%	28.2%
Race	Hispanic	2006	1.1%	0.1%	55.1%	0.2%	0.9%	35.7%	4.4%	51.8%	40.3%
Race	Hispanic	2007	1.0%	0.1%	57.6%	3.9%	1.2%	36.6%	3.8%	50.6%	37.3%
Race	Hispanic	2008	0.9%	0.2%	59.1%	7.0%	1.1%	37.9%	3.6%	48.4%	29.1%
Race	Hispanic	2009	0.9%	0.2%	60.5%	9.0%	1.0%	38.8%	3.3%	45.6%	26.8%
Race	American Indian/Alaska Native	2006	0.9%	0.1%	49.2%	0.1%	1.0%	42.6%	1.8%	45.2%	36.4%
Race	American Indian/Alaska Native	2007	0.7%	0.1%	52.4%	2.2%	1.3%	41.9%	1.4%	45.6%	35.5%
Race	American Indian/Alaska Native	2008	0.8%	0.2%	53.9%	3.7%	1.3%	42.5%	1.3%	44.0%	30.2%
Race	American Indian/Alaska Native	2009	0.7%	0.1%	55.1%	4.5%	1.1%	44.2%	1.0%	41.9%	27.7%

**Prevalence of Drugs by Antidiabetic Class, Among Medicare Parts A, B, and D FFS Population With Diabetes and at Least One Insulin Claim, by Age, Gender, and Race, 2006-2009**

Age is calculated as of December 31 of the year.

Note: An asterisk (\*) signifies small cell count (<11).

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Biguanides	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Meglitinides	Sulfonylureas	Thiazolidinediones
Overall	Overall	2006	0.8%	0.5%	29.7%	0.2%	2.0%	3.7%	29.5%	25.8%
Overall	Overall	2007	0.7%	0.6%	31.4%	3.2%	2.3%	3.4%	29.8%	23.0%
Overall	Overall	2008	0.7%	0.6%	32.4%	5.0%	2.1%	3.2%	29.4%	16.1%
Overall	Overall	2009	0.6%	0.6%	33.3%	6.2%	1.7%	2.8%	28.5%	13.9%
Age	Under 45	2006	0.6%	1.1%	31.8%	0.2%	2.9%	1.9%	19.9%	24.7%
Age	Under 45	2007	0.5%	1.3%	33.1%	2.7%	3.7%	1.7%	19.5%	22.4%
Age	Under 45	2008	0.5%	1.2%	33.9%	4.4%	3.2%	1.4%	19.5%	16.8%
Age	Under 45	2009	0.4%	1.1%	34.8%	5.4%	2.8%	1.2%	18.8%	14.5%
Age	45 to 54	2006	0.8%	1.0%	37.1%	0.2%	3.5%	2.7%	26.2%	30.4%
Age	45 to 54	2007	0.6%	1.2%	38.5%	3.2%	3.9%	2.2%	26.4%	26.9%
Age	45 to 54	2008	0.6%	1.3%	39.8%	5.2%	3.5%	1.9%	25.6%	19.8%
Age	45 to 54	2009	0.6%	1.1%	40.7%	6.3%	3.0%	1.6%	24.6%	17.1%
Age	55 to 64	2006	0.8%	0.9%	35.3%	0.2%	3.2%	3.3%	28.3%	30.0%
Age	55 to 64	2007	0.7%	1.0%	37.0%	3.3%	3.4%	2.7%	28.5%	26.5%
Age	55 to 64	2008	0.7%	1.0%	37.8%	5.1%	3.0%	2.4%	28.1%	18.9%
Age	55 to 64	2009	0.6%	0.9%	38.8%	6.2%	2.6%	2.0%	26.9%	16.3%
Age	65 to 74	2006	0.9%	0.6%	33.8%	0.2%	2.5%	3.8%	30.7%	28.1%
Age	65 to 74	2007	0.8%	0.7%	36.1%	3.6%	2.8%	3.4%	31.2%	25.1%
Age	65 to 74	2008	0.7%	0.7%	37.1%	5.5%	2.6%	3.1%	31.0%	17.3%
Age	65 to 74	2009	0.7%	0.6%	38.0%	6.7%	2.2%	2.7%	30.1%	15.0%
Age	75 to 84	2006	0.9%	0.2%	24.5%	0.2%	1.0%	4.2%	30.5%	22.7%
Age	75 to 84	2007	0.7%	0.3%	26.0%	3.1%	1.1%	4.1%	30.6%	20.2%
Age	75 to 84	2008	0.7%	0.3%	27.0%	5.0%	1.0%	3.9%	30.2%	13.9%
Age	75 to 84	2009	0.7%	0.2%	28.0%	6.1%	0.9%	3.4%	29.5%	11.9%
Age	85 to 94	2006	0.7%	0.1%	17.4%	0.1%	0.3%	4.5%	32.4%	18.7%
Age	85 to 94	2007	0.7%	0.1%	18.4%	2.4%	0.3%	4.6%	32.3%	16.9%
Age	85 to 94	2008	0.7%	0.1%	18.8%	4.1%	0.3%	4.3%	31.2%	11.6%
Age	85 to 94	2009	0.6%	0.1%	19.3%	5.1%	0.2%	4.0%	30.1%	9.6%
Age	95 and over	2006	0.7%	*	13.0%	*	*	4.0%	33.0%	15.0%
Age	95 and over	2007	0.6%	*	13.4%	1.6%	*	4.4%	33.1%	13.0%
Age	95 and over	2008	0.5%	*	13.8%	3.1%	*	4.3%	32.3%	8.6%
Age	95 and over	2009	0.6%	*	14.4%	4.3%	*	4.1%	30.9%	7.4%
Gender	Male	2006	0.9%	0.5%	30.2%	0.2%	2.0%	3.7%	30.6%	27.3%
Gender	Male	2007	0.8%	0.6%	31.8%	3.2%	2.2%	3.4%	30.9%	24.6%

<b>Breakdown</b>	<b>Category</b>	<b>Year</b>	<b>Alpha Glucosidase Inhibitors</b>	<b>Amylin Analogs</b>	<b>Biguanides</b>	<b>Dipeptidyl Peptidase-4 Inhibitors</b>	<b>Glucagonlike Peptide 1 Receptor Agonists</b>	<b>Meglitinides</b>	<b>Sulfonylureas</b>	<b>Thiazolidinediones</b>
Gender	Male	2008	0.7%	0.6%	32.9%	5.0%	2.0%	3.1%	30.4%	17.6%
Gender	Male	2009	0.7%	0.5%	34.0%	6.1%	1.7%	2.7%	29.5%	15.3%
Gender	Female	2006	0.8%	0.5%	29.4%	0.2%	2.0%	3.7%	28.9%	24.9%
Gender	Female	2007	0.7%	0.6%	31.2%	3.2%	2.3%	3.5%	29.2%	22.0%
Gender	Female	2008	0.7%	0.7%	32.0%	5.1%	2.1%	3.2%	28.8%	15.2%
Gender	Female	2009	0.6%	0.6%	32.8%	6.2%	1.8%	2.8%	27.8%	12.9%
Race	White	2006	0.8%	0.6%	29.8%	0.2%	2.4%	3.7%	30.3%	25.2%
Race	White	2007	0.7%	0.7%	31.6%	3.4%	2.6%	3.4%	30.5%	22.4%
Race	White	2008	0.6%	0.7%	32.6%	5.2%	2.3%	3.1%	30.2%	15.6%
Race	White	2009	0.6%	0.6%	33.6%	6.2%	2.0%	2.7%	29.2%	13.3%
Race	Black	2006	0.7%	0.3%	27.0%	0.1%	1.3%	3.2%	25.5%	24.6%
Race	Black	2007	0.6%	0.4%	28.6%	2.3%	1.4%	2.9%	25.7%	21.8%
Race	Black	2008	0.6%	0.4%	29.2%	3.9%	1.3%	2.7%	25.3%	15.3%
Race	Black	2009	0.6%	0.3%	29.9%	4.8%	1.2%	2.4%	24.5%	13.1%
Race	Asian	2006	2.9%	0.3%	35.1%	0.5%	0.9%	8.0%	38.0%	35.8%
Race	Asian	2007	2.5%	0.3%	35.9%	6.2%	1.2%	7.3%	37.6%	33.0%
Race	Asian	2008	2.4%	0.3%	36.3%	9.8%	1.1%	7.6%	37.2%	24.1%
Race	Asian	2009	2.4%	0.3%	37.1%	12.8%	1.0%	7.2%	35.6%	21.1%
Race	Hispanic	2006	1.1%	0.3%	36.2%	0.2%	1.2%	5.0%	33.0%	33.6%
Race	Hispanic	2007	0.9%	0.4%	38.5%	3.2%	1.5%	4.5%	33.2%	30.8%
Race	Hispanic	2008	0.9%	0.4%	39.3%	6.0%	1.4%	4.2%	32.5%	22.5%
Race	Hispanic	2009	0.9%	0.4%	40.4%	7.6%	1.2%	3.7%	30.7%	20.3%
Race	American Indian/Alaska Native	2006	0.8%	0.2%	30.1%	*	1.2%	1.6%	26.5%	30.8%
Race	American Indian/Alaska Native	2007	0.7%	0.3%	32.1%	2.0%	1.5%	1.3%	28.1%	30.5%
Race	American Indian/Alaska Native	2008	0.7%	0.4%	33.7%	3.2%	1.4%	1.3%	27.4%	24.8%
Race	American Indian/Alaska Native	2009	0.6%	0.3%	34.8%	3.9%	1.2%	1.0%	26.6%	22.2%

**Prevalence of Drugs by Antidiabetic Class, Among Medicare Parts A, B, and D FFS Population With Diabetes and No Insulin Claim, by Age, Gender, and Race, 2006-2009**

Age is calculated as of December 31 of the year.

Note: An asterisk (\*) signifies small cell count (<11).

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Biguanides	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Meglitinides	Sulfonylureas	Thiazolidinediones
Overall	Overall	2006	0.9%	0.0%	61.1%	0.2%	1.4%	3.9%	60.9%	37.2%
Overall	Overall	2007	0.7%	0.0%	64.5%	4.5%	1.7%	3.4%	58.7%	33.2%
Overall	Overall	2008	0.7%	0.0%	67.2%	7.3%	1.7%	3.1%	56.4%	25.5%
Overall	Overall	2009	0.6%	0.0%	69.5%	9.0%	1.4%	2.7%	53.6%	23.1%
Age	Under 45	2006	0.7%	0.1%	76.7%	0.2%	3.0%	2.3%	45.0%	36.6%
Age	Under 45	2007	0.6%	0.1%	79.8%	4.1%	4.0%	1.8%	42.6%	32.4%
Age	Under 45	2008	0.5%	0.1%	82.3%	6.7%	3.7%	1.5%	40.0%	25.6%
Age	Under 45	2009	0.5%	0.1%	84.3%	8.1%	2.9%	1.3%	37.2%	22.4%
Age	45 to 54	2006	0.8%	0.0%	72.7%	0.3%	2.7%	2.8%	52.0%	39.4%
Age	45 to 54	2007	0.7%	0.0%	75.8%	4.0%	3.7%	2.2%	50.1%	35.3%
Age	45 to 54	2008	0.6%	0.0%	78.6%	6.8%	3.4%	1.9%	47.4%	27.8%
Age	45 to 54	2009	0.5%	0.0%	81.0%	8.6%	2.8%	1.6%	44.4%	24.7%
Age	55 to 64	2006	0.8%	0.0%	68.7%	0.2%	2.4%	3.2%	57.4%	41.0%
Age	55 to 64	2007	0.7%	0.0%	72.1%	4.3%	3.1%	2.6%	55.5%	36.4%
Age	55 to 64	2008	0.7%	0.0%	74.8%	7.1%	3.0%	2.3%	53.0%	28.3%
Age	55 to 64	2009	0.6%	0.0%	77.0%	8.8%	2.4%	1.9%	49.9%	25.5%
Age	65 to 74	2006	0.9%	0.0%	66.9%	0.3%	1.7%	3.6%	59.8%	39.8%
Age	65 to 74	2007	0.7%	0.0%	71.0%	4.9%	2.1%	2.9%	56.8%	35.3%
Age	65 to 74	2008	0.6%	0.0%	73.7%	7.8%	2.1%	2.6%	54.3%	27.1%
Age	65 to 74	2009	0.6%	0.0%	75.8%	9.5%	1.8%	2.3%	51.3%	24.6%
Age	75 to 84	2006	0.9%	0.0%	54.6%	0.2%	0.6%	4.4%	64.3%	35.3%
Age	75 to 84	2007	0.8%	0.0%	58.3%	4.5%	0.8%	3.9%	62.0%	31.6%
Age	75 to 84	2008	0.7%	0.0%	61.2%	7.2%	0.8%	3.7%	59.8%	24.3%
Age	75 to 84	2009	0.7%	0.0%	63.7%	8.9%	0.7%	3.3%	57.2%	22.1%
Age	85 to 94	2006	0.9%	*	38.9%	0.1%	0.2%	5.2%	69.5%	28.6%
Age	85 to 94	2007	0.8%	*	42.1%	3.6%	0.2%	4.9%	67.8%	26.2%
Age	85 to 94	2008	0.7%	*	45.0%	6.2%	0.2%	4.9%	65.9%	20.0%
Age	85 to 94	2009	0.7%	*	47.6%	8.0%	0.2%	4.5%	63.5%	18.2%
Age	95 and over	2006	0.9%	*	25.8%	*	*	5.7%	73.5%	22.0%
Age	95 and over	2007	0.8%	*	28.9%	2.1%	*	5.9%	72.0%	20.6%
Age	95 and over	2008	0.8%	*	31.9%	4.3%	*	6.1%	70.0%	16.2%
Age	95 and over	2009	0.7%	*	33.8%	6.3%	*	5.7%	68.6%	14.4%
Gender	Male	2006	0.9%	0.0%	61.3%	0.3%	1.3%	3.8%	62.7%	38.2%
Gender	Male	2007	0.7%	0.0%	64.4%	4.6%	1.6%	3.3%	60.5%	34.3%
Gender	Male	2008	0.7%	0.0%	67.3%	7.3%	1.6%	3.0%	58.4%	26.9%
Gender	Male	2009	0.6%	0.0%	69.8%	9.0%	1.3%	2.7%	55.6%	24.4%
Gender	Female	2006	0.8%	0.0%	60.9%	0.2%	1.4%	3.9%	59.8%	36.6%

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Biguanides	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Meglitinides	Sulfonylureas	Thiazolidinediones
Gender	Female	2007	0.7%	0.0%	64.5%	4.4%	1.8%	3.4%	57.5%	32.4%
Gender	Female	2008	0.6%	0.0%	67.2%	7.2%	1.8%	3.2%	55.0%	24.6%
Gender	Female	2009	0.6%	0.0%	69.3%	9.0%	1.5%	2.8%	52.2%	22.2%
Race	White	2006	0.8%	0.0%	60.9%	0.3%	1.6%	3.8%	60.5%	36.3%
Race	White	2007	0.6%	0.0%	64.4%	4.6%	1.9%	3.3%	58.3%	32.2%
Race	White	2008	0.6%	0.0%	67.2%	7.3%	1.9%	3.0%	55.9%	24.6%
Race	White	2009	0.5%	0.0%	69.6%	8.8%	1.6%	2.6%	53.1%	22.1%
Race	Black	2006	0.8%	0.0%	59.3%	0.1%	1.0%	3.7%	61.6%	36.7%
Race	Black	2007	0.7%	0.0%	62.8%	3.5%	1.2%	3.1%	60.2%	33.3%
Race	Black	2008	0.6%	0.0%	65.1%	6.1%	1.3%	2.9%	58.0%	25.7%
Race	Black	2009	0.6%	0.0%	67.3%	7.8%	1.1%	2.6%	55.3%	23.3%
Race	Asian	2006	2.2%	*	62.4%	0.3%	0.3%	6.1%	63.1%	44.0%
Race	Asian	2007	2.1%	*	65.3%	6.4%	0.4%	5.6%	60.9%	41.6%
Race	Asian	2008	2.0%	*	67.7%	10.9%	0.4%	5.4%	58.2%	33.0%
Race	Asian	2009	1.8%	*	69.9%	13.8%	0.4%	4.9%	55.3%	30.4%
Race	Hispanic	2006	1.1%	*	65.6%	0.1%	0.7%	4.1%	62.3%	44.1%
Race	Hispanic	2007	1.0%	*	68.7%	4.2%	1.0%	3.5%	60.7%	41.0%
Race	Hispanic	2008	1.0%	0.0%	71.3%	7.7%	1.0%	3.3%	58.2%	33.1%
Race	Hispanic	2009	0.8%	*	73.3%	9.9%	0.9%	3.0%	55.1%	30.9%
Race	American Indian/Alaska Native	2006	1.0%	*	63.3%	*	0.8%	1.9%	59.0%	40.6%
Race	American Indian/Alaska Native	2007	0.7%	*	67.0%	2.4%	1.2%	1.5%	58.2%	39.0%
Race	American Indian/Alaska Native	2008	0.8%	*	68.9%	4.0%	1.2%	1.4%	56.3%	34.3%
Race	American Indian/Alaska Native	2009	0.7%	*	71.2%	5.0%	0.9%	1.0%	54.0%	32.1%

**Prevalence of Drugs by Antidiabetic Class, Among Medicare Parts A, B, and D FFS Population With Diabetes and At Least One Biguanide Claim, by Age, Gender, and Race, 2006-2009**

Age is calculated as of December 31 of the year.

Note: An asterisk (\*) signifies small cell count (<11).

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Insulins	Meglitinides	Sulfonylureas	Thiazolidinediones
Overall	Overall	2006	0.9%	0.2%	0.3%	2.1%	21.9%	3.2%	51.5%	35.2%
Overall	Overall	2007	0.7%	0.2%	4.8%	2.4%	20.2%	2.6%	49.3%	31.3%
Overall	Overall	2008	0.6%	0.2%	7.5%	2.2%	20.5%	2.3%	46.9%	22.9%
Overall	Overall	2009	0.6%	0.1%	8.9%	1.8%	21.0%	2.1%	44.1%	20.4%
Age	Under 45	2006	0.8%	0.3%	0.3%	3.8%	25.4%	2.2%	40.1%	36.2%
Age	Under 45	2007	0.6%	0.5%	4.5%	4.9%	25.8%	1.8%	38.2%	32.4%
Age	Under 45	2008	0.5%	0.4%	7.1%	4.4%	26.3%	1.4%	36.2%	25.0%
Age	Under 45	2009	0.4%	0.4%	8.6%	3.5%	26.9%	1.2%	33.7%	21.7%
Age	45 to 54	2006	0.9%	0.3%	0.3%	3.8%	28.5%	2.6%	45.8%	38.8%
Age	45 to 54	2007	0.7%	0.4%	4.5%	4.6%	28.3%	2.0%	44.2%	34.7%
Age	45 to 54	2008	0.6%	0.4%	7.4%	4.2%	29.0%	1.6%	41.9%	26.4%
Age	45 to 54	2009	0.6%	0.4%	9.0%	3.4%	29.7%	1.4%	39.3%	23.3%
Age	55 to 64	2006	0.9%	0.3%	0.2%	3.3%	29.2%	3.0%	49.8%	39.1%
Age	55 to 64	2007	0.7%	0.3%	4.7%	3.9%	28.3%	2.3%	48.2%	34.7%
Age	55 to 64	2008	0.7%	0.3%	7.4%	3.6%	28.8%	2.0%	45.9%	25.9%
Age	55 to 64	2009	0.6%	0.3%	8.9%	2.9%	29.7%	1.7%	43.0%	23.0%
Age	65 to74	2006	0.9%	0.1%	0.3%	2.2%	19.5%	3.2%	52.8%	36.7%
Age	65 to74	2007	0.7%	0.1%	5.2%	2.6%	18.1%	2.6%	49.9%	32.7%
Age	65 to74	2008	0.6%	0.1%	7.9%	2.5%	18.4%	2.2%	47.5%	23.9%
Age	65 to74	2009	0.6%	0.1%	9.4%	2.0%	18.9%	2.0%	44.7%	21.3%
Age	75 to 84	2006	0.9%	0.0%	0.3%	0.8%	18.7%	3.6%	54.0%	31.7%
Age	75 to 84	2007	0.7%	0.0%	4.8%	1.0%	16.9%	3.0%	51.4%	28.4%
Age	75 to 84	2008	0.6%	0.0%	7.3%	0.9%	17.1%	2.7%	48.9%	20.5%
Age	75 to 84	2009	0.6%	0.0%	8.7%	0.8%	17.4%	2.4%	46.2%	18.3%
Age	85 to 94	2006	0.8%	*	0.2%	0.3%	22.4%	3.7%	53.3%	26.0%
Age	85 to 94	2007	0.7%	*	4.0%	0.3%	19.6%	3.3%	51.4%	23.4%
Age	85 to 94	2008	0.6%	0.0%	6.2%	0.2%	19.2%	3.1%	48.6%	16.6%
Age	85 to 94	2009	0.5%	0.0%	7.4%	0.2%	19.0%	2.8%	46.0%	14.7%
Age	95 and over	2006	0.5%	*	*	*	28.1%	3.5%	50.5%	20.6%
Age	95 and over	2007	0.4%	*	2.4%	*	24.1%	3.5%	49.3%	19.0%
Age	95 and over	2008	0.5%	*	4.7%	*	23.2%	3.2%	46.7%	13.7%
Age	95 and over	2009	0.6%	*	6.1%	*	23.7%	3.1%	44.5%	11.8%
Gender	Male	2006	0.9%	0.1%	0.3%	2.0%	21.2%	3.2%	54.1%	37.3%
Gender	Male	2007	0.7%	0.1%	4.9%	2.2%	19.8%	2.6%	51.7%	33.4%
Gender	Male	2008	0.7%	0.1%	7.6%	2.1%	20.2%	2.3%	49.4%	25.1%
Gender	Male	2009	0.6%	0.1%	9.0%	1.7%	20.8%	2.0%	46.7%	22.4%
Gender	Female	2006	0.8%	0.2%	0.3%	2.2%	22.3%	3.2%	50.0%	33.8%

<b>Breakdown</b>	<b>Category</b>	<b>Year</b>	<b>Alpha Glucosidase Inhibitors</b>	<b>Amylin Analogs</b>	<b>Dipeptidyl Peptidase-4 Inhibitors</b>	<b>Glucagonlike Peptide 1 Receptor Agonists</b>	<b>Insulins</b>	<b>Meglitinides</b>	<b>Sulfonylureas</b>	<b>Thiazolidinediones</b>
Gender	Female	2007	0.7%	0.2%	4.8%	2.5%	20.5%	2.7%	47.8%	29.9%
Gender	Female	2008	0.6%	0.2%	7.5%	2.4%	20.7%	2.4%	45.2%	21.5%
Gender	Female	2009	0.6%	0.2%	8.9%	1.9%	21.1%	2.1%	42.4%	19.0%
Race	White	2006	0.8%	0.2%	0.3%	2.4%	21.1%	3.1%	50.9%	34.2%
Race	White	2007	0.6%	0.2%	4.9%	2.7%	19.3%	2.5%	48.7%	30.3%
Race	White	2008	0.5%	0.2%	7.5%	2.5%	19.6%	2.2%	46.3%	22.0%
Race	White	2009	0.5%	0.2%	8.8%	2.0%	20.0%	2.0%	43.6%	19.4%
Race	Black	2006	0.7%	0.1%	0.2%	1.5%	27.3%	2.9%	50.2%	34.1%
Race	Black	2007	0.6%	0.1%	3.8%	1.8%	25.9%	2.3%	48.8%	30.8%
Race	Black	2008	0.6%	0.1%	6.3%	1.7%	26.2%	2.1%	46.5%	22.4%
Race	Black	2009	0.6%	0.1%	7.6%	1.4%	26.6%	1.8%	43.9%	19.9%
Race	Asian	2006	2.2%	0.1%	0.3%	0.4%	12.8%	5.3%	59.0%	42.2%
Race	Asian	2007	2.0%	0.0%	7.1%	0.7%	13.1%	4.8%	56.1%	39.7%
Race	Asian	2008	2.0%	0.0%	11.7%	0.7%	13.2%	4.6%	52.9%	30.4%
Race	Asian	2009	1.7%	0.1%	14.2%	0.6%	13.5%	4.2%	49.6%	27.6%
Race	Hispanic	2006	1.2%	0.1%	0.2%	1.1%	23.5%	3.5%	56.9%	43.4%
Race	Hispanic	2007	1.0%	0.1%	4.7%	1.5%	24.5%	3.0%	55.0%	40.4%
Race	Hispanic	2008	0.9%	0.1%	8.4%	1.5%	25.2%	2.7%	52.2%	31.3%
Race	Hispanic	2009	0.8%	0.1%	10.4%	1.3%	25.9%	2.4%	48.9%	28.9%
Race	American Indian/Alaska Native	2006	0.9%	*	0.2%	1.0%	26.1%	1.6%	49.0%	37.6%
Race	American Indian/Alaska Native	2007	0.8%	0.2%	2.6%	1.7%	25.7%	1.2%	48.8%	36.8%
Race	American Indian/Alaska Native	2008	0.8%	0.2%	4.3%	1.5%	26.5%	1.1%	46.9%	30.9%
Race	American Indian/Alaska Native	2009	0.6%	0.1%	5.2%	1.2%	27.9%	0.8%	44.5%	28.6%

**Prevalence of Drugs by Antidiabetic Class, Among Medicare Parts A, B, and D FFS Population with Diabetes and No Biguanide Claim, by Age, Gender, and Race, 2006-2009**

Age is calculated as of December 31 of the year.

Note: An asterisk (\*) signifies small cell count (<11).

Breakdown	Category	Year	Alpha Glucosidase Inhibitors	Amylin Analogs	Dipeptidyl Peptidase-4 Inhibitors	Glucagonlike Peptide 1 Receptor Agonists	Insulins	Meglitinides	Sulfonylureas	Thiazolidinediones
Overall	Overall	2006	0.8%	0.3%	0.2%	1.1%	51.0%	4.4%	47.4%	30.9%
Overall	Overall	2007	0.7%	0.3%	3.2%	1.4%	50.1%	4.2%	48.3%	27.9%
Overall	Overall	2008	0.7%	0.3%	5.2%	1.3%	52.5%	4.1%	47.1%	21.4%
Overall	Overall	2009	0.7%	0.3%	6.7%	1.2%	54.8%	3.7%	45.3%	19.1%
Age	Under 45	2006	0.6%	0.7%	0.1%	1.9%	70.6%	2.0%	25.4%	24.7%
Age	Under 45	2007	0.5%	0.9%	2.1%	2.4%	73.5%	1.8%	23.4%	21.4%
Age	Under 45	2008	0.5%	0.9%	3.3%	2.1%	76.4%	1.6%	21.9%	16.3%
Age	Under 45	2009	0.4%	0.8%	4.2%	1.8%	78.7%	1.3%	20.4%	14.0%
Age	45 to 54	2006	0.7%	0.6%	0.2%	2.1%	64.2%	3.0%	34.0%	31.0%
Age	45 to 54	2007	0.6%	0.7%	2.4%	2.5%	66.4%	2.5%	33.2%	27.0%
Age	45 to 54	2008	0.6%	0.8%	4.1%	2.3%	69.4%	2.3%	30.9%	20.7%
Age	45 to 54	2009	0.5%	0.7%	5.2%	1.9%	72.4%	1.9%	28.9%	17.8%
Age	55 to 64	2006	0.7%	0.6%	0.2%	2.0%	62.4%	3.6%	38.2%	32.6%
Age	55 to 64	2007	0.7%	0.7%	2.7%	2.4%	63.5%	3.1%	37.8%	28.7%
Age	55 to 64	2008	0.6%	0.7%	4.4%	2.2%	66.4%	2.8%	36.4%	21.8%
Age	55 to 64	2009	0.6%	0.6%	5.7%	1.9%	69.0%	2.4%	34.2%	18.9%
Age	65 to 74	2006	0.9%	0.3%	0.2%	1.5%	49.1%	4.2%	47.2%	35.1%
Age	65 to 74	2007	0.7%	0.4%	3.6%	1.9%	48.9%	3.8%	47.7%	31.5%
Age	65 to 74	2008	0.7%	0.4%	5.7%	1.9%	51.7%	3.6%	46.5%	24.4%
Age	65 to 74	2009	0.7%	0.4%	7.2%	1.8%	54.4%	3.2%	44.4%	21.9%
Age	75 to 84	2006	0.9%	0.1%	0.2%	0.6%	46.1%	5.0%	51.8%	30.5%
Age	75 to 84	2007	0.8%	0.1%	3.4%	0.8%	44.7%	4.9%	52.9%	27.8%
Age	75 to 84	2008	0.8%	0.1%	5.7%	0.8%	46.8%	4.7%	51.9%	21.5%
Age	75 to 84	2009	0.8%	0.1%	7.3%	0.7%	48.7%	4.3%	50.4%	19.3%
Age	85 to 94	2006	0.8%	0.0%	0.1%	0.2%	46.6%	5.5%	55.6%	24.1%
Age	85 to 94	2007	0.8%	0.0%	2.7%	0.2%	43.9%	5.6%	57.0%	22.6%
Age	85 to 94	2008	0.7%	0.0%	5.0%	0.2%	45.6%	5.5%	56.0%	17.1%
Age	85 to 94	2009	0.7%	0.0%	6.6%	0.2%	47.0%	5.2%	54.4%	15.2%
Age	95 and over	2006	0.9%	*	0.1%	0.1%	47.6%	5.4%	57.1%	18.6%
Age	95 and over	2007	0.8%	*	1.7%	*	45.5%	5.8%	58.2%	17.1%
Age	95 and over	2008	0.8%	*	3.5%	*	47.0%	6.0%	57.0%	12.9%
Age	95 and over	2009	0.7%	*	5.2%	*	48.4%	5.7%	55.6%	11.3%
Gender	Male	2006	0.8%	0.3%	0.2%	1.1%	49.5%	4.4%	48.7%	31.4%
Gender	Male	2007	0.7%	0.3%	3.2%	1.3%	48.9%	4.1%	49.4%	28.4%
Gender	Male	2008	0.7%	0.3%	5.2%	1.3%	51.5%	3.9%	48.1%	22.1%
Gender	Male	2009	0.7%	0.3%	6.6%	1.1%	54.0%	3.6%	46.2%	19.8%
Gender	Female	2006	0.8%	0.3%	0.1%	1.2%	51.8%	4.5%	46.6%	30.7%

<b>Breakdown</b>	<b>Category</b>	<b>Year</b>	<b>Alpha Glucosidase Inhibitors</b>	<b>Amylin Analogs</b>	<b>Dipeptidyl Peptidase-4 Inhibitors</b>	<b>Glucagonlike Peptide 1 Receptor Agonists</b>	<b>Insulins</b>	<b>Meglitinides</b>	<b>Sulfonylureas</b>	<b>Thiazolidinediones</b>
Gender	Female	2007	0.7%	0.3%	3.2%	1.4%	50.8%	4.3%	47.5%	27.5%
Gender	Female	2008	0.7%	0.3%	5.3%	1.4%	53.1%	4.2%	46.4%	21.0%
Gender	Female	2009	0.7%	0.3%	6.8%	1.2%	55.3%	3.8%	44.6%	18.6%
Race	White	2006	0.8%	0.3%	0.2%	1.3%	49.5%	4.4%	48.8%	30.5%
Race	White	2007	0.7%	0.4%	3.3%	1.5%	48.3%	4.2%	49.7%	27.5%
Race	White	2008	0.6%	0.4%	5.4%	1.5%	50.8%	4.0%	48.6%	21.0%
Race	White	2009	0.6%	0.3%	6.8%	1.3%	53.1%	3.6%	46.8%	18.7%
Race	Black	2006	0.7%	0.2%	0.1%	0.8%	59.7%	3.9%	41.3%	28.9%
Race	Black	2007	0.7%	0.2%	2.3%	0.9%	59.7%	3.7%	41.8%	26.0%
Race	Black	2008	0.6%	0.2%	4.0%	0.9%	61.7%	3.5%	40.6%	19.8%
Race	Black	2009	0.6%	0.2%	5.2%	0.8%	63.6%	3.2%	39.0%	17.6%
Race	Asian	2006	2.6%	0.1%	0.3%	0.3%	31.1%	8.0%	56.4%	42.4%
Race	Asian	2007	2.5%	0.1%	5.3%	0.4%	33.5%	7.7%	55.8%	39.8%
Race	Asian	2008	2.4%	0.1%	9.1%	0.5%	35.8%	7.8%	54.6%	32.0%
Race	Asian	2009	2.4%	0.1%	12.4%	0.5%	38.1%	7.5%	52.7%	29.4%
Race	Hispanic	2006	1.0%	0.1%	0.1%	0.6%	50.7%	5.4%	45.6%	36.6%
Race	Hispanic	2007	0.9%	0.2%	2.8%	0.8%	53.2%	5.0%	44.7%	33.0%
Race	Hispanic	2008	0.9%	0.2%	5.1%	0.7%	56.4%	5.0%	43.0%	25.8%
Race	Hispanic	2009	0.9%	0.2%	7.0%	0.7%	58.5%	4.5%	40.7%	23.6%
Race	American Indian/Alaska Native	2006	0.8%	*	*	0.9%	58.5%	1.9%	41.5%	35.3%
Race	American Indian/Alaska Native	2007	0.7%	*	1.8%	0.9%	59.7%	1.6%	42.0%	34.0%
Race	American Indian/Alaska Native	2008	0.7%	0.2%	2.9%	0.9%	61.2%	1.5%	40.7%	29.4%
Race	American Indian/Alaska Native	2009	0.7%	0.2%	3.6%	0.9%	64.2%	1.3%	38.7%	26.6%

**Utilization of Antidiabetic Drugs, Among Medicare Parts A, B, and D FFS Population With Diabetes, by Drug Class and Hospital Referral Region (HRR), 2006-2009**

Note: An asterisk (\*) signifies small cell count (<11).

		Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																	
		Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
Year	HRR	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	1	0.3%	0.5%	0.1%	0.1%	35.0%	50.4%	0.1%	0.1%	1.4%	2.0%	26.5%	38.2%	1.6%	2.3%	32.3%	46.5%	22.5%	32.4%
2006	2	0.2%	0.3%	0.2%	0.3%	31.5%	43.4%	*	*	0.9%	1.3%	29.4%	40.6%	1.3%	1.8%	38.5%	53.0%	22.5%	30.9%
2006	5	0.2%	0.3%	*	*	31.9%	46.9%	*	*	1.1%	1.6%	25.0%	36.8%	1.8%	2.7%	31.3%	45.9%	22.0%	32.4%
2006	6	0.4%	0.6%	*	*	35.6%	50.1%	*	*	1.2%	1.8%	28.3%	39.8%	2.1%	3.0%	31.7%	44.6%	22.2%	31.2%
2006	7	0.5%	0.7%	*	*	32.3%	47.4%	*	*	1.2%	1.8%	27.9%	40.9%	1.1%	1.6%	32.6%	47.8%	20.6%	30.2%
2006	9	0.5%	0.8%	*	*	35.4%	50.2%	*	*	0.7%	1.0%	28.1%	39.9%	2.5%	3.6%	34.7%	49.3%	23.5%	33.4%
2006	10	0.6%	0.8%	*	*	38.0%	54.9%	*	*	1.9%	2.8%	26.5%	38.3%	1.1%	1.6%	28.6%	41.4%	23.6%	34.1%
2006	11	0.4%	0.6%	*	*	37.0%	55.0%	*	*	0.9%	1.4%	21.3%	31.7%	1.9%	2.9%	31.2%	46.4%	20.6%	30.6%
2006	12	0.6%	0.9%	0.1%	0.1%	36.3%	55.5%	0.1%	0.1%	0.9%	1.4%	22.4%	34.3%	1.6%	2.4%	30.9%	47.2%	21.5%	33.0%
2006	14	*	*	*	*	31.2%	53.1%	*	*	1.3%	2.2%	16.7%	28.5%	2.1%	3.6%	29.5%	50.2%	17.5%	29.8%
2006	15	0.3%	0.4%	*	*	36.2%	56.2%	0.2%	0.4%	0.7%	1.1%	22.8%	35.4%	1.2%	1.9%	32.4%	50.3%	18.2%	28.3%
2006	16	0.5%	0.8%	*	*	31.2%	45.9%	*	*	0.9%	1.3%	22.0%	32.4%	1.9%	2.8%	34.9%	51.3%	21.4%	31.5%
2006	18	0.4%	0.5%	*	*	37.1%	50.8%	*	*	0.6%	0.8%	24.9%	34.1%	1.3%	1.8%	39.8%	54.5%	20.8%	28.5%
2006	19	0.4%	0.5%	*	*	32.7%	46.6%	0.1%	0.1%	0.8%	1.1%	24.5%	35.0%	2.3%	3.2%	36.9%	52.6%	21.3%	30.3%
2006	21	0.5%	0.7%	0.3%	0.4%	35.3%	51.0%	*	*	1.6%	2.3%	23.0%	33.2%	3.1%	4.5%	32.5%	47.1%	20.7%	30.0%
2006	22	*	*	*	*	26.3%	38.0%	*	*	0.3%	0.4%	26.6%	38.5%	2.3%	3.3%	36.6%	53.0%	21.4%	31.0%
2006	23	1.8%	3.0%	0.3%	0.4%	36.6%	60.2%	0.4%	0.7%	0.7%	1.2%	15.8%	25.9%	3.2%	5.3%	33.2%	54.6%	24.9%	40.9%
2006	25	0.4%	0.7%	0.1%	0.1%	39.2%	58.7%	0.1%	0.1%	0.6%	0.9%	20.8%	31.2%	2.9%	4.3%	33.1%	49.6%	31.2%	46.7%
2006	31	1.4%	2.2%	*	*	38.5%	58.2%	*	*	2.1%	3.2%	19.9%	30.1%	1.8%	2.8%	28.0%	42.3%	30.2%	45.6%
2006	33	0.7%	1.2%	*	*	34.2%	56.0%	*	*	0.4%	0.6%	18.5%	30.4%	2.4%	4.0%	29.7%	48.6%	22.3%	36.5%
2006	43	1.2%	1.7%	*	*	35.2%	52.5%	*	*	0.7%	1.0%	22.7%	33.9%	2.5%	3.7%	29.0%	43.4%	32.1%	47.9%
2006	56	1.0%	1.6%	0.1%	0.2%	33.0%	55.2%	0.2%	0.3%	0.5%	0.9%	18.6%	31.0%	4.5%	7.4%	31.7%	53.1%	24.6%	41.1%
2006	58	1.2%	1.7%	*	*	39.6%	57.6%	0.1%	0.2%	1.1%	1.6%	21.6%	31.5%	3.4%	4.9%	34.9%	50.8%	31.1%	45.3%
2006	62	0.9%	1.3%	*	*	39.1%	57.8%	*	*	0.6%	0.9%	21.9%	32.4%	1.3%	2.0%	32.8%	48.6%	27.0%	40.0%
2006	65	1.0%	1.6%	*	*	34.3%	56.3%	*	*	0.3%	0.5%	16.9%	27.8%	2.5%	4.1%	29.9%	49.1%	24.0%	39.4%
2006	69	0.8%	1.4%	0.6%	0.9%	35.4%	58.3%	*	*	1.4%	2.3%	18.0%	29.5%	1.8%	2.9%	27.2%	44.7%	25.6%	42.2%
2006	73	0.7%	1.0%	*	*	38.2%	56.9%	*	*	1.4%	2.0%	20.4%	30.4%	2.4%	3.6%	27.4%	40.8%	28.3%	42.2%
2006	77	0.7%	1.0%	0.1%	0.1%	36.9%	55.2%	0.1%	0.1%	0.9%	1.3%	21.4%	32.0%	2.6%	3.9%	33.4%	50.0%	27.7%	41.4%
2006	78	0.4%	0.6%	*	*	37.9%	54.7%	*	*	1.4%	2.1%	22.1%	31.9%	4.6%	6.6%	32.9%	47.5%	31.5%	45.5%
2006	79	0.8%	1.2%	0.1%	0.2%	35.9%	56.2%	0.1%	0.1%	0.5%	0.7%	22.6%	35.4%	2.1%	3.3%	35.0%	54.8%	25.1%	39.3%
2006	80	0.7%	1.1%	0.1%	0.1%	40.9%	59.9%	0.1%	0.2%	0.7%	1.1%	21.2%	31.0%	3.1%	4.5%	31.9%	46.8%	31.2%	45.8%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	81	1.6%	2.4%	*	*	36.7%	56.2%	*	*	0.5%	0.8%	15.5%	23.8%	2.0%	3.0%	36.1%	55.4%	23.5%	36.0%
2006	82	1.6%	2.5%	0.1%	0.1%	38.5%	58.6%	*	*	0.4%	0.5%	15.7%	23.9%	4.2%	6.4%	34.2%	52.1%	25.2%	38.4%
2006	83	0.5%	0.9%	*	*	39.3%	65.0%	*	*	0.8%	1.4%	18.2%	30.1%	2.0%	3.3%	26.6%	44.0%	21.4%	35.3%
2006	85	1.4%	2.4%	*	*	35.9%	59.7%	*	*	1.0%	1.6%	14.0%	23.3%	3.0%	5.1%	29.8%	49.5%	22.7%	37.7%
2006	86	1.0%	1.6%	*	*	41.3%	63.9%	0.3%	0.4%	1.5%	2.3%	18.3%	28.3%	3.7%	5.7%	29.1%	45.0%	30.8%	47.8%
2006	87	0.6%	0.8%	*	*	39.2%	57.1%	*	*	0.6%	0.9%	22.4%	32.7%	3.0%	4.4%	34.9%	50.8%	27.7%	40.3%
2006	89	0.9%	1.4%	*	*	39.1%	58.5%	*	*	1.1%	1.7%	20.6%	30.7%	1.6%	2.4%	31.0%	46.3%	23.2%	34.7%
2006	91	1.3%	1.8%	*	*	39.8%	56.2%	*	*	0.5%	0.6%	23.4%	33.1%	3.7%	5.3%	34.9%	49.3%	30.8%	43.5%
2006	96	0.5%	0.7%	*	*	40.9%	62.0%	*	*	0.6%	1.0%	20.1%	30.5%	3.9%	5.9%	28.5%	43.2%	27.8%	42.1%
2006	101	*	*	*	*	39.0%	54.0%	*	*	*	*	25.9%	35.9%	1.7%	2.4%	26.2%	36.3%	27.2%	37.7%
2006	102	0.4%	0.6%	*	*	39.3%	55.8%	*	*	0.9%	1.2%	25.2%	35.8%	1.7%	2.4%	32.4%	46.0%	23.0%	32.6%
2006	103	0.4%	0.6%	*	*	38.2%	54.1%	0.1%	0.2%	1.1%	1.6%	24.8%	35.1%	1.3%	1.9%	32.6%	46.2%	23.3%	33.0%
2006	104	*	*	*	*	41.1%	55.6%	*	*	0.8%	1.0%	25.5%	34.4%	1.5%	2.0%	32.5%	43.9%	26.4%	35.7%
2006	105	*	*	*	*	37.1%	53.2%	*	*	1.8%	2.6%	28.3%	40.7%	1.3%	1.9%	29.9%	42.9%	17.8%	25.6%
2006	106	0.7%	0.9%	*	*	42.3%	56.8%	*	*	1.0%	1.4%	25.7%	34.5%	1.2%	1.7%	34.3%	46.1%	28.0%	37.6%
2006	107	*	*	*	*	36.7%	51.4%	*	*	*	*	30.0%	42.1%	1.6%	2.2%	33.4%	46.8%	26.7%	37.4%
2006	109	0.5%	0.8%	*	*	31.6%	49.0%	0.4%	0.6%	0.7%	1.0%	20.9%	32.4%	2.1%	3.2%	31.3%	48.5%	25.1%	39.0%
2006	110	0.4%	0.6%	0.1%	0.1%	31.0%	46.5%	0.1%	0.1%	0.7%	1.0%	25.9%	38.8%	2.5%	3.7%	30.5%	45.7%	21.2%	31.7%
2006	111	0.5%	0.8%	0.1%	0.1%	29.5%	45.3%	0.2%	0.3%	0.7%	1.1%	25.5%	39.1%	1.7%	2.6%	31.0%	47.6%	19.8%	30.5%
2006	112	0.9%	1.4%	0.2%	0.3%	28.1%	45.4%	0.2%	0.2%	0.7%	1.2%	20.8%	33.6%	3.8%	6.1%	30.3%	48.8%	19.4%	31.4%
2006	113	0.6%	1.0%	0.1%	0.2%	29.9%	46.9%	0.1%	0.2%	0.8%	1.2%	24.0%	37.7%	2.6%	4.0%	31.0%	48.6%	18.3%	28.7%
2006	115	0.5%	0.8%	*	*	30.0%	49.9%	*	*	0.6%	1.0%	18.4%	30.6%	1.0%	1.6%	30.3%	50.3%	20.7%	34.4%
2006	116	0.5%	0.8%	*	*	28.2%	46.9%	*	*	1.4%	2.3%	20.8%	34.6%	1.8%	3.1%	29.2%	48.5%	20.6%	34.1%
2006	118	0.3%	0.5%	0.3%	0.6%	25.1%	44.9%	0.2%	0.4%	1.3%	2.3%	20.9%	37.4%	3.4%	6.2%	27.2%	48.6%	17.3%	31.0%
2006	119	0.2%	0.3%	0.3%	0.4%	31.6%	51.3%	0.2%	0.4%	1.2%	1.9%	19.2%	31.2%	3.4%	5.6%	31.0%	50.4%	20.3%	33.0%
2006	120	0.5%	0.8%	*	*	32.2%	48.5%	0.2%	0.3%	0.8%	1.2%	24.9%	37.5%	2.1%	3.2%	32.8%	49.5%	24.0%	36.1%
2006	122	0.4%	0.6%	0.3%	0.5%	30.3%	47.4%	*	*	0.9%	1.4%	23.2%	36.3%	1.4%	2.2%	34.5%	54.0%	20.9%	32.7%
2006	123	0.3%	0.4%	0.1%	0.2%	32.0%	47.1%	0.1%	0.2%	0.9%	1.3%	27.8%	41.0%	3.2%	4.7%	31.6%	46.6%	20.2%	29.7%
2006	124	0.4%	0.5%	*	*	32.4%	48.2%	*	*	1.2%	1.8%	25.8%	38.4%	1.7%	2.5%	34.6%	51.5%	21.9%	32.6%
2006	127	0.4%	0.7%	0.3%	0.4%	29.3%	50.5%	0.2%	0.3%	0.6%	1.1%	26.0%	44.9%	3.1%	5.3%	29.6%	51.0%	20.6%	35.5%
2006	129	0.3%	0.5%	0.2%	0.4%	31.9%	49.8%	0.3%	0.5%	1.1%	1.8%	20.0%	31.2%	2.0%	3.1%	34.2%	53.2%	21.8%	34.0%
2006	130	0.3%	0.5%	0.3%	0.5%	30.7%	48.3%	0.2%	0.3%	1.1%	1.8%	24.1%	37.9%	2.5%	4.0%	32.7%	51.4%	20.6%	32.5%
2006	131	0.5%	0.9%	*	*	29.7%	49.1%	0.5%	0.8%	1.2%	2.0%	23.4%	38.7%	2.1%	3.6%	31.0%	51.3%	18.0%	29.8%
2006	133	0.5%	0.7%	0.5%	0.8%	31.0%	45.1%	0.4%	0.6%	1.4%	2.0%	28.0%	40.7%	2.1%	3.1%	34.5%	50.2%	25.5%	37.0%
2006	134	0.4%	0.5%	0.2%	0.4%	34.2%	48.5%	0.1%	0.2%	1.7%	2.4%	27.5%	39.0%	1.5%	2.1%	31.5%	44.6%	25.4%	36.0%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	137	*	*	*	*	30.0%	50.7%	*	*	1.3%	2.1%	18.6%	31.4%	2.2%	3.8%	26.5%	44.9%	20.8%	35.3%
2006	139	0.5%	0.8%	*	*	30.4%	49.9%	*	*	0.6%	1.0%	22.3%	36.6%	2.2%	3.5%	28.4%	46.6%	24.1%	39.5%
2006	140	0.3%	0.4%	0.1%	0.2%	33.5%	47.4%	0.1%	0.2%	1.3%	1.8%	28.8%	40.7%	2.0%	2.9%	34.5%	48.8%	26.0%	36.7%
2006	141	0.4%	0.6%	0.1%	0.2%	32.5%	49.0%	0.1%	0.2%	0.9%	1.3%	25.1%	37.9%	1.6%	2.4%	33.2%	50.0%	26.1%	39.3%
2006	142	*	*	*	*	32.2%	44.7%	*	*	0.5%	0.7%	31.3%	43.5%	2.1%	3.0%	35.6%	49.4%	20.6%	28.7%
2006	144	0.5%	0.7%	0.1%	0.2%	33.1%	49.7%	0.1%	0.2%	1.0%	1.5%	24.9%	37.4%	2.1%	3.1%	33.1%	49.7%	19.0%	28.5%
2006	145	0.5%	0.7%	0.1%	0.2%	31.4%	44.6%	0.1%	0.2%	0.9%	1.3%	28.4%	40.5%	2.1%	2.9%	32.9%	46.8%	23.3%	33.2%
2006	146	0.9%	1.4%	*	*	28.3%	45.5%	*	*	0.7%	1.2%	24.3%	39.1%	1.6%	2.5%	30.1%	48.4%	20.6%	33.1%
2006	147	0.5%	0.7%	0.3%	0.4%	29.8%	43.1%	0.1%	0.1%	1.4%	2.0%	28.7%	41.5%	2.5%	3.6%	33.4%	48.4%	22.3%	32.2%
2006	148	0.3%	0.4%	*	*	36.6%	53.1%	*	*	1.4%	2.0%	22.4%	32.4%	1.8%	2.7%	35.1%	50.8%	22.9%	33.1%
2006	149	0.4%	0.6%	*	*	31.5%	44.8%	*	*	0.7%	1.0%	29.5%	41.9%	2.1%	3.1%	32.3%	45.9%	25.3%	36.0%
2006	150	1.2%	1.9%	*	*	29.8%	47.6%	*	*	0.2%	0.4%	17.5%	27.8%	3.8%	6.0%	31.3%	49.9%	25.4%	40.6%
2006	151	0.3%	0.4%	*	*	37.5%	51.3%	*	*	1.8%	2.5%	25.4%	34.8%	1.3%	1.8%	31.2%	42.7%	27.8%	38.0%
2006	152	*	*	*	*	52.5%	66.2%	*	*	7.1%	9.0%	19.8%	24.9%	1.1%	1.4%	18.2%	22.9%	36.7%	46.3%
2006	154	*	*	*	*	31.8%	46.6%	*	*	0.6%	0.8%	22.6%	33.2%	0.9%	1.4%	40.0%	58.7%	21.7%	31.8%
2006	155	0.4%	0.7%	*	*	30.2%	48.7%	*	*	0.8%	1.2%	20.7%	33.4%	2.3%	3.7%	33.6%	54.1%	17.4%	28.0%
2006	156	0.9%	1.5%	*	*	31.3%	51.4%	0.0%	0.1%	0.3%	0.4%	20.9%	34.3%	1.9%	3.1%	32.4%	53.2%	20.1%	33.0%
2006	158	0.4%	0.6%	*	*	31.2%	47.7%	*	*	0.5%	0.8%	22.0%	33.8%	3.0%	4.6%	34.5%	52.8%	19.9%	30.5%
2006	161	0.6%	1.0%	0.1%	0.2%	31.4%	49.9%	*	*	0.7%	1.1%	17.6%	28.0%	2.8%	4.4%	34.1%	54.3%	19.4%	30.8%
2006	163	0.5%	0.8%	*	*	31.7%	50.1%	*	*	1.0%	1.5%	18.9%	29.8%	2.3%	3.7%	35.1%	55.4%	19.9%	31.4%
2006	164	0.4%	0.6%	*	*	30.0%	47.3%	*	*	0.6%	1.0%	21.5%	34.0%	2.3%	3.7%	34.2%	54.0%	19.3%	30.4%
2006	166	0.6%	0.9%	*	*	32.9%	50.8%	0.1%	0.2%	0.7%	1.1%	20.0%	30.9%	2.7%	4.1%	35.4%	54.8%	20.9%	32.3%
2006	170	0.7%	0.9%	*	*	32.8%	45.5%	*	*	0.4%	0.5%	25.3%	35.0%	2.1%	2.9%	38.7%	53.7%	25.2%	35.0%
2006	171	0.4%	0.5%	0.1%	0.2%	36.0%	50.8%	*	*	0.7%	1.0%	25.2%	35.7%	2.2%	3.1%	35.1%	49.6%	22.8%	32.2%
2006	172	0.4%	0.5%	0.1%	0.1%	33.1%	46.3%	0.1%	0.1%	0.7%	1.0%	25.3%	35.4%	1.5%	2.1%	39.6%	55.4%	20.3%	28.3%
2006	173	0.4%	0.6%	*	*	33.0%	45.8%	*	*	0.7%	0.9%	28.2%	39.1%	1.5%	2.1%	37.1%	51.5%	21.4%	29.6%
2006	175	*	*	*	*	33.8%	47.4%	*	*	*	*	25.7%	36.0%	1.7%	2.4%	39.0%	54.6%	20.4%	28.6%
2006	179	0.5%	0.6%	0.2%	0.3%	34.4%	47.0%	*	*	1.3%	1.7%	28.6%	39.1%	2.1%	2.9%	36.5%	49.9%	23.1%	31.5%
2006	180	0.4%	0.5%	0.4%	0.6%	35.0%	47.5%	0.3%	0.4%	2.3%	3.1%	31.6%	42.8%	2.5%	3.4%	35.9%	48.7%	23.6%	32.0%
2006	181	0.3%	0.5%	*	*	31.0%	44.0%	*	*	0.6%	0.9%	30.5%	43.3%	3.3%	4.7%	33.4%	47.4%	19.3%	27.4%
2006	183	0.5%	0.7%	0.3%	0.5%	31.7%	44.0%	0.1%	0.2%	1.6%	2.2%	30.0%	41.6%	2.0%	2.8%	35.4%	49.2%	22.5%	31.2%
2006	184	1.0%	1.4%	*	*	38.2%	53.2%	*	*	1.1%	1.6%	27.0%	37.6%	2.1%	3.0%	36.3%	50.6%	20.1%	28.0%
2006	185	*	*	*	*	30.2%	40.8%	*	*	2.0%	2.7%	33.7%	45.4%	1.7%	2.3%	36.7%	49.5%	20.3%	27.4%
2006	186	0.7%	1.1%	*	*	33.1%	51.1%	*	*	0.5%	0.8%	23.0%	35.4%	2.3%	3.5%	34.5%	53.3%	18.1%	27.8%
2006	187	0.3%	0.5%	0.2%	0.3%	37.2%	51.7%	0.2%	0.3%	1.1%	1.5%	28.4%	39.5%	2.8%	3.9%	33.3%	46.3%	21.0%	29.1%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	188	0.4%	0.5%	*	*	34.0%	46.7%	*	*	1.6%	2.2%	29.0%	39.8%	3.2%	4.3%	35.8%	49.2%	20.0%	27.5%
2006	190	0.4%	0.5%	*	*	32.3%	44.4%	*	*	0.9%	1.3%	28.7%	39.4%	1.4%	1.9%	38.6%	53.0%	19.3%	26.6%
2006	191	0.4%	0.6%	*	*	31.6%	45.0%	*	*	0.8%	1.1%	26.0%	37.1%	1.8%	2.6%	38.7%	55.2%	21.0%	29.9%
2006	192	0.3%	0.4%	0.1%	0.2%	34.5%	48.5%	0.1%	0.1%	0.8%	1.2%	25.9%	36.5%	2.0%	2.8%	37.8%	53.2%	20.3%	28.5%
2006	193	*	*	*	*	30.8%	43.9%	*	*	*	*	25.7%	36.6%	1.9%	2.7%	33.5%	47.7%	20.7%	29.5%
2006	194	0.4%	0.5%	*	*	33.1%	45.8%	*	*	0.7%	0.9%	25.3%	35.0%	1.2%	1.7%	42.5%	58.8%	19.4%	26.9%
2006	195	*	*	*	*	35.9%	48.3%	*	*	1.5%	2.1%	26.1%	35.1%	1.2%	1.6%	38.1%	51.3%	21.6%	29.0%
2006	196	*	*	*	*	35.4%	47.5%	*	*	1.8%	2.5%	22.3%	29.9%	1.7%	2.3%	36.0%	48.3%	32.8%	44.0%
2006	197	*	*	*	*	31.8%	44.9%	*	*	0.8%	1.1%	28.0%	39.6%	1.5%	2.0%	38.0%	53.7%	18.5%	26.1%
2006	200	0.7%	1.0%	0.3%	0.4%	33.7%	47.2%	*	*	1.9%	2.7%	26.7%	37.4%	1.1%	1.6%	33.9%	47.4%	21.9%	30.7%
2006	201	0.3%	0.4%	0.8%	1.0%	33.4%	44.7%	0.1%	0.1%	2.0%	2.7%	31.5%	42.2%	2.1%	2.9%	33.3%	44.7%	21.4%	28.7%
2006	203	0.5%	0.7%	*	*	37.1%	51.7%	0.3%	0.5%	0.7%	1.0%	28.6%	39.9%	3.6%	5.0%	33.9%	47.3%	22.1%	30.8%
2006	204	0.6%	0.8%	0.2%	0.3%	38.1%	54.0%	0.2%	0.3%	1.8%	2.5%	25.6%	36.3%	2.5%	3.5%	36.1%	51.2%	23.8%	33.7%
2006	205	0.4%	0.6%	0.2%	0.3%	34.0%	49.0%	0.2%	0.2%	1.0%	1.4%	26.0%	37.5%	2.3%	3.4%	34.3%	49.4%	23.3%	33.5%
2006	207	*	*	1.0%	1.6%	30.8%	46.4%	*	*	3.2%	4.8%	24.8%	37.4%	4.8%	7.3%	27.3%	41.2%	20.7%	31.2%
2006	208	0.4%	0.6%	0.3%	0.5%	33.5%	47.5%	0.2%	0.3%	1.4%	2.0%	26.0%	36.8%	1.5%	2.2%	34.6%	49.1%	23.5%	33.3%
2006	209	0.4%	0.5%	*	*	29.9%	42.9%	*	*	0.4%	0.5%	29.6%	42.6%	2.1%	3.0%	36.0%	51.7%	20.8%	29.9%
2006	210	0.5%	0.8%	0.3%	0.4%	32.7%	48.0%	*	*	1.6%	2.3%	26.9%	39.5%	3.0%	4.4%	29.1%	42.6%	25.1%	36.8%
2006	212	0.6%	0.9%	*	*	35.1%	49.8%	*	*	1.2%	1.8%	27.1%	38.5%	3.8%	5.4%	36.5%	51.8%	23.0%	32.6%
2006	213	0.4%	0.6%	0.2%	0.2%	33.4%	48.6%	0.1%	0.2%	1.7%	2.5%	24.2%	35.3%	4.2%	6.1%	34.5%	50.4%	27.0%	39.4%
2006	214	0.5%	0.7%	*	*	33.7%	49.5%	*	*	1.1%	1.5%	27.9%	41.0%	2.1%	3.1%	34.4%	50.5%	21.0%	30.8%
2006	216	0.6%	0.9%	*	*	30.8%	46.8%	*	*	1.0%	1.6%	25.5%	38.7%	3.8%	5.8%	32.2%	48.9%	17.5%	26.6%
2006	217	0.3%	0.4%	*	*	30.7%	44.6%	0.2%	0.3%	1.7%	2.4%	26.9%	39.1%	2.9%	4.2%	32.4%	47.2%	27.9%	40.6%
2006	218	0.6%	1.0%	*	*	29.9%	46.6%	*	*	0.7%	1.1%	29.0%	45.2%	3.3%	5.1%	30.5%	47.6%	16.2%	25.3%
2006	219	0.3%	0.5%	*	*	32.9%	48.2%	*	*	0.7%	1.1%	27.4%	40.1%	2.2%	3.3%	30.3%	44.4%	23.3%	34.1%
2006	220	*	*	*	*	37.1%	55.6%	*	*	1.2%	1.7%	25.8%	38.6%	1.9%	2.8%	30.7%	46.0%	19.9%	29.8%
2006	221	0.5%	0.7%	*	*	37.9%	57.3%	*	*	0.6%	0.9%	21.5%	32.5%	0.7%	1.1%	31.6%	47.9%	18.5%	28.1%
2006	222	0.4%	0.6%	0.1%	0.1%	34.0%	51.3%	0.1%	0.1%	1.2%	1.8%	22.8%	34.3%	0.9%	1.3%	34.2%	51.6%	17.4%	26.2%
2006	223	0.6%	0.9%	0.1%	0.1%	29.8%	47.9%	0.1%	0.2%	0.7%	1.1%	21.1%	33.9%	1.8%	2.8%	32.2%	51.8%	18.6%	30.0%
2006	225	0.4%	0.6%	*	*	29.4%	43.5%	0.2%	0.3%	1.8%	2.7%	22.0%	32.6%	2.2%	3.3%	35.0%	51.8%	21.9%	32.5%
2006	226	0.7%	1.1%	*	*	33.5%	52.3%	*	*	0.6%	1.0%	21.8%	34.0%	2.9%	4.6%	33.5%	52.3%	21.4%	33.5%
2006	227	0.4%	0.6%	0.1%	0.1%	33.3%	51.6%	0.1%	0.1%	0.5%	0.8%	22.9%	35.4%	1.1%	1.7%	31.0%	47.9%	18.0%	27.9%
2006	230	0.3%	0.5%	0.2%	0.3%	33.0%	48.4%	*	*	0.4%	0.6%	26.1%	38.3%	0.8%	1.2%	33.3%	48.9%	22.8%	33.5%
2006	231	0.2%	0.3%	*	*	35.2%	52.6%	*	*	0.3%	0.5%	24.9%	37.3%	0.5%	0.8%	32.6%	48.7%	19.0%	28.3%
2006	232	0.3%	0.5%	0.1%	0.2%	32.7%	51.6%	*	*	1.0%	1.5%	23.7%	37.5%	2.2%	3.4%	30.4%	48.0%	17.7%	28.0%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	233	0.4%	0.7%	*	*	32.1%	56.4%	*	*	0.5%	0.8%	19.5%	34.1%	1.4%	2.5%	29.3%	51.4%	18.0%	31.6%
2006	234	0.4%	0.8%	*	*	26.5%	47.5%	0.1%	0.2%	0.4%	0.6%	22.6%	40.4%	1.8%	3.2%	27.2%	48.8%	15.4%	27.6%
2006	235	0.4%	0.7%	*	*	28.7%	47.3%	*	*	1.5%	2.4%	23.6%	38.9%	1.1%	1.8%	30.2%	49.7%	17.0%	27.9%
2006	236	0.2%	0.3%	0.1%	0.2%	35.5%	48.7%	*	*	0.8%	1.1%	27.7%	38.0%	1.8%	2.4%	33.6%	46.2%	25.7%	35.3%
2006	238	0.5%	0.6%	*	*	37.3%	50.1%	0.2%	0.2%	1.2%	1.6%	28.8%	38.6%	2.2%	3.0%	33.9%	45.5%	27.2%	36.5%
2006	239	0.6%	0.8%	0.2%	0.2%	37.7%	51.3%	0.2%	0.3%	1.0%	1.3%	27.0%	36.7%	2.0%	2.7%	35.8%	48.7%	26.1%	35.5%
2006	240	0.4%	0.6%	*	*	35.6%	48.8%	*	*	0.5%	0.7%	27.8%	38.2%	1.6%	2.2%	31.6%	43.4%	22.1%	30.3%
2006	242	0.6%	0.8%	*	*	30.0%	41.9%	*	*	0.5%	0.7%	30.4%	42.4%	1.3%	1.9%	31.9%	44.5%	25.0%	34.9%
2006	243	0.5%	0.8%	*	*	34.0%	51.6%	*	*	1.4%	2.1%	24.5%	37.3%	2.0%	3.0%	29.7%	45.1%	21.0%	31.9%
2006	244	0.5%	0.9%	*	*	28.9%	49.5%	*	*	0.9%	1.6%	21.1%	36.2%	2.2%	3.8%	26.0%	44.5%	17.3%	29.6%
2006	245	0.5%	1.0%	0.1%	0.3%	26.7%	50.7%	0.2%	0.4%	0.9%	1.6%	17.1%	32.4%	3.3%	6.2%	26.0%	49.3%	15.3%	29.2%
2006	246	0.5%	0.7%	0.2%	0.3%	33.1%	49.1%	*	*	1.4%	2.1%	25.5%	37.8%	1.8%	2.7%	33.5%	49.8%	20.6%	30.6%
2006	248	0.7%	1.0%	*	*	38.0%	51.2%	*	*	1.1%	1.5%	25.8%	34.7%	2.8%	3.8%	36.5%	49.2%	30.7%	41.4%
2006	249	*	*	*	*	41.0%	56.8%	*	*	3.5%	4.8%	22.5%	31.2%	2.3%	3.2%	33.2%	45.9%	23.9%	33.0%
2006	250	*	*	*	*	33.7%	49.9%	*	*	0.9%	1.3%	26.1%	38.7%	0.7%	1.1%	33.7%	49.9%	15.8%	23.4%
2006	251	0.2%	0.3%	0.1%	0.1%	35.9%	50.7%	0.1%	0.1%	1.1%	1.6%	25.4%	35.8%	0.9%	1.3%	33.9%	47.9%	20.3%	28.7%
2006	253	*	*	*	*	33.5%	47.4%	*	*	0.7%	1.0%	27.7%	39.2%	0.8%	1.2%	34.4%	48.6%	12.3%	17.4%
2006	254	*	*	*	*	38.1%	53.1%	*	*	1.2%	1.7%	24.1%	33.6%	2.2%	3.1%	33.7%	46.9%	21.5%	30.0%
2006	256	0.5%	0.7%	*	*	34.8%	49.6%	*	*	1.3%	1.9%	28.3%	40.4%	0.9%	1.4%	32.7%	46.7%	21.2%	30.2%
2006	257	*	*	*	*	30.7%	46.0%	*	*	1.8%	2.7%	23.7%	35.5%	1.7%	2.5%	32.3%	48.3%	22.2%	33.2%
2006	258	0.4%	0.6%	*	*	34.1%	47.0%	*	*	0.4%	0.5%	27.1%	37.4%	1.1%	1.6%	38.6%	53.2%	20.4%	28.1%
2006	259	0.3%	0.4%	*	*	33.3%	46.6%	0.1%	0.2%	1.1%	1.5%	28.0%	39.1%	2.0%	2.7%	34.0%	47.6%	23.2%	32.4%
2006	260	0.5%	0.7%	*	*	33.4%	44.5%	*	*	0.9%	1.2%	28.5%	37.9%	1.6%	2.1%	39.5%	52.5%	25.5%	33.9%
2006	261	*	*	*	*	36.9%	51.1%	*	*	1.4%	1.9%	25.5%	35.3%	2.6%	3.6%	31.0%	43.0%	26.2%	36.3%
2006	262	0.3%	0.4%	0.2%	0.3%	36.7%	51.2%	*	*	1.9%	2.6%	25.7%	35.8%	3.3%	4.6%	31.2%	43.5%	20.3%	28.2%
2006	263	1.1%	1.5%	*	*	33.9%	48.1%	*	*	1.1%	1.5%	27.3%	38.7%	2.0%	2.9%	36.6%	51.9%	24.4%	34.6%
2006	264	0.4%	0.6%	0.3%	0.4%	36.5%	51.8%	0.1%	0.2%	1.7%	2.4%	25.7%	36.5%	1.6%	2.3%	35.9%	51.1%	21.4%	30.5%
2006	267	0.3%	0.5%	0.5%	0.7%	36.8%	53.4%	*	*	2.3%	3.4%	24.3%	35.2%	2.2%	3.2%	33.4%	48.4%	25.5%	37.0%
2006	268	0.4%	0.6%	0.2%	0.3%	34.4%	48.3%	0.1%	0.2%	1.0%	1.3%	29.4%	41.3%	1.5%	2.1%	34.6%	48.7%	20.2%	28.4%
2006	270	0.6%	0.9%	0.3%	0.5%	40.5%	56.7%	0.1%	0.2%	2.5%	3.5%	25.7%	36.0%	1.7%	2.4%	35.4%	49.5%	22.1%	30.9%
2006	273	0.7%	0.9%	0.1%	0.2%	33.0%	48.1%	0.1%	0.1%	1.1%	1.6%	26.9%	39.2%	1.8%	2.6%	36.0%	52.4%	19.9%	29.0%
2006	274	0.3%	0.4%	*	*	40.9%	55.0%	*	*	2.4%	3.2%	26.7%	35.8%	1.3%	1.7%	32.3%	43.3%	21.7%	29.2%
2006	275	*	*	*	*	37.3%	51.9%	*	*	0.9%	1.3%	26.2%	36.5%	*	*	34.2%	47.6%	26.8%	37.3%
2006	276	*	*	*	*	38.6%	53.0%	*	*	1.6%	2.2%	26.0%	35.8%	1.2%	1.6%	31.2%	42.8%	24.0%	33.0%
2006	277	0.4%	0.6%	*	*	32.2%	43.8%	*	*	1.2%	1.6%	27.2%	37.0%	1.8%	2.4%	35.5%	48.3%	26.6%	36.2%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	278	0.4%	0.6%	0.1%	0.2%	33.2%	46.0%	0.1%	0.2%	1.3%	1.8%	26.6%	36.9%	2.0%	2.8%	35.4%	49.1%	25.0%	34.6%
2006	279	0.7%	1.0%	0.2%	0.3%	35.3%	53.9%	0.2%	0.3%	1.6%	2.5%	20.4%	31.1%	1.9%	3.0%	33.2%	50.6%	24.3%	37.0%
2006	280	0.7%	1.0%	*	*	39.7%	57.8%	*	*	0.8%	1.2%	21.2%	30.8%	1.9%	2.8%	30.2%	44.0%	22.8%	33.3%
2006	281	0.6%	0.8%	0.2%	0.3%	35.3%	51.9%	*	*	0.7%	1.0%	23.8%	35.0%	1.0%	1.4%	32.5%	47.9%	17.1%	25.1%
2006	282	0.4%	0.6%	*	*	34.5%	51.4%	*	*	1.4%	2.1%	23.6%	35.2%	1.5%	2.2%	31.7%	47.2%	19.3%	28.8%
2006	283	0.7%	1.1%	0.1%	0.1%	26.7%	44.2%	0.2%	0.4%	1.2%	1.9%	18.6%	30.8%	8.3%	13.7%	30.0%	49.7%	21.0%	34.8%
2006	284	0.8%	1.4%	0.1%	0.1%	29.5%	51.6%	0.3%	0.5%	1.1%	1.9%	14.7%	25.7%	5.4%	9.4%	31.3%	54.7%	23.6%	41.3%
2006	285	0.6%	1.0%	*	*	30.8%	50.1%	0.2%	0.4%	1.0%	1.6%	17.3%	28.1%	4.9%	7.9%	33.1%	53.9%	20.7%	33.6%
2006	288	1.0%	1.7%	0.1%	0.2%	30.0%	50.2%	0.3%	0.6%	1.4%	2.3%	17.4%	29.1%	8.4%	14.1%	30.8%	51.6%	19.9%	33.2%
2006	289	0.9%	1.4%	0.1%	0.2%	28.2%	47.4%	0.3%	0.4%	1.2%	2.1%	19.5%	32.9%	6.1%	10.3%	31.2%	52.5%	22.8%	38.3%
2006	291	0.7%	1.2%	*	*	32.4%	52.9%	0.2%	0.4%	0.5%	0.8%	17.6%	28.7%	3.3%	5.3%	35.5%	57.9%	23.1%	37.8%
2006	292	0.5%	0.9%	*	*	26.9%	49.1%	0.3%	0.6%	1.3%	2.4%	16.9%	30.8%	4.1%	7.4%	28.2%	51.4%	15.9%	29.0%
2006	293	0.2%	0.3%	*	*	36.2%	53.1%	*	*	0.4%	0.6%	26.2%	38.4%	0.8%	1.2%	34.6%	50.7%	22.4%	32.8%
2006	295	0.5%	0.7%	0.2%	0.3%	31.0%	46.4%	0.2%	0.3%	2.1%	3.1%	26.8%	40.0%	3.0%	4.5%	30.7%	45.9%	20.2%	30.1%
2006	296	0.7%	1.0%	*	*	33.8%	48.6%	*	*	2.4%	3.5%	25.3%	36.3%	4.2%	6.0%	33.2%	47.7%	25.7%	36.9%
2006	297	0.8%	1.3%	0.1%	0.1%	34.5%	54.5%	0.2%	0.2%	0.6%	1.0%	24.0%	37.8%	2.4%	3.8%	31.7%	50.1%	22.7%	35.8%
2006	299	0.5%	0.7%	*	*	38.2%	54.8%	0.1%	0.2%	1.7%	2.5%	27.3%	39.1%	1.9%	2.7%	32.4%	46.5%	21.2%	30.4%
2006	300	0.8%	1.2%	0.3%	0.5%	30.8%	45.5%	0.5%	0.7%	1.9%	2.9%	26.4%	39.0%	4.6%	6.8%	33.7%	49.8%	19.2%	28.4%
2006	301	0.9%	1.8%	0.1%	0.2%	26.9%	50.9%	0.2%	0.4%	0.7%	1.4%	16.2%	30.7%	3.2%	6.1%	29.2%	55.3%	17.7%	33.5%
2006	303	1.6%	2.8%	0.1%	0.2%	31.0%	54.7%	0.2%	0.4%	0.8%	1.3%	16.8%	29.6%	3.9%	6.9%	30.8%	54.3%	22.5%	39.7%
2006	304	0.8%	1.1%	*	*	33.9%	49.8%	0.2%	0.2%	0.7%	1.0%	25.4%	37.3%	2.1%	3.1%	32.9%	48.4%	20.9%	30.8%
2006	307	0.5%	0.7%	0.2%	0.3%	31.4%	45.2%	0.3%	0.4%	1.9%	2.7%	29.2%	42.0%	2.2%	3.2%	31.2%	44.9%	20.8%	29.9%
2006	308	0.7%	1.1%	0.2%	0.3%	29.1%	49.4%	0.2%	0.3%	1.4%	2.3%	20.0%	34.0%	3.0%	5.0%	29.7%	50.4%	20.2%	34.3%
2006	309	0.4%	0.5%	0.4%	0.5%	35.1%	48.8%	0.2%	0.2%	1.3%	1.8%	27.4%	38.1%	2.8%	3.8%	33.3%	46.3%	25.0%	34.8%
2006	311	0.3%	0.4%	0.2%	0.3%	34.6%	48.4%	0.1%	0.2%	1.4%	1.9%	27.6%	38.6%	2.3%	3.2%	34.8%	48.6%	23.6%	33.0%
2006	312	0.4%	0.6%	0.1%	0.2%	31.7%	44.8%	0.1%	0.1%	1.0%	1.4%	28.8%	40.8%	2.2%	3.1%	35.3%	50.0%	21.5%	30.4%
2006	313	0.4%	0.6%	*	*	31.7%	45.5%	*	*	0.9%	1.3%	26.9%	38.5%	1.8%	2.6%	38.3%	55.0%	24.2%	34.7%
2006	314	0.4%	0.6%	0.2%	0.2%	31.6%	43.2%	0.1%	0.2%	1.2%	1.7%	28.9%	39.6%	2.5%	3.4%	35.3%	48.3%	24.1%	32.9%
2006	315	0.2%	0.3%	*	*	34.5%	48.3%	*	*	1.2%	1.7%	25.7%	36.0%	1.8%	2.5%	36.8%	51.7%	25.1%	35.3%
2006	318	0.5%	0.7%	0.2%	0.3%	33.1%	46.6%	0.1%	0.2%	1.2%	1.7%	28.7%	40.4%	2.8%	4.0%	35.1%	49.4%	24.3%	34.2%
2006	319	0.2%	0.3%	0.6%	0.8%	31.2%	44.9%	0.2%	0.3%	1.5%	2.1%	28.3%	40.7%	4.8%	7.0%	31.2%	44.9%	22.5%	32.4%
2006	320	0.3%	0.5%	0.2%	0.2%	32.9%	46.8%	0.2%	0.3%	1.3%	1.9%	26.4%	37.6%	1.6%	2.3%	36.3%	51.7%	22.8%	32.5%
2006	321	*	*	*	*	30.2%	41.2%	*	*	1.8%	2.5%	29.9%	40.9%	0.6%	0.9%	37.9%	51.8%	17.3%	23.7%
2006	322	0.6%	0.8%	*	*	32.3%	44.8%	*	*	0.7%	0.9%	28.9%	40.1%	0.8%	1.1%	35.2%	48.8%	15.2%	21.0%
2006	323	*	*	*	*	34.5%	46.5%	*	*	1.4%	1.8%	29.5%	39.7%	0.6%	0.8%	38.5%	51.8%	18.2%	24.5%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	324	*	*	*	*	37.7%	52.1%	*	*	*	*	27.6%	38.3%	1.1%	1.5%	34.7%	48.0%	14.9%	20.6%
2006	325	0.9%	1.3%	*	*	29.9%	43.1%	*	*	0.7%	1.1%	29.4%	42.3%	2.6%	3.8%	32.4%	46.6%	21.7%	31.2%
2006	326	0.5%	0.7%	*	*	31.3%	42.9%	*	*	1.3%	1.8%	30.5%	41.8%	2.6%	3.5%	34.7%	47.5%	23.6%	32.4%
2006	327	0.5%	0.8%	0.2%	0.3%	33.9%	48.3%	0.2%	0.3%	1.4%	2.1%	29.3%	41.8%	2.3%	3.3%	33.5%	47.8%	22.4%	31.9%
2006	328	0.5%	0.8%	0.1%	0.1%	29.0%	42.3%	0.1%	0.1%	0.7%	1.1%	30.9%	45.1%	1.7%	2.4%	33.8%	49.2%	19.0%	27.7%
2006	329	0.7%	1.0%	0.2%	0.3%	33.4%	47.7%	0.3%	0.4%	2.2%	3.1%	28.0%	39.9%	2.6%	3.7%	35.5%	50.7%	26.0%	37.1%
2006	330	0.7%	1.0%	0.1%	0.2%	31.8%	45.2%	0.2%	0.3%	2.1%	2.9%	30.1%	42.8%	2.5%	3.6%	35.7%	50.7%	22.5%	32.0%
2006	331	*	*	*	*	37.5%	51.0%	*	*	1.7%	2.3%	31.8%	43.2%	2.7%	3.6%	34.6%	47.0%	22.6%	30.7%
2006	332	*	*	*	*	32.2%	47.2%	*	*	0.9%	1.4%	27.9%	41.0%	2.5%	3.7%	30.9%	45.4%	23.3%	34.3%
2006	334	0.6%	0.8%	*	*	34.0%	48.5%	0.2%	0.3%	1.8%	2.5%	28.5%	40.6%	2.5%	3.6%	35.2%	50.1%	19.1%	27.2%
2006	335	0.2%	0.3%	0.4%	0.6%	27.3%	41.5%	*	*	1.4%	2.2%	29.0%	44.1%	3.2%	4.9%	32.0%	48.7%	18.2%	27.6%
2006	336	*	*	*	*	32.3%	48.6%	*	*	0.5%	0.7%	20.6%	31.1%	2.3%	3.5%	29.6%	44.5%	30.6%	46.1%
2006	339	0.4%	0.5%	*	*	36.1%	52.3%	0.1%	0.2%	1.2%	1.7%	21.6%	31.3%	1.5%	2.2%	34.3%	49.6%	27.5%	39.8%
2006	340	0.4%	0.6%	0.1%	0.1%	36.1%	52.7%	*	*	1.3%	1.8%	23.2%	33.9%	2.5%	3.6%	32.2%	47.1%	24.5%	35.8%
2006	341	*	*	*	*	40.8%	59.7%	*	*	1.6%	2.3%	21.1%	30.8%	*	*	31.4%	45.9%	19.4%	28.3%
2006	342	0.4%	0.6%	*	*	35.6%	53.8%	*	*	0.8%	1.3%	22.2%	33.6%	0.8%	1.2%	32.9%	49.8%	17.0%	25.7%
2006	343	0.4%	0.6%	*	*	40.2%	59.3%	*	*	1.6%	2.3%	22.9%	33.8%	1.2%	1.7%	28.9%	42.6%	21.9%	32.2%
2006	344	0.5%	0.8%	0.2%	0.3%	38.2%	54.7%	*	*	1.4%	2.0%	26.3%	37.6%	1.0%	1.4%	32.6%	46.6%	18.6%	26.6%
2006	345	*	*	*	*	38.0%	56.0%	*	*	1.2%	1.8%	24.4%	36.0%	1.1%	1.6%	35.2%	51.9%	16.5%	24.3%
2006	346	0.6%	1.0%	*	*	29.4%	44.6%	0.2%	0.4%	0.9%	1.4%	24.2%	36.6%	4.6%	7.0%	33.4%	50.6%	18.5%	28.0%
2006	347	0.4%	0.5%	*	*	39.1%	55.3%	*	*	0.9%	1.2%	25.1%	35.5%	2.9%	4.2%	32.0%	45.2%	22.5%	31.8%
2006	350	0.4%	0.6%	*	*	34.0%	50.1%	*	*	0.7%	1.0%	25.2%	37.2%	2.3%	3.4%	33.1%	48.8%	19.9%	29.4%
2006	351	0.5%	0.8%	0.2%	0.3%	31.0%	45.1%	*	*	0.9%	1.3%	27.7%	40.3%	2.8%	4.1%	33.0%	48.0%	21.6%	31.3%
2006	352	0.5%	0.8%	*	*	30.3%	45.4%	0.1%	0.2%	0.9%	1.3%	23.9%	35.8%	1.5%	2.3%	36.3%	54.3%	21.2%	31.8%
2006	354	*	*	*	*	32.2%	49.3%	*	*	0.6%	1.0%	24.3%	37.2%	2.2%	3.4%	33.3%	51.0%	19.3%	29.6%
2006	355	0.6%	0.9%	*	*	31.2%	47.0%	0.2%	0.4%	0.6%	0.9%	23.0%	34.7%	2.3%	3.5%	34.9%	52.6%	19.0%	28.7%
2006	356	0.6%	1.0%	0.1%	0.1%	24.7%	42.9%	0.2%	0.3%	0.7%	1.3%	21.5%	37.3%	4.7%	8.1%	27.8%	48.2%	16.7%	29.0%
2006	357	0.6%	0.9%	0.1%	0.1%	28.3%	43.6%	0.1%	0.2%	0.9%	1.4%	26.0%	40.1%	5.0%	7.8%	31.2%	48.2%	18.0%	27.7%
2006	358	0.7%	1.0%	*	*	30.4%	45.6%	0.2%	0.4%	0.7%	1.0%	23.8%	35.7%	2.6%	3.9%	36.7%	55.0%	20.3%	30.5%
2006	359	*	*	*	*	33.9%	49.0%	*	*	2.3%	3.3%	27.0%	39.0%	3.7%	5.4%	33.6%	48.5%	25.5%	36.8%
2006	360	0.3%	0.4%	*	*	35.9%	51.4%	*	*	1.1%	1.6%	26.8%	38.3%	4.3%	6.2%	35.7%	51.1%	20.6%	29.6%
2006	362	1.7%	2.4%	*	*	29.4%	43.2%	*	*	1.4%	2.1%	27.8%	40.7%	6.9%	10.1%	32.6%	47.9%	17.1%	25.0%
2006	363	0.6%	1.0%	*	*	33.5%	50.5%	*	*	0.7%	1.0%	21.2%	31.9%	2.0%	3.1%	37.0%	55.8%	21.1%	31.7%
2006	364	0.7%	1.1%	0.1%	0.2%	29.2%	44.0%	*	*	0.4%	0.6%	24.7%	37.2%	2.4%	3.7%	35.0%	52.7%	19.9%	29.9%
2006	365	0.4%	0.5%	0.2%	0.2%	32.8%	45.6%	0.2%	0.2%	1.2%	1.7%	29.4%	40.8%	2.4%	3.4%	34.2%	47.6%	20.5%	28.5%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	366	0.2%	0.3%	0.2%	0.3%	31.7%	43.9%	0.1%	0.2%	1.4%	2.0%	28.8%	39.9%	3.6%	5.0%	32.1%	44.5%	25.8%	35.8%
2006	367	0.2%	0.3%	0.2%	0.2%	35.1%	46.8%	0.2%	0.2%	0.9%	1.2%	33.2%	44.2%	3.6%	4.8%	30.9%	41.1%	24.6%	32.8%
2006	368	0.4%	0.5%	0.2%	0.3%	34.1%	48.0%	0.2%	0.3%	1.1%	1.5%	26.8%	37.8%	2.1%	2.9%	34.8%	49.1%	23.3%	32.8%
2006	369	0.3%	0.4%	*	*	33.0%	44.8%	0.2%	0.3%	1.3%	1.8%	27.4%	37.2%	1.9%	2.6%	36.2%	49.2%	24.9%	33.8%
2006	370	*	*	*	*	34.9%	48.2%	*	*	1.8%	2.4%	25.3%	34.9%	1.4%	2.0%	32.5%	44.8%	26.2%	36.2%
2006	371	0.2%	0.3%	*	*	32.4%	45.3%	*	*	1.0%	1.4%	25.4%	35.4%	1.3%	1.8%	36.3%	50.6%	22.3%	31.1%
2006	373	0.4%	0.5%	0.3%	0.4%	35.2%	51.1%	0.2%	0.3%	2.7%	3.9%	25.1%	36.4%	3.4%	5.0%	32.5%	47.1%	21.1%	30.7%
2006	374	0.6%	0.8%	*	*	35.8%	49.9%	*	*	1.1%	1.5%	27.2%	38.0%	1.3%	1.8%	37.1%	51.7%	26.3%	36.7%
2006	375	0.3%	0.4%	*	*	36.8%	54.4%	0.2%	0.4%	1.9%	2.8%	25.1%	37.1%	1.3%	2.0%	33.8%	50.0%	20.2%	29.9%
2006	376	0.4%	0.6%	0.4%	0.6%	37.6%	53.6%	0.2%	0.3%	2.8%	4.0%	25.5%	36.4%	2.5%	3.5%	35.0%	49.9%	22.6%	32.3%
2006	377	0.5%	0.7%	0.1%	0.2%	38.0%	52.2%	0.2%	0.3%	3.1%	4.2%	28.3%	38.8%	2.3%	3.1%	34.7%	47.6%	24.3%	33.4%
2006	379	0.5%	0.7%	0.1%	0.1%	32.1%	45.4%	0.1%	0.2%	1.2%	1.7%	27.7%	39.2%	2.5%	3.5%	35.2%	49.8%	23.8%	33.7%
2006	380	0.5%	0.7%	0.1%	0.2%	36.0%	50.9%	0.1%	0.2%	1.9%	2.6%	27.3%	38.6%	3.2%	4.5%	32.7%	46.2%	21.8%	30.9%
2006	382	*	*	*	*	36.7%	52.5%	*	*	2.2%	3.1%	25.3%	36.2%	1.0%	1.4%	34.3%	49.1%	22.2%	31.8%
2006	383	0.9%	1.3%	*	*	36.3%	48.9%	*	*	1.3%	1.8%	28.6%	38.5%	2.9%	3.9%	34.0%	45.8%	27.5%	37.0%
2006	385	0.4%	0.6%	*	*	31.5%	45.1%	*	*	1.3%	1.9%	27.0%	38.6%	1.8%	2.6%	34.6%	49.6%	24.6%	35.3%
2006	386	0.3%	0.5%	*	*	32.8%	49.2%	0.3%	0.5%	2.7%	4.0%	26.5%	39.8%	5.1%	7.6%	26.2%	39.3%	21.8%	32.7%
2006	388	*	*	*	*	35.8%	51.0%	*	*	2.9%	4.1%	27.1%	38.6%	1.7%	2.4%	31.7%	45.1%	23.5%	33.5%
2006	390	0.3%	0.5%	*	*	32.5%	46.7%	0.1%	0.2%	1.1%	1.5%	29.0%	41.6%	1.7%	2.5%	32.9%	47.2%	22.5%	32.3%
2006	391	0.3%	0.4%	0.1%	0.1%	31.8%	47.0%	0.1%	0.1%	0.9%	1.3%	27.2%	40.2%	1.6%	2.3%	31.6%	46.8%	20.6%	30.4%
2006	393	0.7%	1.0%	*	*	39.1%	55.9%	0.1%	0.2%	0.4%	0.5%	24.7%	35.3%	1.7%	2.5%	34.4%	49.1%	25.7%	36.8%
2006	394	0.3%	0.5%	0.1%	0.1%	32.0%	48.2%	0.1%	0.1%	0.8%	1.1%	27.8%	41.9%	2.2%	3.3%	31.0%	46.8%	19.4%	29.3%
2006	396	0.5%	0.8%	*	*	36.2%	52.8%	*	*	1.3%	1.8%	25.0%	36.5%	2.6%	3.7%	35.4%	51.7%	22.8%	33.3%
2006	397	0.4%	0.6%	0.1%	0.1%	32.2%	48.3%	0.2%	0.2%	1.4%	2.1%	26.0%	39.0%	2.9%	4.3%	33.2%	49.8%	19.6%	29.3%
2006	399	*	*	*	*	31.8%	45.8%	*	*	2.6%	3.8%	28.7%	41.4%	1.4%	2.0%	35.6%	51.2%	20.2%	29.0%
2006	400	0.2%	0.3%	*	*	38.6%	53.7%	*	*	1.2%	1.6%	26.4%	36.7%	2.1%	3.0%	35.2%	48.9%	23.3%	32.4%
2006	402	0.6%	0.9%	0.2%	0.3%	35.4%	52.1%	0.2%	0.3%	2.1%	3.1%	25.1%	37.0%	4.5%	6.6%	37.0%	54.5%	25.5%	37.6%
2006	406	0.3%	0.4%	*	*	41.5%	56.4%	*	*	1.6%	2.2%	26.4%	35.8%	3.0%	4.1%	36.6%	49.6%	24.3%	33.0%
2006	411	*	*	*	*	32.9%	46.3%	*	*	0.8%	1.2%	27.3%	38.4%	1.6%	2.2%	37.4%	52.6%	18.8%	26.5%
2006	412	0.8%	1.2%	0.1%	0.2%	31.7%	46.4%	0.1%	0.2%	1.0%	1.5%	25.6%	37.5%	2.2%	3.3%	33.1%	48.6%	25.0%	36.7%
2006	413	*	*	*	*	33.2%	47.7%	*	*	0.8%	1.1%	30.0%	43.1%	0.7%	1.0%	35.2%	50.5%	15.2%	21.8%
2006	416	0.2%	0.2%	0.2%	0.3%	32.2%	46.3%	*	*	3.0%	4.4%	27.6%	39.7%	2.0%	2.9%	33.1%	47.5%	21.8%	31.3%
2006	417	0.8%	1.2%	*	*	35.5%	52.6%	0.4%	0.6%	0.9%	1.3%	22.4%	33.1%	2.9%	4.4%	29.0%	42.9%	29.4%	43.5%
2006	418	*	*	*	*	31.9%	45.4%	*	*	0.5%	0.7%	29.2%	41.6%	1.5%	2.1%	31.7%	45.1%	20.8%	29.6%
2006	420	*	*	*	*	32.6%	46.6%	*	*	1.2%	1.7%	27.7%	39.6%	2.8%	3.9%	30.8%	44.1%	26.4%	37.7%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2006	421	*	*	*	*	41.2%	55.3%	*	*	1.1%	1.5%	25.8%	34.7%	0.9%	1.2%	32.2%	43.2%	26.8%	36.0%
2006	422	*	*	*	*	43.8%	59.9%	*	*	1.1%	1.4%	24.8%	33.9%	1.2%	1.6%	30.3%	41.4%	27.4%	37.4%
2006	423	0.3%	0.4%	0.1%	0.2%	42.3%	58.6%	0.2%	0.3%	1.4%	2.0%	23.7%	32.9%	1.2%	1.6%	30.6%	42.4%	25.2%	34.8%
2006	424	0.6%	0.9%	0.2%	0.3%	35.3%	52.0%	*	*	0.9%	1.4%	23.5%	34.6%	0.9%	1.3%	32.9%	48.6%	22.8%	33.6%
2006	426	0.6%	0.9%	*	*	32.4%	47.6%	*	*	0.7%	1.1%	23.0%	33.7%	2.7%	4.0%	37.1%	54.5%	22.5%	33.0%
2006	427	0.3%	0.5%	*	*	38.6%	54.8%	0.2%	0.2%	0.6%	0.9%	23.9%	34.0%	1.1%	1.5%	33.2%	47.1%	22.4%	31.8%
2006	428	0.3%	0.4%	*	*	30.3%	40.5%	*	*	1.1%	1.4%	28.9%	38.6%	1.1%	1.5%	39.6%	52.9%	22.3%	29.7%
2006	429	1.1%	1.5%	*	*	27.5%	40.1%	*	*	0.6%	0.8%	27.1%	39.4%	3.0%	4.4%	35.1%	51.0%	20.8%	30.3%
2006	430	1.1%	1.6%	*	*	27.6%	40.5%	0.1%	0.2%	0.7%	1.1%	27.2%	39.9%	3.3%	4.9%	33.7%	49.4%	22.4%	32.9%
2006	431	0.3%	0.4%	0.1%	0.1%	32.2%	46.6%	*	*	0.7%	1.1%	26.2%	38.0%	3.0%	4.4%	32.4%	46.9%	18.6%	27.0%
2006	432	0.7%	1.0%	0.1%	0.2%	34.5%	48.5%	0.3%	0.4%	1.5%	2.1%	25.4%	35.7%	2.4%	3.4%	37.4%	52.5%	23.3%	32.8%
2006	435	0.3%	0.4%	*	*	34.9%	48.8%	0.4%	0.6%	1.3%	1.9%	25.8%	36.1%	1.4%	1.9%	38.1%	53.3%	20.0%	28.0%
2006	437	0.5%	0.7%	*	*	36.8%	52.7%	*	*	0.7%	0.9%	29.7%	42.6%	0.5%	0.8%	33.5%	48.0%	14.8%	21.3%
2006	438	0.4%	0.5%	*	*	35.8%	53.1%	*	*	1.3%	1.9%	27.5%	40.9%	1.2%	1.8%	29.8%	44.2%	18.6%	27.7%
2006	439	0.5%	0.7%	0.1%	0.1%	37.6%	55.0%	*	*	0.9%	1.3%	25.6%	37.4%	0.8%	1.2%	32.3%	47.2%	16.4%	24.0%
2006	440	0.7%	0.9%	0.2%	0.2%	37.7%	52.9%	*	*	1.9%	2.6%	26.4%	37.0%	1.3%	1.9%	31.7%	44.4%	23.1%	32.4%
2006	441	0.6%	0.9%	0.2%	0.3%	37.6%	54.0%	*	*	1.0%	1.4%	28.3%	40.7%	1.3%	1.8%	28.0%	40.3%	20.7%	29.8%
2006	442	0.6%	0.9%	0.4%	0.5%	40.6%	57.7%	*	*	1.5%	2.2%	27.4%	39.0%	0.6%	0.8%	33.1%	47.1%	18.8%	26.7%
2006	443	0.9%	1.2%	0.2%	0.3%	34.7%	49.9%	0.2%	0.3%	1.4%	2.0%	24.9%	35.7%	2.7%	3.9%	35.7%	51.2%	25.3%	36.3%
2006	444	0.7%	1.0%	*	*	34.1%	48.0%	*	*	1.1%	1.6%	28.2%	39.7%	1.7%	2.5%	37.2%	52.3%	24.4%	34.3%
2006	445	0.3%	0.5%	*	*	30.3%	45.0%	0.2%	0.4%	0.8%	1.1%	24.1%	35.8%	2.6%	3.8%	33.7%	50.2%	24.5%	36.4%
2006	446	*	*	*	*	33.6%	51.1%	*	*	*	*	24.3%	37.0%	1.3%	2.0%	35.1%	53.5%	17.7%	27.0%
2006	447	0.4%	0.5%	*	*	35.2%	49.9%	*	*	0.7%	1.0%	27.1%	38.4%	2.5%	3.5%	35.9%	50.9%	20.1%	28.5%
2006	448	0.4%	0.5%	*	*	33.8%	47.3%	*	*	1.3%	1.8%	27.9%	39.0%	0.5%	0.7%	36.9%	51.7%	19.7%	27.5%
2006	449	0.5%	0.6%	0.1%	0.2%	35.3%	49.8%	*	*	0.7%	1.0%	27.0%	38.2%	1.3%	1.8%	35.5%	50.1%	18.3%	25.8%
2006	450	0.8%	1.1%	*	*	31.9%	45.1%	*	*	0.3%	0.4%	29.6%	41.9%	1.3%	1.8%	36.2%	51.2%	15.0%	21.2%
2006	451	0.5%	0.8%	0.1%	0.1%	31.5%	45.6%	0.1%	0.1%	0.5%	0.8%	27.5%	39.8%	2.5%	3.7%	32.5%	47.1%	20.7%	30.0%
2006	452	0.6%	0.9%	*	*	38.4%	52.9%	*	*	*	*	25.5%	35.0%	1.6%	2.2%	39.5%	54.3%	19.1%	26.2%
2006	456	*	*	*	*	33.5%	46.8%	*	*	*	*	28.4%	39.7%	1.3%	1.8%	34.5%	48.1%	20.3%	28.3%
2006	457	*	*	*	*	42.6%	57.0%	*	*	1.0%	1.3%	25.2%	33.7%	1.5%	2.0%	28.9%	38.7%	28.2%	37.7%
2007	1	0.3%	0.4%	0.1%	0.1%	36.9%	54.4%	2.2%	3.2%	1.6%	2.4%	23.6%	34.8%	1.2%	1.8%	32.0%	47.2%	20.0%	29.5%
2007	2	0.3%	0.4%	0.3%	0.4%	34.0%	48.0%	2.1%	3.0%	1.4%	2.0%	26.9%	37.9%	1.3%	1.8%	37.1%	52.3%	19.6%	27.7%
2007	5	0.1%	0.2%	*	*	35.8%	53.3%	2.1%	3.2%	1.0%	1.6%	22.6%	33.6%	1.3%	1.9%	30.5%	45.3%	20.7%	30.8%
2007	6	0.4%	0.5%	0.1%	0.2%	37.5%	53.6%	2.3%	3.3%	1.5%	2.1%	25.1%	35.9%	1.6%	2.3%	31.0%	44.3%	19.7%	28.1%
2007	7	0.4%	0.5%	0.2%	0.2%	35.2%	51.7%	1.9%	2.8%	1.1%	1.7%	24.9%	36.6%	1.1%	1.6%	33.3%	49.0%	19.9%	29.3%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	9	0.4%	0.5%	*	*	37.2%	54.6%	1.5%	2.1%	0.9%	1.4%	25.4%	37.3%	1.8%	2.7%	33.4%	48.9%	20.1%	29.4%
2007	10	0.4%	0.6%	*	*	41.4%	59.5%	3.3%	4.8%	2.7%	3.9%	24.5%	35.2%	0.9%	1.2%	28.7%	41.1%	21.8%	31.3%
2007	11	0.3%	0.4%	*	*	37.6%	57.2%	2.0%	3.1%	1.9%	2.9%	19.7%	29.9%	1.3%	1.9%	29.3%	44.6%	18.9%	28.8%
2007	12	0.4%	0.6%	0.1%	0.2%	38.6%	58.6%	1.9%	2.9%	1.4%	2.1%	20.8%	31.6%	1.4%	2.2%	30.0%	45.5%	19.6%	29.7%
2007	14	*	*	*	*	32.2%	54.9%	1.9%	3.3%	2.1%	3.6%	15.3%	26.1%	1.9%	3.2%	28.7%	49.0%	15.1%	25.7%
2007	15	0.2%	0.2%	*	*	36.1%	57.6%	2.0%	3.2%	1.1%	1.7%	20.5%	32.8%	1.1%	1.8%	29.7%	47.4%	17.6%	28.1%
2007	16	0.5%	0.7%	0.3%	0.4%	33.7%	50.9%	1.5%	2.3%	1.0%	1.6%	21.8%	32.9%	1.5%	2.2%	33.4%	50.5%	18.2%	27.6%
2007	18	0.4%	0.6%	*	*	39.7%	55.9%	3.0%	4.2%	1.2%	1.7%	23.7%	33.4%	1.4%	1.9%	38.5%	54.1%	18.3%	25.7%
2007	19	0.3%	0.4%	0.1%	0.1%	34.8%	51.2%	2.3%	3.3%	1.0%	1.5%	22.1%	32.5%	1.9%	2.8%	34.9%	51.3%	18.5%	27.2%
2007	21	0.5%	0.8%	0.3%	0.5%	37.5%	55.8%	2.2%	3.3%	2.0%	3.0%	21.7%	32.3%	2.2%	3.2%	30.2%	45.0%	17.4%	25.9%
2007	22	0.2%	0.3%	*	*	28.5%	42.4%	2.5%	3.8%	0.7%	1.0%	24.9%	37.1%	1.6%	2.4%	36.0%	53.5%	18.4%	27.4%
2007	23	1.5%	2.4%	0.2%	0.4%	37.6%	62.4%	5.1%	8.5%	1.0%	1.7%	15.2%	25.3%	3.0%	4.9%	30.2%	50.1%	23.4%	38.8%
2007	25	0.4%	0.6%	0.1%	0.1%	40.0%	61.0%	2.0%	3.0%	0.9%	1.4%	19.9%	30.3%	2.3%	3.6%	31.3%	47.7%	28.3%	43.2%
2007	31	1.2%	1.9%	0.3%	0.4%	39.0%	61.1%	2.2%	3.4%	2.4%	3.7%	18.4%	28.8%	1.5%	2.4%	26.9%	42.2%	26.1%	40.8%
2007	33	0.6%	1.0%	*	*	35.5%	59.1%	2.2%	3.6%	0.5%	0.8%	18.0%	29.9%	2.4%	4.1%	27.6%	45.9%	20.0%	33.3%
2007	43	0.9%	1.3%	0.1%	0.2%	37.3%	56.8%	1.9%	2.9%	1.2%	1.8%	21.4%	32.5%	1.8%	2.7%	28.5%	43.3%	29.8%	45.2%
2007	56	0.9%	1.5%	0.1%	0.2%	33.7%	57.8%	3.8%	6.5%	0.9%	1.5%	17.8%	30.5%	4.2%	7.3%	29.7%	50.9%	22.5%	38.7%
2007	58	0.9%	1.3%	0.1%	0.2%	40.3%	60.1%	2.2%	3.3%	1.5%	2.2%	20.4%	30.5%	2.7%	4.1%	32.7%	48.8%	28.2%	42.1%
2007	62	0.7%	1.0%	*	*	42.2%	63.0%	2.3%	3.4%	0.9%	1.4%	19.3%	28.9%	1.3%	2.0%	31.4%	46.8%	23.1%	34.4%
2007	65	1.1%	1.7%	0.1%	0.2%	35.5%	58.2%	1.9%	3.1%	0.5%	0.8%	17.2%	28.3%	2.4%	4.0%	29.6%	48.5%	22.0%	36.1%
2007	69	0.7%	1.2%	0.4%	0.7%	36.4%	62.3%	2.4%	4.2%	1.8%	3.1%	15.9%	27.2%	1.9%	3.2%	26.5%	45.5%	21.8%	37.4%
2007	73	0.5%	0.7%	*	*	39.3%	60.4%	1.2%	1.9%	1.6%	2.4%	18.5%	28.5%	2.0%	3.1%	27.5%	42.2%	24.7%	37.9%
2007	77	0.6%	0.9%	0.1%	0.1%	38.2%	58.1%	2.7%	4.1%	1.2%	1.9%	19.7%	29.9%	2.2%	3.3%	31.3%	47.6%	25.6%	38.9%
2007	78	0.4%	0.6%	0.2%	0.4%	37.0%	56.6%	2.1%	3.3%	1.7%	2.6%	19.9%	30.5%	3.9%	6.0%	30.0%	45.9%	26.5%	40.6%
2007	79	0.7%	1.1%	0.2%	0.2%	37.2%	58.9%	2.2%	3.4%	0.8%	1.3%	21.5%	34.0%	2.0%	3.1%	33.9%	53.7%	23.2%	36.8%
2007	80	0.7%	1.0%	0.2%	0.4%	41.7%	62.7%	3.1%	4.6%	1.2%	1.8%	20.1%	30.2%	2.7%	4.0%	29.7%	44.7%	27.6%	41.5%
2007	81	1.5%	2.4%	*	*	38.0%	59.0%	2.0%	3.1%	0.7%	1.0%	15.6%	24.2%	2.1%	3.2%	34.2%	53.0%	21.7%	33.6%
2007	82	1.5%	2.5%	0.1%	0.1%	37.9%	60.4%	2.2%	3.5%	0.6%	1.0%	14.9%	23.7%	3.8%	6.0%	31.5%	50.2%	23.9%	38.0%
2007	83	0.6%	1.0%	*	*	38.1%	65.9%	2.1%	3.6%	1.1%	1.9%	15.9%	27.5%	1.9%	3.3%	24.6%	42.5%	18.3%	31.7%
2007	85	1.2%	2.0%	*	*	37.1%	63.8%	2.8%	4.8%	1.3%	2.2%	12.2%	21.0%	3.3%	5.7%	27.1%	46.6%	21.3%	36.6%
2007	86	0.6%	1.0%	0.3%	0.4%	40.3%	64.3%	3.5%	5.6%	1.9%	3.1%	16.3%	26.0%	3.1%	5.0%	27.2%	43.4%	26.8%	42.8%
2007	87	0.5%	0.8%	*	*	37.2%	57.6%	1.4%	2.2%	0.7%	1.0%	19.5%	30.2%	2.2%	3.4%	33.2%	51.4%	24.3%	37.7%
2007	89	0.8%	1.2%	*	*	38.8%	61.7%	2.4%	3.7%	1.3%	2.0%	18.3%	29.1%	1.4%	2.2%	28.3%	44.9%	20.7%	32.9%
2007	91	0.9%	1.2%	0.2%	0.3%	40.7%	57.7%	2.0%	2.9%	0.8%	1.1%	23.1%	32.7%	2.8%	3.9%	34.2%	48.5%	28.1%	39.9%
2007	96	0.5%	0.8%	*	*	39.0%	62.6%	2.7%	4.3%	1.0%	1.6%	18.0%	28.9%	3.4%	5.4%	26.3%	42.2%	24.3%	38.9%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	101	*	*	*	*	43.3%	62.1%	3.0%	4.2%	1.4%	2.0%	22.9%	32.8%	1.4%	2.0%	27.0%	38.7%	23.3%	33.4%
2007	102	0.5%	0.7%	*	*	42.0%	60.3%	2.5%	3.5%	1.6%	2.2%	23.4%	33.6%	1.4%	2.1%	31.1%	44.6%	20.0%	28.8%
2007	103	0.3%	0.4%	0.1%	0.2%	39.6%	56.9%	2.6%	3.7%	1.5%	2.2%	23.1%	33.2%	1.1%	1.5%	31.4%	45.1%	21.9%	31.4%
2007	104	*	*	*	*	43.7%	59.5%	4.3%	5.9%	1.3%	1.8%	21.6%	29.4%	1.4%	1.9%	33.0%	44.9%	25.1%	34.2%
2007	105	0.5%	0.7%	*	*	40.7%	58.8%	3.1%	4.5%	1.5%	2.1%	23.9%	34.6%	0.9%	1.3%	29.8%	43.0%	16.4%	23.7%
2007	106	0.5%	0.7%	*	*	43.5%	60.6%	2.1%	3.0%	1.5%	2.2%	21.6%	30.1%	0.9%	1.2%	33.5%	46.7%	24.3%	33.8%
2007	107	*	*	0.4%	0.6%	38.6%	54.5%	3.0%	4.3%	0.9%	1.3%	28.2%	39.9%	1.5%	2.1%	31.1%	43.9%	22.2%	31.3%
2007	109	0.4%	0.6%	*	*	33.4%	53.5%	4.4%	7.1%	0.8%	1.3%	17.6%	28.1%	1.8%	2.9%	29.3%	47.0%	23.3%	37.4%
2007	110	0.3%	0.4%	0.0%	0.1%	32.4%	49.2%	2.5%	3.8%	0.8%	1.3%	23.1%	35.1%	2.4%	3.6%	30.6%	46.4%	19.5%	29.6%
2007	111	0.4%	0.6%	0.1%	0.1%	30.4%	48.8%	2.6%	4.1%	1.0%	1.6%	21.4%	34.5%	1.5%	2.5%	29.5%	47.5%	18.0%	28.9%
2007	112	0.7%	1.2%	0.1%	0.2%	29.7%	48.9%	2.4%	4.0%	1.0%	1.6%	20.2%	33.2%	3.4%	5.6%	29.3%	48.3%	17.6%	29.0%
2007	113	0.4%	0.7%	0.1%	0.1%	31.4%	50.0%	2.4%	3.9%	0.8%	1.3%	22.1%	35.1%	2.2%	3.6%	30.7%	48.9%	16.5%	26.3%
2007	115	*	*	*	*	31.1%	54.0%	3.3%	5.8%	0.7%	1.3%	17.0%	29.5%	1.0%	1.7%	28.9%	50.2%	16.5%	28.6%
2007	116	0.3%	0.6%	0.2%	0.3%	27.8%	48.8%	2.7%	4.7%	1.1%	1.9%	18.7%	32.9%	1.5%	2.7%	27.0%	47.5%	16.9%	29.7%
2007	118	0.2%	0.3%	0.3%	0.5%	25.5%	49.3%	3.0%	5.8%	1.2%	2.4%	16.8%	32.5%	3.3%	6.3%	25.0%	48.4%	14.1%	27.3%
2007	119	0.2%	0.3%	0.3%	0.4%	33.2%	55.6%	3.9%	6.5%	1.6%	2.6%	16.2%	27.1%	3.1%	5.2%	29.1%	48.7%	18.0%	30.2%
2007	120	0.3%	0.4%	0.1%	0.2%	34.8%	53.2%	2.9%	4.4%	1.4%	2.2%	22.4%	34.2%	1.9%	2.9%	32.7%	50.0%	20.2%	30.9%
2007	122	0.3%	0.5%	0.2%	0.3%	31.7%	51.7%	3.0%	4.9%	1.2%	1.9%	20.6%	33.7%	1.2%	2.0%	33.9%	55.4%	16.6%	27.1%
2007	123	0.3%	0.4%	0.2%	0.3%	33.1%	50.5%	3.1%	4.7%	1.2%	1.8%	25.2%	38.5%	2.9%	4.4%	30.0%	45.8%	16.8%	25.6%
2007	124	0.2%	0.4%	0.2%	0.3%	32.5%	51.6%	3.0%	4.8%	1.8%	2.9%	22.1%	35.0%	1.6%	2.5%	32.3%	51.3%	19.1%	30.4%
2007	127	0.3%	0.6%	0.2%	0.4%	31.0%	52.4%	2.7%	4.5%	0.9%	1.6%	28.9%	48.8%	2.9%	4.8%	28.2%	47.7%	19.3%	32.6%
2007	129	0.3%	0.4%	0.2%	0.3%	33.1%	53.4%	3.8%	6.2%	1.2%	1.9%	17.8%	28.7%	1.6%	2.6%	33.0%	53.3%	18.6%	29.9%
2007	130	0.3%	0.5%	0.3%	0.5%	32.9%	52.8%	3.0%	4.8%	1.4%	2.3%	21.1%	33.9%	2.3%	3.7%	31.8%	51.1%	18.2%	29.3%
2007	131	0.5%	0.8%	*	*	30.0%	51.0%	4.1%	7.0%	1.2%	2.1%	19.6%	33.4%	2.0%	3.4%	30.2%	51.3%	15.2%	25.8%
2007	133	0.2%	0.4%	1.1%	1.7%	33.3%	49.7%	4.2%	6.3%	2.4%	3.5%	24.5%	36.5%	1.8%	2.7%	34.1%	50.9%	21.0%	31.3%
2007	134	0.2%	0.3%	0.3%	0.4%	36.5%	52.9%	3.3%	4.8%	1.9%	2.7%	24.3%	35.2%	1.2%	1.8%	30.9%	44.9%	22.6%	32.8%
2007	137	0.2%	0.4%	0.2%	0.4%	32.0%	56.2%	3.4%	5.9%	1.5%	2.6%	15.6%	27.4%	1.7%	3.0%	26.2%	46.0%	16.5%	29.0%
2007	139	0.3%	0.5%	*	*	31.1%	51.5%	2.7%	4.5%	0.7%	1.2%	21.0%	34.8%	1.9%	3.1%	26.8%	44.5%	22.4%	37.1%
2007	140	0.2%	0.3%	0.2%	0.3%	36.2%	52.0%	2.9%	4.2%	1.8%	2.6%	26.2%	37.6%	1.6%	2.4%	33.9%	48.7%	23.2%	33.4%
2007	141	0.3%	0.5%	0.2%	0.2%	32.5%	51.4%	2.8%	4.4%	1.2%	1.9%	22.5%	35.6%	1.3%	2.1%	31.1%	49.1%	22.4%	35.4%
2007	142	0.3%	0.4%	*	*	35.6%	50.3%	2.7%	3.8%	0.9%	1.2%	27.8%	39.3%	1.7%	2.3%	35.5%	50.1%	17.7%	25.0%
2007	144	0.3%	0.5%	0.1%	0.2%	35.2%	53.5%	2.7%	4.2%	1.1%	1.7%	22.6%	34.4%	1.8%	2.7%	32.0%	48.6%	17.3%	26.3%
2007	145	0.6%	0.8%	0.2%	0.2%	33.0%	48.4%	2.7%	4.0%	1.0%	1.5%	25.4%	37.2%	1.9%	2.7%	31.5%	46.3%	20.8%	30.6%
2007	146	0.8%	1.3%	*	*	32.5%	50.5%	2.4%	3.7%	1.2%	1.9%	22.8%	35.4%	1.4%	2.2%	30.3%	47.1%	18.6%	28.9%
2007	147	0.4%	0.6%	0.2%	0.4%	32.6%	48.6%	2.4%	3.6%	1.5%	2.3%	25.4%	37.9%	1.9%	2.8%	32.4%	48.3%	18.7%	27.9%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	148	0.2%	0.3%	0.2%	0.3%	38.3%	56.0%	3.3%	4.8%	1.8%	2.6%	21.4%	31.3%	1.3%	1.9%	34.0%	49.8%	20.3%	29.7%
2007	149	0.3%	0.4%	0.1%	0.1%	34.2%	50.5%	2.6%	3.8%	1.0%	1.4%	25.8%	38.1%	1.6%	2.4%	30.9%	45.6%	22.1%	32.7%
2007	150	1.0%	1.7%	0.1%	0.2%	31.6%	52.3%	3.5%	5.8%	0.4%	0.7%	14.8%	24.4%	4.0%	6.6%	28.7%	47.6%	23.9%	39.6%
2007	151	0.2%	0.3%	0.2%	0.3%	39.9%	55.6%	1.9%	2.6%	1.7%	2.3%	23.2%	32.4%	1.0%	1.4%	29.8%	41.5%	24.2%	33.7%
2007	152	*	*	*	*	52.7%	68.9%	1.7%	2.2%	6.6%	8.7%	18.1%	23.7%	1.1%	1.5%	18.7%	24.4%	28.7%	37.6%
2007	154	*	*	*	*	36.1%	52.6%	2.0%	2.9%	1.0%	1.5%	22.7%	33.1%	1.1%	1.6%	38.2%	55.6%	19.4%	28.3%
2007	155	0.5%	0.7%	0.1%	0.1%	33.2%	52.3%	2.6%	4.1%	1.1%	1.8%	20.2%	31.8%	2.5%	3.9%	34.4%	54.1%	16.3%	25.6%
2007	156	0.9%	1.4%	0.0%	0.0%	33.9%	54.5%	1.5%	2.5%	0.5%	0.8%	21.5%	34.5%	1.8%	2.9%	32.7%	52.5%	18.8%	30.2%
2007	158	0.3%	0.4%	0.1%	0.2%	34.8%	53.4%	2.8%	4.3%	0.8%	1.2%	19.6%	30.1%	2.9%	4.5%	34.6%	53.0%	18.1%	27.7%
2007	161	0.4%	0.7%	0.1%	0.1%	33.0%	53.6%	3.2%	5.3%	0.9%	1.5%	17.0%	27.7%	2.5%	4.1%	32.1%	52.1%	17.2%	28.0%
2007	163	0.6%	1.0%	*	*	33.9%	53.6%	3.3%	5.2%	1.1%	1.8%	18.3%	28.9%	2.1%	3.3%	33.3%	52.6%	17.7%	28.0%
2007	164	0.4%	0.6%	*	*	31.9%	50.1%	2.3%	3.6%	0.8%	1.3%	21.0%	32.9%	2.2%	3.5%	33.9%	53.3%	17.6%	27.6%
2007	166	0.4%	0.7%	0.1%	0.1%	35.1%	54.2%	3.1%	4.8%	1.0%	1.5%	18.9%	29.1%	2.4%	3.7%	34.9%	53.9%	19.3%	29.8%
2007	170	0.6%	0.9%	*	*	36.6%	50.7%	1.6%	2.2%	0.7%	1.0%	23.5%	32.6%	1.9%	2.6%	37.7%	52.2%	22.7%	31.4%
2007	171	0.2%	0.4%	0.2%	0.2%	39.3%	55.8%	1.8%	2.6%	1.0%	1.4%	23.0%	32.6%	1.7%	2.3%	33.9%	48.1%	21.4%	30.4%
2007	172	0.3%	0.4%	0.2%	0.2%	35.5%	50.4%	1.8%	2.6%	1.0%	1.4%	23.6%	33.4%	1.4%	1.9%	37.7%	53.5%	18.8%	26.7%
2007	173	0.3%	0.4%	0.3%	0.5%	35.8%	49.8%	1.9%	2.6%	0.9%	1.2%	26.9%	37.4%	1.6%	2.2%	35.9%	49.9%	19.4%	26.9%
2007	175	*	*	*	*	36.4%	51.9%	2.0%	2.8%	0.5%	0.7%	24.8%	35.4%	1.0%	1.5%	37.6%	53.7%	17.6%	25.1%
2007	179	0.4%	0.6%	0.2%	0.3%	36.3%	50.6%	2.4%	3.3%	1.5%	2.1%	26.3%	36.7%	1.6%	2.3%	35.4%	49.2%	20.5%	28.5%
2007	180	0.3%	0.4%	0.3%	0.4%	37.2%	51.1%	3.7%	5.1%	1.8%	2.5%	27.8%	38.2%	2.1%	2.9%	35.6%	48.9%	20.4%	28.1%
2007	181	0.3%	0.4%	*	*	33.0%	47.9%	2.3%	3.3%	0.7%	1.1%	26.8%	38.9%	2.8%	4.0%	33.7%	48.8%	16.2%	23.5%
2007	183	0.4%	0.6%	0.3%	0.4%	34.7%	49.1%	2.3%	3.2%	1.7%	2.5%	27.1%	38.4%	1.7%	2.4%	33.8%	47.9%	19.8%	28.0%
2007	184	0.6%	0.8%	*	*	39.8%	56.4%	1.6%	2.2%	1.8%	2.6%	25.5%	36.1%	1.2%	1.7%	35.3%	50.0%	17.2%	24.4%
2007	185	*	*	0.5%	0.7%	33.9%	47.2%	2.3%	3.2%	1.4%	1.9%	28.9%	40.3%	1.2%	1.6%	34.6%	48.1%	17.7%	24.6%
2007	186	0.7%	1.0%	*	*	33.3%	52.5%	2.6%	4.1%	0.7%	1.1%	21.3%	33.6%	1.7%	2.6%	33.9%	53.5%	15.4%	24.3%
2007	187	0.3%	0.4%	0.3%	0.4%	40.1%	56.2%	2.5%	3.5%	1.2%	1.7%	25.2%	35.4%	2.6%	3.7%	32.7%	45.8%	18.8%	26.4%
2007	188	0.2%	0.3%	0.4%	0.5%	36.3%	50.8%	3.1%	4.4%	1.7%	2.4%	26.3%	36.7%	3.6%	5.1%	33.0%	46.1%	17.1%	23.9%
2007	190	*	*	*	*	34.0%	48.9%	1.4%	2.0%	1.0%	1.5%	24.3%	34.9%	1.1%	1.6%	36.0%	51.9%	17.0%	24.5%
2007	191	0.3%	0.4%	0.2%	0.2%	33.8%	48.9%	2.1%	3.0%	1.0%	1.5%	23.9%	34.6%	1.3%	1.9%	37.6%	54.5%	18.9%	27.4%
2007	192	0.2%	0.3%	0.2%	0.3%	36.5%	52.7%	2.3%	3.3%	0.9%	1.3%	23.4%	33.8%	1.5%	2.1%	36.2%	52.4%	18.0%	26.1%
2007	193	*	*	*	*	32.6%	48.1%	1.3%	1.9%	0.8%	1.1%	24.5%	36.2%	1.7%	2.5%	32.6%	48.1%	18.8%	27.8%
2007	194	0.2%	0.4%	*	*	35.4%	50.2%	2.0%	2.8%	1.0%	1.4%	22.5%	32.0%	1.0%	1.5%	40.2%	57.2%	16.7%	23.8%
2007	195	*	*	0.3%	0.4%	36.8%	51.9%	3.9%	5.5%	2.0%	2.8%	23.8%	33.5%	1.1%	1.6%	36.6%	51.6%	17.8%	25.0%
2007	196	0.3%	0.4%	*	*	37.7%	52.2%	3.0%	4.1%	1.6%	2.3%	20.3%	28.1%	1.3%	1.8%	33.2%	46.0%	28.9%	40.0%
2007	197	*	*	*	*	33.6%	49.0%	1.5%	2.3%	1.4%	2.1%	24.0%	35.0%	1.5%	2.2%	36.7%	53.4%	17.4%	25.3%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	200	0.6%	0.9%	0.4%	0.6%	35.4%	51.8%	2.0%	2.9%	2.2%	3.2%	23.2%	33.9%	0.9%	1.3%	32.4%	47.4%	18.8%	27.5%
2007	201	0.2%	0.3%	0.6%	0.9%	36.4%	50.4%	2.3%	3.2%	2.2%	3.0%	27.2%	37.6%	1.9%	2.6%	31.8%	44.1%	19.3%	26.8%
2007	203	0.5%	0.7%	*	*	37.1%	54.0%	2.8%	4.1%	0.8%	1.1%	24.7%	35.9%	3.0%	4.4%	31.5%	45.8%	18.4%	26.8%
2007	204	0.5%	0.7%	0.2%	0.3%	40.3%	58.0%	3.5%	5.1%	1.7%	2.5%	23.5%	33.8%	1.9%	2.7%	35.0%	50.4%	20.5%	29.4%
2007	205	0.5%	0.7%	0.2%	0.3%	35.2%	52.2%	2.3%	3.4%	1.1%	1.7%	23.1%	34.3%	2.0%	3.0%	32.9%	48.8%	19.8%	29.4%
2007	207	*	*	1.0%	1.6%	32.9%	50.2%	3.6%	5.5%	3.0%	4.6%	22.2%	33.9%	3.3%	5.0%	28.1%	43.0%	19.5%	29.9%
2007	208	0.4%	0.6%	0.3%	0.5%	36.6%	52.4%	1.9%	2.7%	2.1%	3.0%	24.3%	34.8%	1.3%	1.8%	33.9%	48.5%	20.2%	28.9%
2007	209	0.4%	0.6%	0.4%	0.6%	33.3%	48.5%	2.6%	3.8%	0.8%	1.2%	27.4%	39.9%	1.7%	2.4%	35.9%	52.2%	19.5%	28.4%
2007	210	0.4%	0.6%	0.3%	0.5%	36.6%	52.4%	2.6%	3.7%	2.3%	3.3%	25.9%	37.2%	2.9%	4.1%	30.3%	43.5%	23.0%	32.9%
2007	212	0.7%	1.0%	*	*	38.5%	53.8%	2.0%	2.8%	1.1%	1.6%	23.9%	33.5%	3.8%	5.4%	38.0%	53.2%	23.4%	32.8%
2007	213	0.3%	0.4%	0.2%	0.2%	36.6%	53.6%	2.5%	3.7%	1.9%	2.7%	22.2%	32.4%	3.3%	4.8%	34.7%	50.7%	25.8%	37.7%
2007	214	0.5%	0.7%	*	*	38.2%	55.2%	3.5%	5.0%	1.2%	1.7%	25.8%	37.2%	1.5%	2.2%	35.0%	50.5%	19.2%	27.6%
2007	216	0.6%	0.9%	*	*	33.8%	50.1%	2.1%	3.2%	1.5%	2.2%	24.8%	36.7%	3.5%	5.1%	34.0%	50.4%	16.6%	24.6%
2007	217	0.3%	0.4%	*	*	35.1%	51.2%	3.3%	4.9%	1.7%	2.5%	25.0%	36.6%	2.7%	4.0%	33.0%	48.2%	23.9%	34.9%
2007	218	0.5%	0.7%	*	*	32.9%	50.6%	2.0%	3.1%	1.1%	1.6%	27.1%	41.6%	3.2%	4.9%	31.2%	47.9%	16.7%	25.7%
2007	219	0.2%	0.4%	0.1%	0.1%	36.3%	52.2%	3.0%	4.3%	0.7%	1.1%	25.6%	36.9%	1.8%	2.5%	31.2%	44.9%	21.6%	31.0%
2007	220	*	*	*	*	37.1%	56.0%	3.6%	5.5%	1.5%	2.2%	23.6%	35.6%	2.6%	3.9%	31.6%	47.7%	17.7%	26.8%
2007	221	0.4%	0.6%	*	*	40.0%	60.7%	1.5%	2.3%	1.2%	1.8%	20.5%	31.2%	0.6%	1.0%	31.3%	47.5%	16.2%	24.6%
2007	222	0.3%	0.5%	0.1%	0.1%	34.9%	53.8%	1.8%	2.7%	1.6%	2.4%	21.0%	32.3%	0.8%	1.3%	33.2%	51.1%	15.7%	24.2%
2007	223	0.5%	0.7%	0.1%	0.1%	31.1%	51.1%	2.4%	4.0%	0.8%	1.3%	19.6%	32.2%	1.5%	2.4%	31.7%	52.2%	16.3%	26.7%
2007	225	0.3%	0.5%	0.1%	0.2%	32.7%	49.0%	3.2%	4.8%	1.6%	2.5%	20.4%	30.6%	1.9%	2.8%	35.4%	53.0%	19.2%	28.8%
2007	226	0.5%	0.8%	*	*	34.1%	54.5%	3.2%	5.1%	0.8%	1.3%	20.3%	32.5%	2.4%	3.8%	31.5%	50.4%	18.5%	29.7%
2007	227	0.4%	0.6%	0.1%	0.2%	35.6%	55.5%	1.0%	1.6%	0.8%	1.3%	21.4%	33.4%	1.2%	1.9%	30.4%	47.4%	16.6%	25.9%
2007	230	0.2%	0.3%	0.1%	0.1%	35.2%	52.1%	1.1%	1.7%	0.6%	0.9%	25.0%	37.0%	0.9%	1.4%	32.9%	48.7%	21.5%	31.8%
2007	231	0.2%	0.3%	*	*	37.4%	56.7%	0.9%	1.4%	0.9%	1.3%	24.2%	36.7%	0.6%	0.9%	31.3%	47.5%	17.4%	26.4%
2007	232	0.3%	0.5%	0.1%	0.1%	32.9%	53.9%	1.7%	2.9%	1.1%	1.9%	21.6%	35.4%	1.8%	2.9%	29.2%	47.9%	14.0%	23.0%
2007	233	0.3%	0.6%	*	*	31.1%	57.5%	2.0%	3.6%	0.5%	0.8%	17.8%	32.9%	1.2%	2.3%	28.5%	52.8%	13.5%	25.1%
2007	234	0.3%	0.6%	0.0%	0.1%	27.5%	50.3%	1.6%	3.0%	0.4%	0.7%	21.0%	38.5%	1.5%	2.7%	26.9%	49.4%	12.4%	22.7%
2007	235	0.2%	0.3%	*	*	30.1%	50.8%	1.3%	2.3%	1.3%	2.2%	22.2%	37.5%	0.9%	1.6%	29.9%	50.4%	13.0%	21.9%
2007	236	0.2%	0.3%	0.1%	0.2%	35.5%	50.1%	1.5%	2.1%	0.7%	1.0%	27.4%	38.6%	1.3%	1.9%	31.9%	45.0%	20.7%	29.1%
2007	238	0.4%	0.5%	0.1%	0.1%	38.9%	53.5%	2.1%	2.9%	1.2%	1.7%	27.1%	37.2%	1.6%	2.2%	32.9%	45.2%	21.9%	30.1%
2007	239	0.4%	0.6%	*	*	39.1%	54.4%	2.9%	4.1%	1.1%	1.5%	25.7%	35.8%	1.4%	1.9%	34.8%	48.5%	21.7%	30.2%
2007	240	0.3%	0.4%	*	*	38.1%	54.8%	0.8%	1.2%	0.5%	0.8%	26.3%	37.8%	1.1%	1.6%	31.4%	45.1%	17.4%	25.0%
2007	242	0.2%	0.3%	*	*	33.8%	48.0%	1.9%	2.7%	0.7%	1.0%	29.3%	41.6%	1.2%	1.7%	30.9%	43.9%	20.8%	29.4%
2007	243	0.4%	0.6%	*	*	34.4%	53.6%	2.2%	3.5%	1.4%	2.2%	23.8%	37.1%	1.2%	1.9%	27.6%	42.9%	16.8%	26.2%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	244	0.4%	0.8%	*	*	29.8%	54.0%	2.2%	4.0%	0.9%	1.7%	19.5%	35.4%	1.6%	3.0%	24.9%	45.1%	13.0%	23.6%
2007	245	0.4%	0.7%	0.1%	0.2%	26.7%	52.0%	2.9%	5.6%	0.7%	1.5%	16.0%	31.3%	3.2%	6.2%	24.7%	48.2%	12.1%	23.6%
2007	246	0.4%	0.6%	0.1%	0.2%	34.8%	52.8%	1.4%	2.1%	1.5%	2.2%	23.4%	35.5%	1.4%	2.1%	32.9%	49.9%	16.3%	24.8%
2007	248	0.7%	0.9%	*	*	39.7%	54.3%	1.8%	2.5%	1.7%	2.4%	24.0%	32.8%	2.6%	3.6%	35.8%	49.1%	25.7%	35.2%
2007	249	*	*	0.4%	0.6%	41.1%	60.0%	2.8%	4.1%	2.8%	4.0%	21.9%	32.0%	1.5%	2.2%	30.7%	44.8%	19.0%	27.7%
2007	250	*	*	*	*	34.6%	52.5%	1.2%	1.8%	1.2%	1.7%	25.6%	38.9%	0.6%	1.0%	31.3%	47.5%	14.0%	21.3%
2007	251	0.2%	0.3%	0.1%	0.2%	37.1%	53.6%	1.4%	2.0%	1.6%	2.3%	23.9%	34.5%	0.9%	1.3%	32.7%	47.3%	18.1%	26.1%
2007	253	0.2%	0.3%	*	*	34.5%	50.0%	1.0%	1.5%	0.9%	1.3%	26.1%	37.9%	0.9%	1.3%	32.9%	47.7%	11.2%	16.3%
2007	254	*	*	*	*	37.7%	54.7%	1.3%	1.9%	1.7%	2.4%	21.6%	31.4%	1.9%	2.8%	31.2%	45.3%	19.0%	27.5%
2007	256	0.3%	0.4%	*	*	36.2%	52.2%	1.3%	1.9%	1.8%	2.6%	27.1%	39.0%	0.9%	1.4%	31.9%	46.0%	18.1%	26.1%
2007	257	*	*	*	*	34.3%	51.0%	2.3%	3.4%	1.6%	2.5%	22.7%	33.8%	1.4%	2.1%	31.2%	46.4%	22.2%	33.0%
2007	258	0.3%	0.4%	*	*	36.2%	51.1%	2.3%	3.2%	0.8%	1.2%	25.0%	35.3%	0.8%	1.1%	37.3%	52.7%	19.6%	27.7%
2007	259	0.2%	0.3%	0.1%	0.1%	35.6%	50.2%	2.7%	3.8%	1.4%	1.9%	26.7%	37.7%	1.6%	2.3%	33.6%	47.5%	21.3%	30.0%
2007	260	0.3%	0.4%	*	*	35.6%	48.1%	1.7%	2.2%	1.0%	1.4%	26.4%	35.6%	1.8%	2.4%	39.7%	53.5%	22.7%	30.7%
2007	261	*	*	*	*	39.0%	53.8%	3.2%	4.5%	1.5%	2.1%	25.2%	34.8%	2.5%	3.4%	29.5%	40.8%	24.4%	33.7%
2007	262	0.2%	0.3%	0.3%	0.4%	38.9%	54.2%	2.0%	2.8%	2.1%	3.0%	25.4%	35.4%	2.8%	4.0%	30.1%	42.0%	18.6%	25.9%
2007	263	0.8%	1.1%	0.2%	0.3%	37.4%	53.6%	2.9%	4.2%	1.4%	2.0%	25.2%	36.2%	1.3%	1.9%	34.4%	49.3%	21.0%	30.1%
2007	264	0.3%	0.4%	0.2%	0.3%	38.3%	55.9%	1.8%	2.7%	1.7%	2.5%	23.7%	34.6%	1.2%	1.7%	34.0%	49.6%	19.1%	27.8%
2007	267	0.3%	0.4%	0.4%	0.6%	37.8%	55.5%	2.6%	3.8%	2.4%	3.5%	22.2%	32.6%	1.8%	2.6%	32.8%	48.2%	22.7%	33.3%
2007	268	0.3%	0.5%	0.2%	0.3%	35.8%	52.3%	1.7%	2.5%	1.1%	1.6%	25.5%	37.3%	1.3%	1.9%	32.8%	48.0%	17.7%	25.9%
2007	270	0.4%	0.6%	0.4%	0.5%	41.4%	59.2%	2.1%	3.0%	2.5%	3.6%	23.8%	34.0%	1.1%	1.6%	33.7%	48.3%	19.1%	27.4%
2007	273	0.5%	0.8%	0.2%	0.2%	34.7%	51.5%	2.6%	3.9%	1.4%	2.1%	24.6%	36.5%	1.5%	2.3%	34.8%	51.7%	17.2%	25.6%
2007	274	0.2%	0.2%	*	*	42.5%	57.6%	2.1%	2.9%	2.5%	3.4%	24.0%	32.6%	0.8%	1.1%	31.0%	42.1%	20.9%	28.4%
2007	275	*	*	*	*	38.5%	55.6%	3.1%	4.5%	0.9%	1.2%	23.0%	33.1%	0.6%	0.8%	34.1%	49.3%	24.8%	35.8%
2007	276	0.2%	0.3%	*	*	40.8%	58.1%	1.7%	2.4%	2.0%	2.9%	22.6%	32.2%	1.0%	1.4%	29.6%	42.1%	20.9%	29.7%
2007	277	0.3%	0.4%	0.2%	0.2%	33.8%	48.1%	2.4%	3.4%	1.4%	2.0%	23.8%	33.9%	1.4%	2.0%	34.2%	48.7%	23.4%	33.2%
2007	278	0.3%	0.5%	0.1%	0.2%	35.0%	50.1%	2.6%	3.8%	1.2%	1.8%	23.5%	33.6%	1.5%	2.2%	34.3%	49.0%	22.1%	31.7%
2007	279	0.6%	0.9%	0.1%	0.1%	36.2%	57.4%	3.0%	4.7%	1.8%	2.9%	18.0%	28.5%	1.5%	2.4%	31.1%	49.3%	21.3%	33.7%
2007	280	0.5%	0.8%	*	*	40.4%	60.5%	2.4%	3.5%	1.2%	1.8%	19.1%	28.7%	1.4%	2.1%	30.0%	44.9%	20.4%	30.6%
2007	281	0.4%	0.6%	0.3%	0.4%	36.5%	55.8%	1.0%	1.6%	0.9%	1.4%	22.9%	35.0%	1.0%	1.5%	30.8%	47.1%	15.3%	23.4%
2007	282	0.3%	0.5%	0.2%	0.3%	35.5%	54.1%	1.7%	2.6%	1.8%	2.7%	21.5%	32.8%	1.3%	1.9%	31.6%	48.2%	16.9%	25.7%
2007	283	0.5%	0.8%	0.1%	0.2%	27.6%	47.5%	3.9%	6.7%	1.2%	2.1%	17.1%	29.4%	7.7%	13.2%	28.0%	48.2%	18.6%	31.9%
2007	284	0.8%	1.3%	0.1%	0.1%	30.8%	54.8%	4.8%	8.5%	0.9%	1.6%	14.5%	25.8%	4.7%	8.3%	29.7%	52.9%	20.6%	36.6%
2007	285	0.6%	0.9%	0.2%	0.3%	32.6%	53.7%	4.2%	7.0%	1.6%	2.6%	16.6%	27.4%	4.7%	7.8%	31.8%	52.5%	18.5%	30.5%
2007	288	0.8%	1.4%	0.2%	0.3%	30.8%	53.1%	4.7%	8.1%	1.2%	2.1%	16.4%	28.4%	7.3%	12.6%	29.5%	51.0%	17.5%	30.3%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	289	0.8%	1.3%	0.1%	0.1%	29.7%	51.1%	4.2%	7.2%	1.1%	1.9%	19.0%	32.7%	5.3%	9.2%	29.7%	51.1%	20.4%	35.1%
2007	291	0.6%	1.0%	*	*	33.9%	55.8%	4.0%	6.6%	0.5%	0.9%	17.5%	28.9%	3.2%	5.3%	33.7%	55.4%	20.0%	32.9%
2007	292	0.4%	0.8%	*	*	27.6%	52.0%	3.6%	6.7%	1.6%	3.0%	15.8%	29.7%	4.0%	7.6%	26.5%	49.9%	14.3%	26.9%
2007	293	0.1%	0.2%	0.1%	0.1%	38.6%	56.6%	1.2%	1.8%	0.9%	1.3%	24.8%	36.4%	0.7%	1.1%	34.2%	50.2%	21.2%	31.1%
2007	295	0.4%	0.6%	0.2%	0.3%	32.7%	50.4%	2.8%	4.4%	2.2%	3.5%	23.6%	36.4%	2.6%	4.0%	30.0%	46.2%	17.6%	27.1%
2007	296	0.5%	0.7%	0.2%	0.3%	34.2%	50.6%	3.2%	4.8%	2.0%	3.0%	24.2%	35.8%	4.0%	5.9%	31.3%	46.3%	22.4%	33.2%
2007	297	0.7%	1.1%	0.1%	0.1%	34.7%	56.0%	2.2%	3.6%	0.7%	1.1%	22.8%	36.8%	2.3%	3.7%	30.7%	49.5%	20.3%	32.7%
2007	299	0.4%	0.6%	0.1%	0.2%	38.5%	55.9%	2.7%	3.9%	2.1%	3.0%	26.4%	38.3%	1.7%	2.5%	31.1%	45.1%	19.8%	28.7%
2007	300	0.5%	0.7%	*	*	33.6%	49.9%	4.6%	6.8%	1.9%	2.8%	24.6%	36.4%	3.7%	5.4%	33.1%	49.1%	18.6%	27.6%
2007	301	0.8%	1.6%	0.1%	0.2%	26.2%	53.4%	3.6%	7.4%	1.0%	2.0%	14.4%	29.4%	2.7%	5.6%	26.4%	54.0%	14.8%	30.3%
2007	303	1.6%	2.9%	0.1%	0.2%	30.4%	56.5%	4.3%	8.1%	1.0%	1.9%	15.9%	29.4%	3.9%	7.2%	28.4%	52.7%	19.4%	36.0%
2007	304	0.7%	1.0%	0.1%	0.2%	36.0%	52.9%	2.8%	4.2%	0.9%	1.3%	25.3%	37.2%	1.7%	2.6%	31.7%	46.7%	19.3%	28.4%
2007	307	0.4%	0.6%	0.1%	0.2%	33.5%	49.0%	4.0%	5.9%	1.9%	2.8%	26.5%	38.8%	2.0%	2.9%	29.7%	43.5%	19.3%	28.3%
2007	308	0.5%	0.9%	0.2%	0.3%	29.9%	53.4%	3.9%	6.9%	1.5%	2.6%	17.3%	31.0%	2.5%	4.5%	27.8%	49.7%	17.1%	30.6%
2007	309	0.3%	0.4%	0.3%	0.4%	37.1%	52.9%	2.7%	3.9%	1.2%	1.7%	25.2%	35.9%	2.2%	3.2%	32.2%	45.9%	21.9%	31.2%
2007	311	0.2%	0.3%	0.3%	0.4%	36.7%	52.5%	2.6%	3.7%	1.4%	2.0%	24.6%	35.2%	1.8%	2.6%	33.9%	48.6%	20.4%	29.3%
2007	312	0.4%	0.5%	0.1%	0.2%	33.8%	48.3%	2.4%	3.4%	0.8%	1.2%	26.5%	37.9%	1.8%	2.6%	35.1%	50.3%	19.4%	27.8%
2007	313	0.3%	0.5%	0.1%	0.2%	33.2%	49.3%	2.9%	4.3%	1.0%	1.5%	24.5%	36.4%	1.3%	1.9%	36.5%	54.2%	21.3%	31.7%
2007	314	0.4%	0.5%	0.1%	0.2%	33.8%	47.4%	2.6%	3.6%	1.3%	1.9%	26.6%	37.3%	2.0%	2.8%	34.7%	48.6%	20.5%	28.7%
2007	315	0.2%	0.3%	0.1%	0.2%	37.3%	53.9%	2.3%	3.4%	0.9%	1.2%	22.7%	32.8%	1.2%	1.8%	35.3%	51.0%	21.2%	30.7%
2007	318	0.4%	0.6%	0.2%	0.4%	34.4%	49.6%	2.8%	4.1%	1.3%	1.8%	26.3%	38.0%	2.1%	3.0%	34.0%	48.9%	21.6%	31.2%
2007	319	0.2%	0.3%	0.4%	0.6%	33.7%	49.9%	3.7%	5.5%	2.0%	3.0%	24.9%	36.8%	3.6%	5.3%	29.8%	44.2%	19.5%	28.9%
2007	320	0.3%	0.5%	0.1%	0.2%	35.8%	51.6%	3.0%	4.3%	1.4%	2.1%	24.6%	35.5%	1.4%	2.0%	35.6%	51.3%	19.8%	28.5%
2007	321	0.4%	0.5%	*	*	32.4%	45.7%	1.7%	2.4%	1.5%	2.1%	25.4%	35.8%	0.3%	0.5%	36.4%	51.3%	15.1%	21.3%
2007	322	0.4%	0.5%	*	*	34.5%	49.1%	1.6%	2.2%	1.3%	1.9%	25.9%	36.9%	0.5%	0.7%	34.2%	48.7%	13.8%	19.6%
2007	323	*	*	*	*	36.7%	50.8%	2.7%	3.7%	1.3%	1.7%	26.3%	36.4%	0.4%	0.6%	35.8%	49.5%	15.2%	21.1%
2007	324	*	*	*	*	40.0%	56.1%	0.9%	1.3%	0.7%	0.9%	23.9%	33.5%	0.5%	0.8%	34.9%	49.0%	13.7%	19.2%
2007	325	0.6%	0.9%	*	*	32.1%	47.1%	2.2%	3.2%	0.9%	1.3%	27.1%	39.8%	2.4%	3.6%	30.9%	45.3%	20.2%	29.6%
2007	326	0.4%	0.6%	0.1%	0.2%	35.1%	49.6%	2.8%	4.0%	1.3%	1.8%	25.5%	36.1%	2.2%	3.1%	34.0%	48.1%	21.4%	30.2%
2007	327	0.5%	0.7%	0.2%	0.4%	35.4%	51.8%	2.4%	3.5%	1.3%	1.9%	26.2%	38.3%	1.8%	2.7%	32.5%	47.6%	18.7%	27.3%
2007	328	0.4%	0.7%	0.1%	0.1%	31.8%	47.6%	2.2%	3.3%	0.9%	1.4%	26.7%	40.0%	1.6%	2.3%	33.1%	49.7%	16.5%	24.7%
2007	329	0.6%	0.8%	0.3%	0.4%	36.1%	52.4%	3.7%	5.3%	2.2%	3.2%	24.7%	35.8%	2.0%	2.9%	34.5%	50.1%	22.7%	32.9%
2007	330	0.6%	0.8%	0.2%	0.3%	33.9%	50.0%	2.8%	4.1%	2.0%	2.9%	25.6%	37.8%	1.9%	2.8%	34.2%	50.5%	18.7%	27.6%
2007	331	*	*	*	*	38.5%	54.0%	2.5%	3.4%	2.2%	3.0%	27.1%	37.9%	2.7%	3.8%	35.0%	49.1%	20.2%	28.3%
2007	332	0.3%	0.5%	*	*	33.6%	51.3%	2.7%	4.2%	1.2%	1.8%	24.4%	37.2%	2.2%	3.3%	30.6%	46.6%	19.8%	30.2%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	334	0.4%	0.6%	0.1%	0.2%	37.0%	53.1%	2.8%	4.0%	1.9%	2.8%	25.2%	36.2%	1.9%	2.8%	34.5%	49.6%	17.2%	24.7%
2007	335	0.2%	0.3%	0.3%	0.4%	29.1%	45.9%	2.5%	4.0%	1.5%	2.4%	24.7%	39.0%	2.9%	4.5%	32.1%	50.8%	15.6%	24.7%
2007	336	*	*	*	*	35.2%	51.1%	5.0%	7.3%	0.7%	1.1%	22.0%	32.0%	2.0%	3.0%	29.3%	42.6%	29.8%	43.4%
2007	339	0.4%	0.6%	0.1%	0.1%	38.8%	55.2%	3.5%	5.0%	1.4%	2.0%	22.3%	31.7%	1.5%	2.1%	34.9%	49.7%	25.8%	36.7%
2007	340	0.4%	0.6%	0.2%	0.2%	37.8%	54.8%	2.9%	4.2%	1.5%	2.2%	23.2%	33.7%	2.0%	2.9%	31.9%	46.2%	22.7%	32.9%
2007	341	*	*	*	*	43.4%	63.2%	2.1%	3.1%	1.7%	2.5%	19.5%	28.4%	0.7%	1.0%	31.9%	46.5%	18.5%	26.9%
2007	342	0.3%	0.4%	0.1%	0.2%	37.2%	57.4%	0.8%	1.2%	1.0%	1.5%	21.0%	32.4%	0.8%	1.2%	32.1%	49.5%	15.3%	23.6%
2007	343	0.4%	0.6%	0.2%	0.2%	42.3%	62.7%	2.0%	3.0%	2.3%	3.4%	21.0%	31.1%	0.7%	1.1%	28.7%	42.6%	19.0%	28.2%
2007	344	0.4%	0.6%	0.1%	0.2%	40.2%	58.6%	1.2%	1.8%	1.4%	2.1%	24.1%	35.1%	0.9%	1.3%	32.3%	47.0%	16.5%	24.0%
2007	345	*	*	*	*	40.3%	58.9%	1.3%	1.9%	1.2%	1.8%	22.6%	33.0%	0.7%	1.1%	33.9%	49.5%	15.1%	22.1%
2007	346	0.5%	0.8%	0.1%	0.2%	31.5%	48.3%	3.8%	5.8%	1.2%	1.8%	20.5%	31.5%	4.7%	7.2%	33.7%	51.8%	17.1%	26.2%
2007	347	0.4%	0.5%	*	*	40.5%	57.9%	2.3%	3.3%	1.2%	1.7%	21.4%	30.6%	2.7%	3.9%	32.6%	46.6%	20.9%	29.9%
2007	350	0.4%	0.6%	*	*	35.9%	53.3%	2.1%	3.2%	0.9%	1.3%	22.4%	33.3%	2.3%	3.4%	34.7%	51.5%	17.1%	25.4%
2007	351	0.5%	0.8%	0.3%	0.4%	32.5%	48.3%	2.4%	3.5%	1.0%	1.4%	24.4%	36.2%	2.5%	3.8%	33.4%	49.6%	19.6%	29.1%
2007	352	0.6%	0.8%	0.1%	0.1%	33.6%	50.0%	2.3%	3.4%	1.1%	1.6%	21.3%	31.7%	1.7%	2.6%	36.8%	54.9%	19.3%	28.8%
2007	354	0.4%	0.6%	*	*	33.8%	50.0%	2.6%	3.9%	1.0%	1.5%	22.8%	33.8%	2.1%	3.2%	35.2%	52.0%	17.2%	25.5%
2007	355	0.5%	0.8%	*	*	34.0%	51.4%	2.1%	3.2%	0.9%	1.3%	20.3%	30.8%	2.0%	3.0%	35.6%	53.8%	18.2%	27.5%
2007	356	0.5%	0.9%	0.1%	0.1%	26.9%	46.7%	2.9%	5.0%	0.7%	1.3%	20.0%	34.8%	4.8%	8.3%	27.3%	47.4%	15.6%	27.1%
2007	357	0.4%	0.7%	0.1%	0.2%	30.4%	47.5%	2.6%	4.0%	1.1%	1.7%	22.3%	34.8%	5.2%	8.2%	30.4%	47.6%	16.2%	25.4%
2007	358	0.6%	0.8%	0.1%	0.2%	32.7%	49.3%	3.1%	4.7%	0.8%	1.2%	20.9%	31.5%	2.6%	3.9%	37.6%	56.7%	17.7%	26.7%
2007	359	0.4%	0.6%	*	*	36.3%	52.5%	2.8%	4.1%	1.8%	2.6%	25.0%	36.2%	3.1%	4.5%	33.8%	48.9%	21.9%	31.7%
2007	360	0.2%	0.3%	*	*	35.4%	52.0%	3.6%	5.3%	0.8%	1.1%	22.1%	32.5%	3.8%	5.6%	36.6%	53.7%	16.4%	24.1%
2007	362	1.4%	2.1%	0.3%	0.4%	29.9%	45.0%	3.9%	5.9%	1.4%	2.1%	22.0%	33.0%	6.5%	9.7%	33.7%	50.7%	15.5%	23.4%
2007	363	0.7%	1.0%	*	*	33.9%	50.4%	1.6%	2.3%	0.8%	1.1%	19.3%	28.8%	1.8%	2.7%	38.2%	56.9%	20.3%	30.3%
2007	364	0.4%	0.7%	0.1%	0.2%	29.6%	46.6%	1.6%	2.5%	0.7%	1.1%	21.3%	33.5%	2.0%	3.1%	34.4%	54.1%	16.8%	26.4%
2007	365	0.3%	0.4%	0.1%	0.2%	34.9%	51.0%	2.8%	4.1%	1.3%	1.8%	25.0%	36.5%	1.9%	2.8%	32.5%	47.5%	18.0%	26.3%
2007	366	0.2%	0.3%	0.2%	0.3%	33.1%	47.4%	3.0%	4.3%	1.3%	1.9%	26.3%	37.7%	3.1%	4.5%	31.1%	44.5%	21.8%	31.1%
2007	367	0.2%	0.2%	0.2%	0.3%	36.8%	50.8%	2.9%	4.0%	0.8%	1.1%	30.0%	41.5%	2.6%	3.6%	29.1%	40.2%	21.5%	29.7%
2007	368	0.3%	0.4%	0.2%	0.3%	35.2%	51.6%	2.9%	4.2%	1.0%	1.4%	23.6%	34.6%	1.8%	2.7%	33.0%	48.4%	20.4%	29.9%
2007	369	0.3%	0.4%	0.3%	0.4%	35.9%	49.8%	4.2%	5.8%	1.2%	1.6%	25.5%	35.3%	1.5%	2.0%	35.5%	49.2%	21.9%	30.4%
2007	370	0.4%	0.5%	*	*	37.4%	52.7%	3.3%	4.7%	1.1%	1.6%	22.7%	32.0%	1.2%	1.7%	30.5%	43.0%	22.7%	31.9%
2007	371	0.2%	0.2%	*	*	34.2%	49.4%	2.1%	3.0%	1.1%	1.5%	22.6%	32.6%	1.0%	1.5%	34.3%	49.5%	19.8%	28.6%
2007	373	0.2%	0.4%	0.2%	0.4%	37.2%	54.5%	2.5%	3.7%	2.7%	3.9%	23.2%	33.9%	2.9%	4.2%	32.6%	47.7%	18.8%	27.5%
2007	374	0.5%	0.8%	*	*	37.8%	53.9%	1.5%	2.1%	1.8%	2.6%	24.2%	34.5%	1.1%	1.6%	36.9%	52.6%	23.1%	32.9%
2007	375	0.2%	0.4%	*	*	38.3%	57.0%	2.3%	3.4%	1.6%	2.4%	23.9%	35.6%	1.2%	1.8%	32.9%	48.9%	18.6%	27.7%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	376	0.4%	0.6%	0.3%	0.5%	38.8%	56.7%	3.2%	4.7%	2.6%	3.8%	23.9%	35.0%	1.8%	2.7%	34.1%	49.9%	19.6%	28.7%
2007	377	0.4%	0.5%	0.1%	0.2%	39.5%	55.5%	3.3%	4.7%	2.8%	3.9%	25.9%	36.4%	1.7%	2.4%	33.5%	47.1%	20.9%	29.3%
2007	379	0.6%	0.8%	0.2%	0.3%	34.5%	49.1%	2.0%	2.9%	1.3%	1.9%	26.0%	37.0%	2.2%	3.1%	34.7%	49.5%	21.6%	30.8%
2007	380	0.4%	0.6%	0.1%	0.2%	38.1%	54.5%	2.2%	3.1%	1.9%	2.7%	24.9%	35.6%	2.6%	3.8%	32.3%	46.2%	19.5%	27.9%
2007	382	0.2%	0.3%	*	*	39.3%	55.8%	2.8%	3.9%	2.0%	2.9%	22.9%	32.5%	1.1%	1.5%	34.5%	49.0%	20.2%	28.7%
2007	383	0.8%	1.0%	*	*	39.4%	53.3%	2.3%	3.1%	1.4%	1.8%	26.1%	35.3%	2.5%	3.3%	33.8%	45.7%	24.8%	33.6%
2007	385	0.3%	0.4%	0.1%	0.2%	34.6%	50.3%	3.2%	4.6%	1.6%	2.4%	24.5%	35.6%	2.0%	2.9%	32.9%	47.8%	23.0%	33.4%
2007	386	0.3%	0.4%	0.2%	0.3%	34.9%	52.9%	4.1%	6.2%	2.6%	4.0%	22.7%	34.3%	4.4%	6.7%	26.6%	40.3%	19.6%	29.7%
2007	388	*	*	*	*	39.1%	55.2%	2.9%	4.1%	2.3%	3.3%	24.0%	33.9%	1.3%	1.9%	33.2%	47.0%	22.1%	31.2%
2007	390	0.2%	0.3%	0.1%	0.2%	34.4%	50.9%	2.7%	4.1%	1.8%	2.6%	26.6%	39.3%	1.3%	2.0%	31.4%	46.6%	20.1%	29.8%
2007	391	0.3%	0.4%	0.1%	0.1%	34.8%	51.9%	2.5%	3.7%	1.0%	1.5%	25.0%	37.2%	1.4%	2.1%	31.2%	46.5%	18.1%	26.9%
2007	393	0.6%	0.9%	*	*	40.0%	58.7%	3.2%	4.7%	0.5%	0.7%	23.4%	34.3%	1.5%	2.2%	33.0%	48.4%	22.7%	33.2%
2007	394	0.2%	0.3%	0.1%	0.2%	35.0%	52.4%	3.0%	4.6%	1.0%	1.5%	25.6%	38.3%	1.8%	2.7%	31.9%	47.7%	18.0%	26.9%
2007	396	0.5%	0.7%	0.1%	0.2%	36.9%	55.8%	3.0%	4.5%	1.3%	2.0%	24.2%	36.6%	2.0%	3.1%	33.5%	50.7%	19.7%	29.8%
2007	397	0.4%	0.7%	0.1%	0.1%	35.9%	53.9%	3.1%	4.7%	1.4%	2.1%	22.9%	34.5%	2.4%	3.7%	33.3%	50.1%	17.4%	26.2%
2007	399	*	*	*	*	35.5%	51.2%	2.4%	3.5%	2.4%	3.5%	27.2%	39.2%	1.1%	1.5%	34.3%	49.5%	18.2%	26.2%
2007	400	0.3%	0.4%	0.1%	0.1%	40.6%	57.7%	2.5%	3.6%	1.5%	2.2%	24.0%	34.1%	1.6%	2.3%	34.3%	48.7%	22.1%	31.4%
2007	402	0.6%	0.9%	0.3%	0.4%	35.9%	54.6%	4.4%	6.7%	1.8%	2.7%	23.7%	36.1%	3.6%	5.5%	35.5%	54.0%	21.6%	32.9%
2007	406	0.3%	0.4%	*	*	43.1%	59.2%	3.6%	5.0%	1.5%	2.0%	24.6%	33.7%	2.2%	3.0%	35.1%	48.2%	21.5%	29.5%
2007	411	*	*	*	*	36.7%	52.6%	1.8%	2.5%	1.8%	2.5%	25.3%	36.2%	1.5%	2.2%	39.2%	56.2%	17.8%	25.5%
2007	412	0.6%	0.9%	0.2%	0.3%	34.4%	50.8%	2.8%	4.2%	1.5%	2.2%	24.7%	36.5%	1.6%	2.4%	32.7%	48.3%	23.1%	34.1%
2007	413	0.3%	0.5%	*	*	36.0%	52.1%	2.0%	2.9%	0.8%	1.2%	27.9%	40.4%	0.7%	1.0%	33.8%	48.9%	14.2%	20.6%
2007	416	0.2%	0.3%	0.1%	0.2%	35.7%	52.6%	3.4%	5.0%	2.6%	3.8%	24.2%	35.7%	1.5%	2.2%	32.5%	48.0%	18.8%	27.7%
2007	417	0.4%	0.6%	*	*	37.9%	57.4%	3.8%	5.8%	1.2%	1.8%	19.7%	29.9%	2.4%	3.7%	27.5%	41.7%	24.8%	37.7%
2007	418	0.3%	0.4%	*	*	35.0%	50.4%	2.0%	2.8%	0.9%	1.2%	26.7%	38.5%	1.1%	1.6%	30.8%	44.4%	19.4%	28.0%
2007	420	0.4%	0.6%	*	*	36.5%	51.5%	2.1%	3.0%	1.6%	2.3%	25.3%	35.8%	2.4%	3.4%	32.2%	45.4%	24.4%	34.5%
2007	421	*	*	*	*	44.3%	59.5%	1.9%	2.6%	1.4%	1.9%	24.6%	33.0%	0.9%	1.2%	31.3%	42.1%	23.6%	31.7%
2007	422	*	*	*	*	44.3%	61.3%	3.7%	5.1%	0.8%	1.1%	24.0%	33.3%	0.7%	1.0%	30.3%	41.9%	24.3%	33.7%
2007	423	0.2%	0.3%	0.2%	0.3%	44.0%	61.1%	2.6%	3.6%	1.6%	2.3%	22.4%	31.2%	1.1%	1.5%	30.1%	41.8%	22.0%	30.6%
2007	424	0.4%	0.6%	0.3%	0.4%	36.3%	54.4%	2.4%	3.5%	1.5%	2.2%	22.2%	33.3%	0.9%	1.3%	31.7%	47.6%	20.2%	30.3%
2007	426	0.5%	0.8%	0.1%	0.2%	35.1%	53.0%	3.3%	5.0%	0.7%	1.1%	20.3%	30.6%	2.0%	3.1%	35.3%	53.2%	20.1%	30.3%
2007	427	0.3%	0.4%	*	*	41.0%	58.7%	2.7%	3.8%	0.8%	1.2%	22.0%	31.5%	1.0%	1.5%	32.3%	46.3%	20.3%	29.1%
2007	428	0.2%	0.3%	*	*	33.3%	46.3%	1.9%	2.6%	0.7%	1.0%	25.2%	35.0%	0.9%	1.2%	38.3%	53.4%	19.8%	27.5%
2007	429	0.8%	1.2%	*	*	31.4%	45.6%	2.7%	3.9%	0.5%	0.7%	24.9%	36.2%	2.6%	3.7%	35.2%	51.2%	19.6%	28.5%
2007	430	0.9%	1.4%	0.1%	0.1%	30.3%	45.4%	3.0%	4.5%	0.8%	1.2%	24.1%	36.1%	2.7%	4.0%	33.1%	49.6%	20.2%	30.3%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2007	431	0.2%	0.3%	0.1%	0.1%	34.5%	50.5%	1.9%	2.8%	0.9%	1.3%	24.1%	35.3%	2.5%	3.6%	32.7%	47.9%	16.6%	24.2%
2007	432	0.5%	0.8%	0.1%	0.1%	37.3%	53.6%	3.4%	4.9%	1.5%	2.1%	22.7%	32.6%	1.9%	2.7%	36.7%	52.8%	20.7%	29.8%
2007	435	0.3%	0.5%	*	*	38.3%	54.1%	3.2%	4.6%	1.3%	1.9%	23.9%	33.8%	1.0%	1.4%	37.0%	52.3%	18.5%	26.1%
2007	437	0.4%	0.6%	*	*	38.6%	57.8%	1.0%	1.5%	0.8%	1.2%	25.3%	37.8%	0.5%	0.7%	31.2%	46.7%	11.7%	17.6%
2007	438	0.3%	0.4%	*	*	37.8%	57.4%	1.4%	2.1%	1.6%	2.5%	25.3%	38.3%	1.1%	1.7%	28.9%	43.8%	15.8%	24.0%
2007	439	0.4%	0.6%	0.1%	0.1%	39.3%	58.3%	1.4%	2.0%	1.1%	1.6%	23.7%	35.1%	0.7%	1.0%	31.2%	46.3%	14.6%	21.7%
2007	440	0.4%	0.7%	0.1%	0.2%	38.7%	56.3%	1.6%	2.4%	1.9%	2.7%	23.4%	34.0%	1.1%	1.6%	30.5%	44.4%	18.9%	27.5%
2007	441	0.4%	0.6%	0.2%	0.3%	38.9%	57.0%	1.8%	2.7%	1.1%	1.7%	25.8%	37.9%	1.1%	1.6%	27.9%	40.9%	17.9%	26.3%
2007	442	0.6%	0.9%	0.4%	0.6%	43.1%	62.2%	1.3%	1.8%	1.3%	1.8%	23.6%	34.0%	0.6%	0.9%	32.3%	46.6%	15.1%	21.8%
2007	443	0.6%	0.9%	0.1%	0.2%	37.5%	54.1%	3.8%	5.4%	1.5%	2.1%	23.4%	33.7%	2.3%	3.4%	35.6%	51.2%	22.0%	31.7%
2007	444	0.5%	0.8%	*	*	36.0%	51.8%	3.5%	5.1%	1.4%	2.0%	24.6%	35.5%	1.6%	2.2%	35.8%	51.5%	21.3%	30.7%
2007	445	0.3%	0.4%	0.2%	0.3%	33.9%	50.9%	3.5%	5.2%	1.0%	1.4%	22.1%	33.2%	2.1%	3.1%	33.4%	50.2%	21.7%	32.6%
2007	446	*	*	*	*	34.8%	52.5%	0.9%	1.3%	*	*	23.6%	35.5%	1.1%	1.6%	34.0%	51.3%	16.6%	25.0%
2007	447	0.4%	0.5%	0.2%	0.3%	36.2%	52.4%	2.1%	3.1%	0.8%	1.2%	24.3%	35.2%	2.1%	3.0%	34.2%	49.6%	17.8%	25.8%
2007	448	0.3%	0.5%	*	*	36.4%	51.9%	1.1%	1.6%	1.6%	2.3%	25.8%	36.9%	0.5%	0.8%	35.1%	50.1%	17.8%	25.4%
2007	449	0.4%	0.6%	*	*	37.6%	52.9%	1.4%	2.0%	1.1%	1.6%	25.2%	35.5%	1.2%	1.8%	35.4%	49.9%	17.0%	23.9%
2007	450	0.6%	0.9%	*	*	34.6%	49.9%	0.9%	1.2%	0.6%	0.9%	26.7%	38.5%	1.2%	1.8%	35.8%	51.6%	13.6%	19.6%
2007	451	0.4%	0.6%	0.1%	0.1%	32.9%	49.2%	1.8%	2.7%	0.9%	1.3%	24.5%	36.6%	2.0%	3.0%	31.8%	47.5%	18.0%	26.8%
2007	452	0.4%	0.6%	*	*	41.3%	57.6%	0.8%	1.1%	0.5%	0.7%	23.7%	33.1%	1.6%	2.3%	38.2%	53.3%	17.7%	24.7%
2007	456	*	*	*	*	36.7%	51.8%	1.5%	2.1%	*	*	25.8%	36.4%	1.4%	1.9%	32.4%	45.8%	18.8%	26.6%
2007	457	*	*	*	*	45.7%	62.8%	3.3%	4.5%	1.0%	1.4%	22.2%	30.6%	1.1%	1.5%	28.9%	39.8%	24.3%	33.4%
2008	1	0.2%	0.3%	0.1%	0.1%	38.4%	56.4%	3.1%	4.6%	1.4%	2.1%	24.0%	35.3%	1.1%	1.6%	31.0%	45.7%	14.9%	21.9%
2008	2	0.3%	0.4%	0.2%	0.2%	36.3%	51.7%	4.2%	6.0%	1.3%	1.8%	27.1%	38.6%	1.3%	1.9%	36.1%	51.4%	14.2%	20.2%
2008	5	0.1%	0.2%	0.1%	0.1%	37.3%	55.3%	3.0%	4.5%	1.1%	1.6%	23.4%	34.8%	1.1%	1.7%	28.9%	43.0%	14.8%	22.0%
2008	6	0.3%	0.5%	0.1%	0.2%	40.0%	56.5%	3.7%	5.3%	1.3%	1.8%	25.0%	35.3%	1.4%	2.0%	30.7%	43.4%	15.6%	22.1%
2008	7	0.3%	0.4%	0.3%	0.4%	35.6%	53.1%	3.4%	5.0%	1.1%	1.6%	25.2%	37.5%	1.0%	1.5%	31.8%	47.4%	16.2%	24.2%
2008	9	0.4%	0.6%	*	*	37.2%	55.2%	2.2%	3.3%	0.7%	1.1%	25.7%	38.2%	1.7%	2.5%	32.0%	47.5%	15.8%	23.4%
2008	10	0.3%	0.4%	*	*	43.7%	61.0%	4.8%	6.8%	2.5%	3.5%	26.1%	36.4%	0.8%	1.1%	27.5%	38.4%	16.6%	23.2%
2008	11	0.3%	0.4%	*	*	37.9%	57.6%	3.2%	4.9%	2.0%	3.0%	20.7%	31.4%	1.1%	1.7%	28.1%	42.8%	14.2%	21.6%
2008	12	0.4%	0.5%	0.1%	0.2%	40.0%	60.3%	2.9%	4.3%	1.3%	1.9%	21.8%	32.9%	1.2%	1.8%	29.3%	44.1%	14.8%	22.3%
2008	14	*	*	*	*	33.7%	56.1%	3.5%	5.7%	2.1%	3.5%	16.5%	27.4%	1.5%	2.4%	27.8%	46.3%	11.2%	18.6%
2008	15	0.2%	0.4%	*	*	37.0%	59.5%	2.9%	4.7%	1.1%	1.8%	21.2%	34.0%	0.9%	1.5%	28.4%	45.7%	12.4%	19.9%
2008	16	0.6%	0.8%	0.3%	0.4%	36.0%	53.9%	2.8%	4.1%	0.9%	1.4%	22.7%	34.0%	1.3%	2.0%	32.4%	48.6%	14.7%	22.0%
2008	18	0.5%	0.6%	*	*	42.2%	58.3%	4.5%	6.3%	1.3%	1.9%	24.6%	34.0%	1.1%	1.5%	38.3%	53.0%	13.0%	17.9%
2008	19	0.2%	0.4%	0.1%	0.2%	36.9%	53.9%	3.4%	5.0%	0.9%	1.4%	22.9%	33.5%	1.7%	2.5%	34.3%	50.2%	13.6%	19.9%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	21	0.4%	0.6%	0.4%	0.5%	38.1%	56.9%	3.3%	4.9%	1.7%	2.5%	22.3%	33.3%	1.6%	2.4%	28.9%	43.1%	13.7%	20.5%
2008	22	0.3%	0.4%	*	*	31.4%	46.2%	3.5%	5.1%	0.8%	1.2%	25.3%	37.2%	1.3%	1.9%	35.4%	52.1%	12.9%	19.0%
2008	23	1.4%	2.3%	0.2%	0.4%	38.5%	64.7%	8.2%	13.7%	1.0%	1.7%	15.3%	25.7%	2.9%	4.9%	28.2%	47.3%	18.1%	30.4%
2008	25	0.4%	0.7%	0.1%	0.2%	41.0%	62.6%	4.0%	6.1%	0.9%	1.4%	20.5%	31.3%	2.0%	3.0%	30.1%	45.9%	24.0%	36.7%
2008	31	1.1%	1.7%	0.2%	0.3%	39.8%	62.0%	3.7%	5.8%	2.4%	3.7%	18.4%	28.7%	1.5%	2.3%	26.0%	40.5%	20.7%	32.3%
2008	33	0.6%	1.0%	0.2%	0.3%	36.6%	59.6%	4.2%	6.8%	0.5%	0.8%	18.8%	30.5%	2.1%	3.4%	27.4%	44.7%	16.0%	26.0%
2008	43	0.7%	1.1%	0.1%	0.2%	38.4%	58.6%	3.6%	5.4%	1.2%	1.9%	21.9%	33.4%	1.5%	2.3%	27.5%	41.9%	24.8%	37.7%
2008	56	0.8%	1.4%	0.1%	0.2%	34.1%	59.3%	6.5%	11.3%	0.8%	1.5%	18.2%	31.5%	4.1%	7.1%	28.0%	48.7%	17.7%	30.7%
2008	58	0.9%	1.4%	0.2%	0.3%	41.3%	61.9%	4.0%	6.0%	1.7%	2.6%	20.8%	31.2%	2.5%	3.7%	31.4%	47.1%	23.5%	35.2%
2008	62	0.7%	1.0%	*	*	43.9%	65.0%	3.1%	4.6%	1.0%	1.4%	20.2%	30.0%	1.0%	1.5%	30.6%	45.3%	17.3%	25.6%
2008	65	0.9%	1.5%	0.1%	0.2%	36.5%	60.0%	3.2%	5.2%	0.5%	0.8%	18.2%	29.9%	2.3%	3.7%	27.9%	45.9%	17.4%	28.7%
2008	69	0.8%	1.3%	0.3%	0.5%	37.0%	64.0%	4.4%	7.6%	1.4%	2.5%	16.4%	28.4%	1.8%	3.1%	24.8%	42.9%	15.8%	27.4%
2008	73	0.5%	0.8%	*	*	41.9%	64.0%	2.4%	3.7%	1.5%	2.3%	19.7%	30.1%	1.6%	2.5%	26.6%	40.7%	18.9%	28.9%
2008	77	0.6%	0.9%	0.1%	0.2%	40.2%	60.3%	5.0%	7.5%	1.2%	1.8%	20.5%	30.8%	1.9%	2.8%	30.4%	45.6%	20.5%	30.8%
2008	78	0.2%	0.4%	*	*	38.7%	59.3%	3.3%	5.0%	1.5%	2.3%	20.3%	31.1%	3.7%	5.7%	29.4%	45.1%	20.8%	31.9%
2008	79	0.6%	1.0%	0.1%	0.2%	37.3%	59.6%	4.2%	6.8%	1.0%	1.5%	21.9%	34.9%	1.7%	2.6%	32.0%	51.1%	17.8%	28.4%
2008	80	0.7%	1.0%	0.2%	0.3%	41.7%	63.7%	5.8%	8.9%	1.3%	1.9%	20.6%	31.6%	2.2%	3.4%	27.3%	41.7%	20.4%	31.1%
2008	81	1.5%	2.4%	*	*	38.8%	60.3%	4.0%	6.3%	0.8%	1.2%	15.9%	24.7%	1.9%	2.9%	33.0%	51.3%	15.8%	24.6%
2008	82	1.4%	2.3%	0.1%	0.1%	37.7%	61.1%	4.4%	7.1%	0.6%	1.0%	15.2%	24.7%	3.7%	6.0%	30.0%	48.7%	18.4%	29.9%
2008	83	*	*	*	*	38.6%	68.6%	3.7%	6.5%	1.2%	2.2%	14.9%	26.5%	1.5%	2.6%	23.4%	41.5%	12.5%	22.2%
2008	85	1.4%	2.4%	*	*	39.1%	66.2%	4.9%	8.2%	1.1%	1.9%	12.5%	21.1%	3.5%	5.9%	27.2%	46.0%	16.0%	27.1%
2008	86	0.6%	1.0%	0.2%	0.3%	41.3%	65.7%	6.7%	10.6%	2.0%	3.2%	17.5%	27.8%	2.9%	4.6%	26.1%	41.5%	21.9%	34.8%
2008	87	0.5%	0.7%	*	*	37.2%	59.7%	2.9%	4.6%	0.7%	1.1%	20.2%	32.4%	2.0%	3.2%	30.9%	49.6%	18.1%	29.0%
2008	89	1.0%	1.5%	*	*	39.7%	61.6%	3.7%	5.8%	1.3%	1.9%	18.9%	29.3%	1.4%	2.2%	28.5%	44.1%	16.6%	25.7%
2008	91	0.8%	1.1%	0.2%	0.3%	41.7%	59.7%	3.9%	5.6%	0.9%	1.4%	22.7%	32.6%	2.8%	4.0%	32.6%	46.7%	22.9%	32.8%
2008	96	0.5%	0.7%	0.1%	0.2%	40.6%	65.0%	5.0%	8.0%	1.1%	1.7%	18.5%	29.6%	3.0%	4.9%	25.6%	40.9%	19.2%	30.8%
2008	101	*	*	*	*	43.1%	62.1%	4.1%	5.9%	1.6%	2.2%	22.5%	32.4%	*	*	25.8%	37.3%	16.4%	23.6%
2008	102	0.4%	0.5%	*	*	43.9%	62.4%	4.2%	6.0%	1.3%	1.9%	24.4%	34.7%	1.2%	1.7%	30.1%	42.8%	15.0%	21.4%
2008	103	0.2%	0.3%	0.1%	0.2%	41.2%	58.6%	4.4%	6.2%	1.7%	2.4%	23.9%	34.0%	0.9%	1.3%	29.7%	42.3%	17.8%	25.3%
2008	104	*	*	*	*	44.4%	61.7%	6.2%	8.7%	1.0%	1.4%	21.5%	29.8%	1.3%	1.8%	31.0%	43.0%	17.1%	23.8%
2008	105	*	*	*	*	44.6%	61.9%	4.8%	6.7%	1.5%	2.1%	24.3%	33.6%	0.8%	1.1%	30.4%	42.2%	13.1%	18.1%
2008	106	0.5%	0.7%	*	*	45.9%	63.5%	3.6%	5.0%	1.2%	1.7%	22.0%	30.5%	0.9%	1.2%	33.5%	46.4%	17.9%	24.8%
2008	107	*	*	*	*	39.9%	57.4%	4.7%	6.8%	0.8%	1.2%	28.4%	40.9%	1.2%	1.7%	30.1%	43.4%	15.6%	22.5%
2008	109	0.3%	0.5%	*	*	33.3%	54.6%	6.0%	9.8%	0.8%	1.3%	17.8%	29.2%	1.7%	2.7%	27.2%	44.5%	17.8%	29.2%
2008	110	0.3%	0.4%	0.1%	0.1%	33.2%	50.2%	4.1%	6.2%	0.7%	1.1%	23.7%	35.9%	2.3%	3.4%	29.3%	44.3%	14.4%	21.8%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	111	0.3%	0.5%	0.1%	0.1%	31.1%	50.1%	4.1%	6.6%	1.0%	1.6%	21.7%	35.0%	1.5%	2.4%	27.8%	44.8%	13.2%	21.3%
2008	112	0.6%	1.0%	0.2%	0.3%	30.7%	51.1%	4.0%	6.7%	0.9%	1.4%	20.4%	33.9%	2.9%	4.9%	27.9%	46.4%	12.9%	21.6%
2008	113	0.4%	0.7%	0.1%	0.1%	32.5%	51.8%	3.7%	6.0%	0.8%	1.2%	22.6%	36.0%	2.1%	3.3%	29.3%	46.7%	11.9%	19.0%
2008	115	*	*	*	*	30.9%	55.4%	4.1%	7.4%	0.8%	1.4%	16.4%	29.3%	0.9%	1.6%	27.8%	49.9%	11.9%	21.3%
2008	116	0.3%	0.5%	*	*	30.3%	52.6%	4.9%	8.4%	0.9%	1.5%	19.6%	33.9%	1.3%	2.2%	26.2%	45.4%	12.5%	21.6%
2008	118	0.2%	0.3%	0.3%	0.5%	26.3%	51.3%	4.3%	8.4%	1.2%	2.4%	16.9%	33.0%	3.0%	5.9%	23.7%	46.2%	9.7%	18.9%
2008	119	0.2%	0.3%	0.3%	0.4%	35.4%	58.3%	5.6%	9.3%	1.5%	2.5%	17.0%	27.9%	2.9%	4.8%	28.7%	47.3%	13.3%	21.9%
2008	120	0.3%	0.5%	0.2%	0.2%	36.9%	55.9%	4.3%	6.5%	1.2%	1.9%	22.5%	34.1%	1.4%	2.2%	32.5%	49.2%	14.8%	22.4%
2008	122	0.3%	0.5%	*	*	32.6%	54.7%	4.2%	7.0%	1.2%	2.0%	19.8%	33.3%	1.1%	1.8%	31.7%	53.3%	11.1%	18.7%
2008	123	0.3%	0.4%	0.2%	0.3%	34.1%	51.7%	4.5%	6.9%	1.2%	1.8%	25.9%	39.3%	2.6%	4.0%	28.8%	43.6%	12.3%	18.7%
2008	124	0.2%	0.3%	0.2%	0.3%	34.7%	55.2%	4.2%	6.6%	1.8%	2.9%	21.9%	34.8%	1.5%	2.3%	32.1%	50.9%	13.3%	21.2%
2008	127	0.3%	0.6%	0.3%	0.4%	32.0%	52.0%	4.1%	6.7%	0.9%	1.5%	32.1%	52.1%	2.8%	4.5%	27.3%	44.3%	14.2%	23.0%
2008	129	0.2%	0.3%	0.1%	0.2%	34.5%	56.3%	5.0%	8.1%	1.4%	2.3%	17.5%	28.6%	1.4%	2.4%	31.7%	51.8%	12.7%	20.8%
2008	130	0.2%	0.3%	0.3%	0.4%	33.9%	54.5%	4.3%	6.9%	1.5%	2.3%	21.4%	34.4%	2.1%	3.4%	31.1%	50.1%	13.1%	21.1%
2008	131	0.5%	0.9%	0.3%	0.5%	32.1%	54.6%	5.5%	9.3%	1.4%	2.4%	18.5%	31.5%	1.6%	2.7%	28.7%	48.9%	10.5%	17.8%
2008	133	*	*	1.1%	1.7%	35.3%	52.7%	6.7%	9.9%	2.2%	3.2%	25.4%	37.9%	1.7%	2.5%	33.1%	49.4%	13.1%	19.5%
2008	134	0.2%	0.3%	0.3%	0.5%	37.8%	55.0%	4.9%	7.2%	1.6%	2.3%	24.7%	36.0%	0.9%	1.3%	29.6%	43.1%	15.3%	22.3%
2008	137	0.2%	0.3%	0.2%	0.3%	33.4%	58.7%	4.1%	7.3%	1.3%	2.3%	16.2%	28.6%	1.5%	2.6%	25.6%	45.0%	11.5%	20.2%
2008	139	0.3%	0.6%	*	*	32.4%	54.2%	4.2%	7.1%	0.8%	1.4%	20.7%	34.7%	1.7%	2.8%	25.9%	43.4%	17.3%	28.9%
2008	140	0.2%	0.2%	0.2%	0.3%	38.0%	54.1%	4.5%	6.4%	1.7%	2.5%	26.9%	38.3%	1.4%	2.1%	32.8%	46.7%	18.0%	25.5%
2008	141	0.3%	0.4%	0.2%	0.3%	33.0%	52.5%	4.4%	7.1%	1.1%	1.8%	22.3%	35.6%	1.0%	1.6%	29.8%	47.4%	16.3%	25.9%
2008	142	0.3%	0.4%	*	*	37.1%	51.6%	4.0%	5.6%	1.1%	1.5%	28.6%	39.8%	1.2%	1.7%	35.2%	49.0%	13.3%	18.5%
2008	144	0.3%	0.5%	0.1%	0.2%	36.3%	54.0%	4.3%	6.3%	1.1%	1.7%	24.4%	36.2%	1.6%	2.4%	31.5%	46.9%	13.3%	19.7%
2008	145	0.5%	0.8%	0.2%	0.3%	34.1%	50.0%	4.6%	6.8%	0.9%	1.3%	25.4%	37.3%	1.6%	2.4%	30.7%	45.1%	16.3%	24.0%
2008	146	0.8%	1.2%	*	*	33.3%	51.2%	4.0%	6.1%	1.2%	1.9%	23.5%	36.2%	1.5%	2.2%	30.1%	46.3%	14.4%	22.2%
2008	147	0.3%	0.5%	0.2%	0.2%	34.2%	50.7%	3.9%	5.8%	1.3%	1.9%	25.2%	37.4%	1.8%	2.7%	31.9%	47.2%	14.4%	21.3%
2008	148	0.2%	0.3%	0.2%	0.3%	39.3%	56.3%	4.9%	7.0%	1.7%	2.4%	22.8%	32.8%	1.1%	1.6%	33.3%	47.9%	15.7%	22.5%
2008	149	0.2%	0.3%	0.1%	0.1%	35.7%	52.3%	3.9%	5.8%	1.0%	1.5%	26.2%	38.3%	1.3%	1.9%	29.8%	43.7%	17.6%	25.7%
2008	150	0.8%	1.3%	0.1%	0.2%	32.8%	54.5%	6.4%	10.7%	0.6%	0.9%	14.9%	24.8%	3.8%	6.3%	27.5%	45.7%	18.5%	30.7%
2008	151	0.2%	0.3%	0.2%	0.3%	42.3%	59.3%	2.9%	4.1%	1.6%	2.2%	23.1%	32.5%	0.7%	1.0%	28.7%	40.3%	18.8%	26.4%
2008	152	*	*	*	*	54.6%	71.6%	2.4%	3.2%	5.9%	7.8%	18.3%	24.1%	0.9%	1.2%	19.8%	26.0%	19.9%	26.1%
2008	154	*	*	*	*	38.2%	55.6%	3.5%	5.1%	1.1%	1.6%	23.2%	33.8%	0.9%	1.4%	37.3%	54.3%	14.3%	20.8%
2008	155	0.4%	0.7%	0.1%	0.2%	34.3%	53.6%	4.2%	6.5%	1.1%	1.7%	21.2%	33.2%	2.4%	3.7%	33.4%	52.2%	11.1%	17.4%
2008	156	0.8%	1.3%	0.0%	0.0%	35.1%	56.1%	2.6%	4.2%	0.6%	0.9%	22.4%	35.7%	1.7%	2.7%	31.6%	50.5%	13.7%	22.0%
2008	158	0.4%	0.6%	0.2%	0.3%	37.2%	56.1%	4.3%	6.4%	1.0%	1.5%	20.4%	30.8%	2.7%	4.1%	33.7%	50.8%	13.8%	20.8%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	161	0.4%	0.7%	0.1%	0.1%	34.5%	55.8%	4.7%	7.5%	0.9%	1.5%	17.5%	28.3%	2.5%	4.0%	31.0%	50.2%	12.9%	20.8%
2008	163	0.4%	0.6%	*	*	35.9%	56.1%	5.1%	7.9%	1.3%	2.0%	18.9%	29.6%	1.8%	2.9%	32.0%	50.1%	12.7%	19.9%
2008	164	0.3%	0.5%	*	*	34.6%	53.4%	3.8%	5.8%	1.1%	1.7%	21.7%	33.4%	1.9%	3.0%	33.9%	52.4%	13.1%	20.2%
2008	166	0.4%	0.7%	0.1%	0.2%	36.3%	56.2%	4.7%	7.3%	1.0%	1.6%	19.7%	30.4%	2.1%	3.2%	33.6%	51.9%	14.0%	21.7%
2008	170	0.5%	0.7%	*	*	38.7%	54.0%	2.5%	3.5%	0.7%	1.0%	23.5%	32.8%	1.5%	2.1%	36.9%	51.5%	16.8%	23.5%
2008	171	0.3%	0.5%	0.2%	0.2%	39.9%	57.2%	2.9%	4.1%	1.0%	1.4%	23.4%	33.5%	1.6%	2.3%	32.4%	46.4%	16.4%	23.5%
2008	172	0.3%	0.4%	0.2%	0.3%	37.9%	53.4%	3.0%	4.2%	0.9%	1.3%	24.4%	34.3%	1.1%	1.6%	36.6%	51.6%	14.8%	20.9%
2008	173	0.2%	0.3%	0.3%	0.4%	38.5%	53.4%	2.8%	3.9%	0.9%	1.2%	27.3%	37.8%	1.3%	1.8%	34.1%	47.3%	14.4%	20.0%
2008	175	*	*	*	*	37.5%	53.3%	3.5%	5.0%	0.6%	0.9%	24.8%	35.2%	1.2%	1.7%	36.3%	51.5%	12.5%	17.8%
2008	179	0.3%	0.4%	0.2%	0.3%	37.0%	52.1%	3.4%	4.8%	1.3%	1.8%	26.6%	37.5%	1.5%	2.1%	34.2%	48.1%	15.1%	21.2%
2008	180	0.2%	0.3%	0.3%	0.4%	38.2%	52.9%	5.4%	7.5%	1.8%	2.4%	28.4%	39.3%	1.8%	2.5%	33.4%	46.3%	15.7%	21.8%
2008	181	0.2%	0.3%	*	*	34.7%	50.6%	3.3%	4.9%	0.7%	1.1%	27.0%	39.4%	2.3%	3.4%	32.3%	47.1%	11.6%	16.9%
2008	183	0.4%	0.5%	0.2%	0.3%	35.8%	50.8%	3.7%	5.2%	1.6%	2.3%	27.4%	38.9%	1.5%	2.1%	32.3%	45.9%	15.1%	21.4%
2008	184	0.5%	0.7%	0.3%	0.4%	40.4%	58.1%	3.1%	4.5%	1.7%	2.5%	25.5%	36.7%	1.0%	1.4%	33.3%	47.9%	12.0%	17.2%
2008	185	*	*	0.4%	0.5%	35.2%	49.4%	3.8%	5.4%	1.2%	1.7%	29.9%	42.1%	1.0%	1.4%	32.0%	45.0%	13.5%	18.9%
2008	186	0.9%	1.5%	*	*	34.1%	54.2%	3.8%	6.1%	0.7%	1.1%	21.8%	34.6%	1.6%	2.5%	32.6%	51.8%	10.6%	16.8%
2008	187	0.3%	0.4%	0.2%	0.3%	41.1%	57.6%	3.9%	5.4%	0.9%	1.3%	26.2%	36.8%	2.2%	3.1%	31.7%	44.4%	13.9%	19.5%
2008	188	0.4%	0.6%	0.4%	0.6%	38.7%	53.6%	4.4%	6.1%	1.3%	1.8%	27.0%	37.4%	3.2%	4.4%	32.1%	44.5%	12.8%	17.8%
2008	190	*	*	*	*	35.5%	51.1%	2.0%	2.8%	1.2%	1.7%	24.6%	35.4%	1.0%	1.4%	34.6%	49.7%	13.1%	18.8%
2008	191	0.3%	0.4%	0.2%	0.3%	36.1%	51.7%	3.2%	4.5%	1.1%	1.5%	24.1%	34.5%	1.0%	1.5%	36.8%	52.7%	15.2%	21.8%
2008	192	0.2%	0.3%	0.2%	0.3%	39.1%	55.7%	3.3%	4.7%	1.0%	1.5%	23.9%	34.2%	1.2%	1.7%	35.3%	50.4%	14.7%	20.9%
2008	193	*	*	*	*	32.4%	48.1%	2.2%	3.2%	0.9%	1.3%	24.6%	36.5%	1.2%	1.8%	31.9%	47.4%	15.8%	23.5%
2008	194	0.2%	0.2%	*	*	37.0%	53.0%	2.5%	3.6%	1.0%	1.4%	22.8%	32.6%	0.9%	1.2%	39.0%	55.7%	13.9%	19.9%
2008	195	*	*	*	*	38.4%	52.6%	4.8%	6.6%	2.1%	2.9%	24.8%	34.0%	1.0%	1.3%	36.2%	49.7%	12.9%	17.6%
2008	196	0.3%	0.4%	*	*	39.5%	55.0%	4.1%	5.7%	1.6%	2.2%	21.2%	29.5%	1.1%	1.6%	31.8%	44.3%	24.4%	34.0%
2008	197	*	*	*	*	35.6%	51.6%	2.6%	3.8%	1.5%	2.2%	24.6%	35.6%	1.2%	1.7%	34.5%	50.0%	13.5%	19.6%
2008	200	0.6%	0.8%	0.4%	0.6%	37.6%	54.6%	3.6%	5.3%	1.9%	2.8%	24.0%	34.8%	0.7%	1.1%	31.1%	45.1%	14.7%	21.4%
2008	201	0.2%	0.3%	0.6%	0.8%	38.6%	53.3%	3.6%	4.9%	2.0%	2.8%	26.9%	37.1%	1.8%	2.5%	30.5%	42.0%	15.4%	21.3%
2008	203	0.4%	0.6%	*	*	38.4%	56.1%	4.0%	5.9%	0.8%	1.1%	25.3%	37.0%	2.5%	3.6%	29.2%	42.7%	14.5%	21.1%
2008	204	0.4%	0.6%	0.2%	0.3%	41.8%	60.0%	5.1%	7.3%	1.6%	2.2%	24.1%	34.6%	1.7%	2.5%	33.8%	48.5%	14.9%	21.4%
2008	205	0.4%	0.6%	0.1%	0.2%	37.1%	54.7%	3.9%	5.7%	1.1%	1.6%	23.6%	34.7%	1.8%	2.7%	31.9%	47.1%	14.6%	21.5%
2008	207	*	*	1.2%	1.8%	35.3%	53.8%	5.4%	8.2%	2.6%	4.0%	21.9%	33.3%	2.8%	4.3%	26.7%	40.6%	15.4%	23.4%
2008	208	0.4%	0.6%	0.2%	0.3%	38.6%	54.7%	3.3%	4.7%	1.8%	2.5%	25.0%	35.5%	1.0%	1.4%	33.1%	47.0%	15.2%	21.5%
2008	209	0.3%	0.4%	0.2%	0.3%	34.6%	50.3%	4.2%	6.1%	0.8%	1.1%	27.9%	40.5%	1.3%	1.8%	34.4%	50.0%	13.8%	20.1%
2008	210	0.4%	0.5%	0.4%	0.6%	37.2%	53.0%	3.9%	5.6%	1.8%	2.6%	27.7%	39.4%	2.6%	3.7%	28.9%	41.1%	17.6%	25.1%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	212	0.6%	0.8%	*	*	39.6%	56.3%	3.6%	5.1%	1.0%	1.4%	23.9%	34.0%	3.3%	4.6%	35.9%	51.0%	18.8%	26.8%
2008	213	0.2%	0.3%	0.1%	0.2%	38.1%	55.9%	4.4%	6.4%	1.6%	2.3%	22.4%	32.9%	2.8%	4.1%	34.0%	49.9%	19.8%	29.0%
2008	214	0.3%	0.4%	0.2%	0.3%	40.4%	57.9%	4.9%	7.0%	1.1%	1.5%	25.9%	37.1%	1.1%	1.5%	35.1%	50.4%	13.5%	19.4%
2008	216	0.5%	0.8%	*	*	34.0%	51.5%	3.4%	5.1%	1.1%	1.7%	25.2%	38.1%	2.9%	4.4%	31.3%	47.4%	12.2%	18.5%
2008	217	0.3%	0.4%	*	*	37.3%	54.5%	5.2%	7.6%	1.8%	2.7%	25.4%	37.1%	2.3%	3.3%	31.4%	45.9%	18.4%	26.9%
2008	218	0.4%	0.6%	0.2%	0.2%	34.0%	51.5%	4.0%	6.1%	1.0%	1.5%	27.5%	41.7%	2.8%	4.2%	30.2%	45.7%	12.6%	19.1%
2008	219	0.3%	0.4%	*	*	37.4%	54.1%	4.8%	6.9%	0.6%	0.9%	26.3%	37.9%	1.3%	1.9%	30.3%	43.7%	16.3%	23.5%
2008	220	*	*	*	*	38.1%	56.2%	5.9%	8.7%	1.3%	1.9%	24.1%	35.7%	2.1%	3.1%	30.8%	45.5%	13.7%	20.3%
2008	221	0.4%	0.6%	*	*	40.2%	61.6%	3.0%	4.6%	1.2%	1.8%	21.0%	32.2%	0.6%	0.9%	29.6%	45.4%	11.7%	17.9%
2008	222	0.3%	0.4%	0.1%	0.1%	36.2%	55.2%	3.5%	5.4%	1.6%	2.4%	22.0%	33.5%	0.8%	1.2%	32.5%	49.6%	10.7%	16.3%
2008	223	0.4%	0.6%	0.1%	0.1%	32.1%	53.1%	3.8%	6.3%	0.9%	1.5%	19.8%	32.9%	1.4%	2.4%	30.1%	49.8%	11.7%	19.4%
2008	225	0.3%	0.4%	0.2%	0.3%	34.8%	52.1%	4.5%	6.8%	1.5%	2.2%	20.9%	31.3%	1.6%	2.4%	34.9%	52.3%	14.5%	21.7%
2008	226	0.4%	0.7%	*	*	34.8%	55.8%	4.7%	7.5%	0.6%	0.9%	20.6%	33.0%	2.3%	3.8%	30.3%	48.6%	13.5%	21.6%
2008	227	0.3%	0.5%	0.1%	0.2%	37.3%	57.8%	2.0%	3.1%	0.9%	1.4%	22.1%	34.3%	1.2%	1.8%	29.3%	45.5%	12.1%	18.7%
2008	230	0.2%	0.4%	*	*	36.7%	54.3%	1.9%	2.8%	0.8%	1.2%	25.4%	37.7%	0.9%	1.4%	31.0%	45.9%	15.9%	23.5%
2008	231	0.2%	0.3%	*	*	39.2%	59.1%	1.9%	2.9%	0.8%	1.2%	24.7%	37.3%	0.5%	0.7%	29.8%	44.9%	12.9%	19.5%
2008	232	0.3%	0.5%	0.1%	0.2%	34.5%	56.1%	2.9%	4.7%	1.0%	1.6%	22.2%	36.1%	1.5%	2.5%	29.1%	47.3%	9.9%	16.1%
2008	233	0.3%	0.6%	*	*	33.1%	59.9%	3.0%	5.3%	0.5%	0.8%	18.9%	34.1%	1.2%	2.1%	28.0%	50.7%	10.5%	19.0%
2008	234	0.3%	0.5%	0.1%	0.1%	28.5%	52.4%	2.6%	4.9%	0.4%	0.7%	21.2%	39.1%	1.4%	2.5%	25.9%	47.6%	9.1%	16.8%
2008	235	0.3%	0.5%	*	*	31.6%	53.2%	2.3%	3.8%	1.2%	2.1%	23.1%	38.8%	0.8%	1.3%	29.7%	49.8%	9.0%	15.1%
2008	236	0.2%	0.3%	0.2%	0.2%	37.0%	52.1%	2.4%	3.5%	0.9%	1.2%	27.9%	39.4%	1.0%	1.5%	30.2%	42.5%	16.4%	23.1%
2008	238	0.4%	0.6%	*	*	40.8%	56.0%	3.0%	4.1%	1.1%	1.5%	27.6%	37.8%	1.4%	1.9%	32.1%	44.0%	16.5%	22.6%
2008	239	0.3%	0.4%	0.2%	0.2%	40.0%	55.9%	4.1%	5.8%	1.2%	1.7%	26.2%	36.6%	1.2%	1.7%	33.1%	46.2%	16.1%	22.5%
2008	240	0.3%	0.4%	*	*	38.2%	55.3%	1.7%	2.4%	0.8%	1.2%	26.8%	38.8%	0.9%	1.3%	30.4%	44.0%	12.9%	18.7%
2008	242	*	*	0.3%	0.4%	34.7%	50.0%	2.8%	4.1%	1.0%	1.4%	28.4%	41.0%	0.9%	1.3%	28.6%	41.2%	16.0%	23.1%
2008	243	*	*	*	*	35.8%	55.6%	3.7%	5.8%	1.2%	1.8%	24.6%	38.2%	1.3%	2.0%	27.2%	42.3%	12.2%	19.0%
2008	244	0.6%	1.0%	*	*	31.0%	56.6%	3.1%	5.7%	0.9%	1.7%	19.6%	35.9%	1.4%	2.5%	23.9%	43.6%	8.9%	16.2%
2008	245	0.3%	0.6%	0.1%	0.2%	27.7%	54.2%	4.1%	8.0%	0.7%	1.4%	16.2%	31.6%	2.8%	5.5%	23.7%	46.3%	8.3%	16.2%
2008	246	0.3%	0.4%	0.2%	0.3%	36.3%	55.1%	2.5%	3.7%	1.4%	2.1%	24.3%	36.9%	1.2%	1.8%	31.6%	48.0%	11.7%	17.8%
2008	248	0.5%	0.7%	*	*	39.9%	55.0%	3.7%	5.2%	1.4%	2.0%	25.2%	34.8%	2.6%	3.6%	34.3%	47.4%	18.7%	25.9%
2008	249	*	*	0.5%	0.7%	42.2%	61.3%	4.7%	6.9%	2.0%	2.9%	22.5%	32.8%	1.2%	1.7%	29.1%	42.4%	14.3%	20.9%
2008	250	*	*	*	*	35.9%	54.7%	2.1%	3.3%	1.2%	1.8%	26.3%	40.0%	0.6%	0.8%	29.5%	45.0%	10.4%	15.9%
2008	251	0.2%	0.3%	0.1%	0.2%	38.8%	55.8%	2.3%	3.3%	1.5%	2.2%	25.0%	36.0%	0.8%	1.1%	31.9%	45.9%	13.7%	19.7%
2008	253	0.2%	0.3%	*	*	35.5%	51.3%	1.8%	2.7%	0.8%	1.2%	27.1%	39.2%	0.9%	1.3%	31.9%	46.1%	8.5%	12.2%
2008	254	*	*	*	*	40.8%	58.2%	3.6%	5.1%	1.6%	2.2%	23.2%	33.1%	1.9%	2.8%	30.8%	43.8%	14.9%	21.2%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	256	0.3%	0.4%	*	*	38.6%	54.7%	2.2%	3.1%	1.8%	2.6%	28.3%	40.1%	0.8%	1.2%	31.2%	44.1%	14.8%	21.0%
2008	257	0.3%	0.5%	*	*	37.8%	53.2%	3.7%	5.3%	1.4%	2.0%	26.0%	36.5%	1.5%	2.1%	31.5%	44.3%	17.5%	24.6%
2008	258	0.2%	0.3%	*	*	37.5%	51.9%	3.5%	4.8%	0.8%	1.2%	26.9%	37.2%	0.9%	1.2%	36.5%	50.6%	14.6%	20.2%
2008	259	0.2%	0.3%	0.1%	0.1%	36.8%	51.2%	4.0%	5.6%	1.2%	1.7%	28.2%	39.2%	1.4%	2.0%	33.1%	45.9%	16.0%	22.3%
2008	260	0.2%	0.3%	0.3%	0.4%	36.3%	48.8%	2.6%	3.5%	1.1%	1.5%	27.9%	37.5%	1.4%	1.9%	39.0%	52.4%	17.5%	23.4%
2008	261	*	*	*	*	40.2%	53.9%	5.4%	7.2%	1.7%	2.3%	26.6%	35.7%	2.3%	3.1%	31.4%	42.2%	18.3%	24.5%
2008	262	0.2%	0.3%	0.2%	0.3%	39.2%	53.7%	3.0%	4.1%	1.9%	2.6%	28.1%	38.5%	2.5%	3.5%	29.1%	39.9%	12.6%	17.2%
2008	263	0.7%	1.0%	0.3%	0.4%	38.6%	55.6%	4.5%	6.5%	1.5%	2.2%	25.5%	36.7%	1.1%	1.5%	32.5%	46.7%	15.8%	22.7%
2008	264	0.3%	0.5%	0.2%	0.3%	40.1%	58.6%	3.0%	4.4%	1.6%	2.3%	24.1%	35.3%	1.1%	1.6%	32.7%	47.8%	14.1%	20.6%
2008	267	0.2%	0.4%	0.4%	0.5%	39.2%	57.9%	3.9%	5.8%	2.3%	3.4%	23.0%	34.0%	1.5%	2.2%	31.9%	47.1%	17.2%	25.5%
2008	268	0.3%	0.4%	0.2%	0.4%	36.9%	54.7%	2.9%	4.4%	1.2%	1.7%	25.5%	37.8%	1.1%	1.6%	30.8%	45.6%	13.2%	19.6%
2008	270	0.4%	0.6%	0.3%	0.4%	43.1%	60.7%	3.3%	4.7%	2.3%	3.2%	24.9%	35.1%	1.1%	1.5%	33.0%	46.5%	15.5%	21.8%
2008	273	0.5%	0.8%	0.2%	0.3%	36.2%	53.4%	4.0%	5.9%	1.4%	2.1%	25.1%	37.0%	1.4%	2.0%	33.8%	49.8%	12.9%	19.0%
2008	274	0.2%	0.3%	0.2%	0.2%	43.9%	59.3%	3.3%	4.5%	2.4%	3.2%	24.1%	32.5%	0.7%	1.0%	29.5%	39.8%	18.5%	25.0%
2008	275	*	*	*	*	40.5%	57.2%	5.2%	7.4%	0.8%	1.2%	23.4%	33.0%	*	*	33.0%	46.6%	21.2%	30.0%
2008	276	0.2%	0.3%	*	*	41.2%	58.5%	2.9%	4.1%	2.0%	2.8%	23.0%	32.6%	0.9%	1.3%	28.8%	40.9%	16.2%	23.0%
2008	277	0.3%	0.4%	0.2%	0.3%	36.8%	52.1%	3.1%	4.4%	1.5%	2.1%	24.3%	34.4%	1.2%	1.6%	33.0%	46.7%	18.6%	26.4%
2008	278	0.3%	0.4%	0.1%	0.2%	37.3%	53.0%	3.7%	5.2%	1.3%	1.8%	23.9%	33.9%	1.2%	1.8%	33.1%	46.9%	17.7%	25.1%
2008	279	0.5%	0.8%	0.1%	0.2%	37.9%	59.4%	5.4%	8.4%	1.7%	2.7%	18.8%	29.5%	1.5%	2.4%	30.0%	47.1%	16.3%	25.6%
2008	280	0.5%	0.7%	*	*	42.1%	62.8%	4.1%	6.1%	1.3%	2.0%	19.3%	28.8%	1.3%	1.9%	29.2%	43.6%	16.2%	24.2%
2008	281	0.4%	0.6%	0.3%	0.4%	37.8%	57.3%	1.9%	2.9%	0.9%	1.3%	24.0%	36.5%	0.7%	1.0%	29.7%	45.0%	9.8%	14.9%
2008	282	0.3%	0.4%	0.2%	0.3%	36.7%	56.1%	3.0%	4.6%	1.9%	2.9%	22.0%	33.6%	1.1%	1.7%	30.4%	46.4%	12.8%	19.5%
2008	283	0.5%	0.8%	0.1%	0.2%	28.3%	49.3%	5.8%	10.0%	1.2%	2.1%	17.5%	30.5%	7.2%	12.5%	26.8%	46.7%	12.8%	22.3%
2008	284	0.8%	1.5%	0.1%	0.1%	31.4%	57.0%	6.9%	12.5%	0.7%	1.4%	14.6%	26.5%	4.4%	8.0%	27.6%	50.1%	14.6%	26.4%
2008	285	0.6%	1.0%	0.2%	0.4%	33.3%	55.6%	6.5%	10.8%	1.4%	2.4%	16.5%	27.5%	4.4%	7.3%	30.3%	50.5%	12.6%	21.0%
2008	288	0.8%	1.4%	0.1%	0.2%	31.5%	55.0%	6.8%	12.0%	1.1%	1.9%	16.6%	29.0%	6.7%	11.8%	27.8%	48.7%	12.1%	21.1%
2008	289	0.7%	1.3%	0.1%	0.2%	30.3%	53.5%	6.2%	10.9%	1.0%	1.8%	18.6%	32.8%	5.0%	8.8%	27.7%	48.9%	14.5%	25.5%
2008	291	0.6%	1.1%	*	*	33.2%	55.9%	5.4%	9.0%	0.5%	0.9%	17.6%	29.7%	3.2%	5.4%	31.4%	52.8%	14.8%	24.8%
2008	292	0.4%	0.7%	*	*	27.2%	52.1%	5.1%	9.8%	1.4%	2.7%	16.0%	30.7%	4.0%	7.7%	24.7%	47.4%	10.0%	19.1%
2008	293	0.2%	0.3%	0.2%	0.3%	40.8%	60.0%	2.9%	4.2%	1.2%	1.7%	23.7%	34.8%	0.8%	1.1%	32.5%	47.7%	17.0%	25.0%
2008	295	0.4%	0.6%	0.1%	0.2%	33.0%	51.2%	5.3%	8.3%	2.1%	3.2%	23.1%	36.0%	2.3%	3.6%	28.9%	44.9%	13.0%	20.3%
2008	296	0.4%	0.6%	0.2%	0.4%	34.5%	51.0%	6.0%	8.9%	1.9%	2.7%	24.0%	35.4%	4.5%	6.7%	30.9%	45.6%	17.5%	25.8%
2008	297	0.6%	1.0%	0.1%	0.1%	34.8%	57.4%	4.2%	7.0%	0.7%	1.1%	22.0%	36.2%	2.3%	3.7%	28.5%	47.1%	13.8%	22.8%
2008	299	0.3%	0.5%	0.1%	0.1%	37.9%	56.1%	4.8%	7.1%	1.9%	2.8%	25.5%	37.7%	1.8%	2.6%	29.5%	43.7%	15.2%	22.5%
2008	300	0.4%	0.6%	*	*	33.4%	49.8%	7.6%	11.4%	1.9%	2.9%	23.6%	35.2%	4.1%	6.1%	32.0%	47.7%	13.7%	20.4%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	301	0.7%	1.4%	0.1%	0.2%	25.8%	54.6%	5.6%	11.8%	0.9%	1.9%	13.6%	28.7%	2.6%	5.6%	24.8%	52.5%	9.5%	20.2%
2008	303	1.4%	2.7%	0.1%	0.2%	29.7%	57.2%	6.9%	13.3%	0.9%	1.8%	15.2%	29.3%	4.0%	7.7%	26.2%	50.6%	12.7%	24.6%
2008	304	0.6%	0.9%	0.2%	0.3%	36.2%	53.8%	4.7%	6.9%	1.1%	1.6%	25.1%	37.2%	1.5%	2.3%	30.5%	45.2%	13.9%	20.7%
2008	307	0.5%	0.7%	0.1%	0.2%	34.1%	50.1%	6.6%	9.7%	1.5%	2.2%	25.2%	36.9%	2.0%	3.0%	29.4%	43.1%	13.8%	20.2%
2008	308	0.5%	0.9%	0.1%	0.2%	29.9%	54.4%	5.9%	10.8%	1.3%	2.4%	16.1%	29.4%	2.3%	4.1%	26.6%	48.4%	11.8%	21.4%
2008	309	0.2%	0.3%	0.2%	0.3%	40.0%	56.9%	3.7%	5.3%	1.3%	1.8%	25.5%	36.3%	1.9%	2.7%	31.0%	44.1%	17.1%	24.4%
2008	311	0.2%	0.3%	0.2%	0.3%	38.6%	55.2%	4.2%	6.0%	1.4%	2.0%	25.0%	35.7%	1.7%	2.4%	32.7%	46.8%	15.8%	22.5%
2008	312	0.4%	0.5%	0.1%	0.2%	35.2%	50.3%	3.7%	5.3%	0.8%	1.1%	27.1%	38.7%	1.5%	2.2%	34.1%	48.6%	15.4%	21.9%
2008	313	0.2%	0.3%	0.2%	0.2%	34.7%	51.4%	4.8%	7.1%	1.0%	1.5%	24.4%	36.2%	1.1%	1.6%	34.3%	50.8%	16.0%	23.8%
2008	314	0.3%	0.4%	0.1%	0.2%	35.2%	49.6%	4.2%	5.9%	1.4%	2.0%	27.0%	38.0%	1.8%	2.5%	33.5%	47.1%	15.9%	22.3%
2008	315	0.2%	0.3%	0.3%	0.4%	38.8%	56.5%	3.0%	4.3%	1.1%	1.7%	22.5%	32.8%	0.9%	1.3%	33.8%	49.2%	16.8%	24.5%
2008	318	0.4%	0.5%	0.2%	0.3%	36.0%	51.9%	4.2%	6.1%	1.4%	1.9%	26.6%	38.3%	1.9%	2.7%	32.6%	47.0%	16.9%	24.3%
2008	319	0.2%	0.2%	0.3%	0.4%	35.1%	52.4%	5.4%	8.0%	2.0%	2.9%	24.9%	37.1%	2.8%	4.2%	28.2%	42.0%	14.3%	21.3%
2008	320	0.3%	0.4%	0.1%	0.2%	37.5%	54.4%	4.3%	6.3%	1.2%	1.7%	24.6%	35.6%	1.2%	1.7%	33.8%	49.0%	14.4%	20.9%
2008	321	0.3%	0.4%	*	*	34.9%	48.6%	3.0%	4.2%	1.2%	1.7%	26.7%	37.2%	0.3%	0.4%	35.3%	49.2%	12.8%	17.8%
2008	322	0.3%	0.5%	*	*	36.3%	51.2%	2.6%	3.7%	1.3%	1.8%	27.3%	38.5%	0.5%	0.7%	33.2%	46.8%	10.3%	14.5%
2008	323	*	*	*	*	38.9%	53.0%	4.5%	6.1%	1.1%	1.6%	28.3%	38.5%	0.4%	0.6%	33.4%	45.6%	11.8%	16.1%
2008	324	*	*	*	*	41.1%	57.6%	1.4%	2.0%	0.7%	0.9%	23.9%	33.5%	0.6%	0.8%	33.1%	46.4%	11.4%	15.9%
2008	325	0.4%	0.5%	*	*	32.9%	48.9%	4.3%	6.4%	0.8%	1.2%	26.6%	39.5%	2.2%	3.3%	29.2%	43.4%	15.5%	23.0%
2008	326	0.4%	0.5%	*	*	36.3%	51.5%	4.5%	6.4%	1.2%	1.7%	26.0%	36.8%	1.9%	2.7%	33.0%	46.7%	16.6%	23.6%
2008	327	0.4%	0.6%	0.2%	0.3%	36.4%	53.5%	4.1%	6.1%	1.1%	1.7%	26.6%	39.0%	1.6%	2.4%	30.6%	45.0%	14.6%	21.5%
2008	328	0.4%	0.5%	0.1%	0.1%	32.8%	49.4%	3.7%	5.5%	0.9%	1.4%	26.7%	40.3%	1.6%	2.4%	31.6%	47.6%	12.0%	18.0%
2008	329	0.5%	0.7%	0.3%	0.4%	37.0%	53.8%	5.6%	8.2%	1.9%	2.8%	24.9%	36.3%	1.7%	2.5%	32.6%	47.4%	17.0%	24.7%
2008	330	0.5%	0.7%	0.2%	0.2%	35.6%	52.5%	4.7%	6.9%	1.6%	2.3%	26.2%	38.6%	1.6%	2.4%	33.0%	48.6%	13.9%	20.4%
2008	331	*	*	*	*	39.8%	56.0%	3.9%	5.5%	2.0%	2.8%	28.0%	39.4%	2.5%	3.5%	34.4%	48.4%	14.3%	20.1%
2008	332	0.3%	0.5%	*	*	34.6%	53.0%	5.2%	8.0%	1.1%	1.7%	24.4%	37.4%	2.0%	3.1%	29.2%	44.7%	14.2%	21.8%
2008	334	0.3%	0.4%	0.1%	0.2%	38.9%	55.8%	4.1%	5.9%	1.9%	2.7%	25.6%	36.7%	1.8%	2.5%	33.1%	47.6%	13.1%	18.8%
2008	335	0.2%	0.3%	0.4%	0.6%	30.1%	47.4%	4.2%	6.7%	1.4%	2.2%	25.0%	39.3%	2.9%	4.6%	31.0%	48.8%	11.7%	18.4%
2008	336	0.3%	0.4%	*	*	36.9%	54.6%	8.4%	12.4%	0.9%	1.3%	22.5%	33.2%	1.9%	2.8%	27.9%	41.3%	21.7%	32.0%
2008	339	0.4%	0.6%	0.1%	0.1%	40.7%	57.9%	5.6%	7.9%	1.3%	1.9%	22.6%	32.2%	1.3%	1.8%	33.7%	48.0%	19.2%	27.3%
2008	340	0.3%	0.5%	0.1%	0.2%	38.9%	56.5%	4.4%	6.3%	1.4%	2.0%	23.8%	34.5%	1.6%	2.3%	30.6%	44.4%	18.1%	26.2%
2008	341	*	*	*	*	44.4%	63.0%	3.2%	4.6%	1.9%	2.7%	20.9%	29.6%	*	*	30.9%	43.8%	14.4%	20.5%
2008	342	0.2%	0.4%	0.1%	0.2%	39.6%	60.0%	1.5%	2.3%	0.9%	1.4%	21.9%	33.3%	0.6%	1.0%	31.2%	47.4%	11.6%	17.7%
2008	343	0.3%	0.4%	*	*	44.1%	64.7%	2.8%	4.1%	1.7%	2.4%	21.4%	31.4%	0.7%	1.0%	27.9%	40.9%	14.5%	21.3%
2008	344	0.5%	0.7%	0.1%	0.2%	41.5%	60.1%	1.8%	2.7%	1.3%	1.9%	25.0%	36.2%	0.8%	1.2%	31.6%	45.7%	11.8%	17.1%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	345	*	*	*	*	40.9%	60.9%	1.5%	2.3%	1.1%	1.6%	23.3%	34.7%	0.7%	1.0%	31.8%	47.3%	10.1%	15.0%
2008	346	0.5%	0.8%	0.2%	0.3%	32.6%	50.2%	6.2%	9.5%	1.1%	1.7%	21.1%	32.5%	4.5%	6.9%	32.0%	49.2%	12.6%	19.4%
2008	347	0.5%	0.7%	*	*	42.6%	60.9%	4.6%	6.5%	1.1%	1.6%	22.0%	31.5%	2.3%	3.3%	31.1%	44.5%	15.5%	22.2%
2008	350	0.4%	0.6%	0.1%	0.2%	36.6%	55.0%	3.6%	5.4%	0.8%	1.2%	22.7%	34.2%	2.1%	3.2%	32.4%	48.7%	13.7%	20.5%
2008	351	0.5%	0.7%	0.2%	0.3%	33.8%	49.9%	4.4%	6.4%	0.8%	1.2%	24.8%	36.5%	2.3%	3.3%	31.4%	46.3%	15.6%	23.0%
2008	352	0.6%	0.8%	0.1%	0.2%	34.5%	51.8%	3.9%	5.9%	1.1%	1.6%	22.1%	33.3%	1.8%	2.7%	34.9%	52.4%	14.5%	21.8%
2008	354	0.4%	0.6%	*	*	36.2%	52.7%	4.6%	6.7%	1.0%	1.4%	24.1%	35.1%	1.5%	2.2%	34.2%	49.8%	13.1%	19.1%
2008	355	0.5%	0.7%	*	*	35.0%	53.1%	3.6%	5.4%	0.9%	1.4%	20.9%	31.7%	1.9%	2.9%	34.0%	51.6%	14.5%	22.1%
2008	356	0.5%	0.9%	0.1%	0.2%	27.9%	48.6%	4.4%	7.6%	0.8%	1.4%	20.5%	35.6%	4.8%	8.3%	26.0%	45.2%	11.3%	19.7%
2008	357	0.4%	0.6%	0.2%	0.2%	31.5%	48.9%	4.5%	7.0%	1.1%	1.7%	23.5%	36.5%	4.9%	7.6%	29.2%	45.3%	12.2%	19.0%
2008	358	0.5%	0.7%	0.2%	0.3%	35.1%	52.4%	6.0%	9.0%	0.8%	1.2%	21.7%	32.4%	2.4%	3.6%	35.8%	53.5%	13.2%	19.7%
2008	359	0.5%	0.7%	0.3%	0.5%	37.2%	53.2%	4.7%	6.7%	1.6%	2.3%	26.1%	37.3%	2.8%	4.0%	32.6%	46.6%	16.4%	23.4%
2008	360	0.3%	0.4%	*	*	36.2%	53.7%	6.0%	8.9%	0.9%	1.3%	22.0%	32.6%	3.4%	5.1%	34.4%	51.1%	12.3%	18.2%
2008	362	1.3%	2.0%	0.3%	0.5%	30.9%	46.1%	5.8%	8.6%	1.4%	2.1%	23.0%	34.3%	6.3%	9.4%	32.3%	48.1%	11.9%	17.7%
2008	363	0.5%	0.8%	*	*	35.6%	52.5%	2.7%	3.9%	0.8%	1.2%	19.9%	29.4%	1.6%	2.4%	36.4%	53.7%	16.1%	23.8%
2008	364	0.4%	0.7%	0.1%	0.2%	31.2%	49.5%	2.7%	4.3%	0.8%	1.2%	21.6%	34.3%	1.8%	2.8%	33.0%	52.3%	12.0%	19.1%
2008	365	0.2%	0.3%	0.1%	0.2%	36.5%	53.6%	4.3%	6.3%	1.2%	1.8%	24.5%	36.1%	1.5%	2.3%	31.7%	46.6%	13.8%	20.2%
2008	366	0.2%	0.3%	0.2%	0.3%	35.5%	50.6%	4.7%	6.7%	1.3%	1.8%	26.4%	37.7%	2.9%	4.1%	30.1%	42.9%	16.5%	23.6%
2008	367	0.2%	0.2%	0.1%	0.2%	38.9%	52.9%	4.1%	5.7%	0.8%	1.1%	29.9%	40.8%	2.3%	3.1%	28.3%	38.6%	17.7%	24.1%
2008	368	0.2%	0.3%	0.2%	0.3%	36.6%	53.7%	4.2%	6.2%	1.0%	1.4%	24.1%	35.3%	1.5%	2.2%	31.9%	46.9%	15.8%	23.2%
2008	369	0.2%	0.3%	0.2%	0.3%	37.3%	52.4%	6.2%	8.8%	1.0%	1.4%	25.5%	35.9%	1.2%	1.7%	33.9%	47.6%	15.6%	21.9%
2008	370	*	*	*	*	39.5%	56.1%	3.7%	5.3%	0.8%	1.2%	23.1%	32.8%	1.4%	2.0%	30.1%	42.7%	18.6%	26.4%
2008	371	0.2%	0.2%	*	*	36.7%	52.6%	3.3%	4.7%	1.0%	1.4%	23.0%	33.1%	0.9%	1.2%	32.8%	47.1%	15.5%	22.3%
2008	373	0.2%	0.3%	0.3%	0.4%	38.1%	55.9%	3.9%	5.7%	2.3%	3.4%	24.0%	35.2%	2.7%	3.9%	31.3%	46.0%	12.8%	18.8%
2008	374	0.5%	0.7%	*	*	40.0%	56.5%	2.7%	3.8%	1.6%	2.2%	24.4%	34.4%	1.0%	1.4%	35.5%	50.1%	17.7%	25.0%
2008	375	*	*	*	*	39.8%	60.0%	3.2%	4.8%	1.3%	1.9%	23.7%	35.7%	0.9%	1.4%	31.3%	47.1%	13.4%	20.2%
2008	376	0.3%	0.5%	0.2%	0.3%	40.0%	58.5%	4.9%	7.2%	2.0%	3.0%	23.8%	34.8%	1.4%	2.0%	32.8%	48.0%	15.1%	22.1%
2008	377	0.3%	0.4%	0.1%	0.2%	40.6%	57.1%	4.8%	6.7%	2.3%	3.3%	26.0%	36.7%	1.4%	2.0%	32.1%	45.2%	15.2%	21.4%
2008	379	0.6%	0.9%	0.2%	0.3%	36.4%	51.5%	3.8%	5.4%	1.3%	1.8%	26.7%	37.8%	2.0%	2.8%	34.0%	48.1%	16.2%	22.9%
2008	380	0.4%	0.5%	0.1%	0.2%	39.3%	56.3%	3.5%	5.0%	1.6%	2.4%	25.4%	36.4%	2.2%	3.2%	31.5%	45.2%	14.6%	20.9%
2008	382	*	*	*	*	40.6%	58.4%	4.2%	6.1%	1.7%	2.4%	23.3%	33.5%	0.8%	1.1%	33.1%	47.7%	16.0%	23.0%
2008	383	0.7%	1.0%	0.2%	0.2%	39.6%	53.4%	4.0%	5.4%	1.2%	1.6%	27.1%	36.5%	2.3%	3.0%	33.6%	45.3%	18.8%	25.3%
2008	385	0.3%	0.5%	0.1%	0.1%	36.6%	53.5%	4.9%	7.1%	1.5%	2.2%	24.6%	36.0%	1.7%	2.5%	31.3%	45.7%	17.2%	25.2%
2008	386	0.2%	0.3%	0.1%	0.2%	35.2%	53.8%	5.6%	8.5%	2.2%	3.4%	23.0%	35.1%	4.1%	6.3%	25.1%	38.3%	13.7%	20.9%
2008	388	*	*	*	*	40.5%	58.2%	4.5%	6.4%	2.5%	3.5%	24.0%	34.5%	1.2%	1.7%	31.1%	44.7%	16.9%	24.3%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	390	0.2%	0.3%	0.1%	0.2%	35.4%	53.5%	4.3%	6.5%	1.6%	2.4%	27.2%	41.1%	1.4%	2.2%	28.9%	43.7%	15.0%	22.6%
2008	391	0.3%	0.4%	0.1%	0.1%	36.6%	54.2%	3.7%	5.5%	0.9%	1.3%	25.7%	38.0%	1.2%	1.8%	30.3%	44.8%	12.9%	19.0%
2008	393	0.5%	0.8%	0.1%	0.2%	40.4%	59.9%	5.4%	8.0%	0.8%	1.1%	23.3%	34.6%	1.2%	1.8%	30.4%	45.1%	16.3%	24.2%
2008	394	0.2%	0.3%	0.1%	0.2%	37.1%	54.9%	5.0%	7.4%	0.9%	1.3%	26.5%	39.2%	1.4%	2.1%	30.7%	45.5%	13.9%	20.5%
2008	396	0.5%	0.7%	0.3%	0.5%	38.0%	57.7%	5.2%	7.9%	1.2%	1.9%	24.5%	37.2%	1.9%	2.9%	32.0%	48.7%	15.4%	23.5%
2008	397	0.4%	0.6%	0.1%	0.1%	36.2%	55.5%	4.4%	6.7%	1.3%	1.9%	22.9%	35.2%	2.2%	3.4%	31.3%	48.0%	12.5%	19.2%
2008	399	*	*	*	*	38.1%	54.7%	3.5%	5.0%	1.8%	2.5%	28.1%	40.3%	0.9%	1.2%	33.4%	48.0%	13.3%	19.0%
2008	400	0.3%	0.4%	0.1%	0.1%	40.8%	58.2%	3.9%	5.6%	1.3%	1.9%	24.9%	35.5%	1.4%	1.9%	33.7%	48.1%	16.7%	23.8%
2008	402	0.6%	0.9%	0.3%	0.4%	37.3%	56.9%	8.1%	12.3%	1.6%	2.4%	24.2%	36.9%	4.0%	6.1%	33.6%	51.2%	17.0%	25.9%
2008	406	0.2%	0.3%	*	*	42.8%	59.7%	5.4%	7.5%	1.1%	1.5%	26.0%	36.2%	1.9%	2.6%	33.3%	46.3%	15.2%	21.2%
2008	411	*	*	*	*	37.8%	54.7%	4.0%	5.7%	1.3%	1.9%	25.4%	36.8%	1.4%	2.0%	36.5%	52.8%	12.4%	17.9%
2008	412	0.6%	1.0%	0.2%	0.3%	34.8%	52.0%	5.0%	7.4%	1.4%	2.1%	25.1%	37.5%	1.5%	2.3%	30.7%	45.9%	18.4%	27.5%
2008	413	*	*	*	*	37.3%	54.5%	3.8%	5.6%	0.9%	1.3%	28.3%	41.3%	0.7%	1.0%	33.0%	48.2%	11.3%	16.4%
2008	416	0.1%	0.2%	0.1%	0.1%	38.1%	55.8%	4.9%	7.2%	2.0%	2.9%	24.4%	35.8%	1.1%	1.6%	32.6%	47.8%	14.1%	20.7%
2008	417	0.2%	0.4%	*	*	38.7%	59.7%	5.2%	8.0%	1.1%	1.7%	19.5%	30.1%	1.8%	2.8%	26.3%	40.6%	17.9%	27.6%
2008	418	*	*	*	*	37.5%	53.0%	2.9%	4.2%	0.8%	1.1%	27.2%	38.5%	0.8%	1.2%	30.6%	43.3%	14.4%	20.4%
2008	420	0.2%	0.3%	*	*	37.9%	54.4%	3.2%	4.5%	1.1%	1.6%	25.8%	37.0%	2.5%	3.6%	30.8%	44.2%	18.5%	26.5%
2008	421	*	*	*	*	44.5%	60.7%	3.2%	4.3%	1.3%	1.8%	24.6%	33.5%	0.6%	0.9%	30.4%	41.5%	16.4%	22.4%
2008	422	*	*	*	*	44.6%	62.0%	6.1%	8.5%	1.3%	1.8%	24.1%	33.5%	0.7%	0.9%	28.0%	38.9%	18.5%	25.8%
2008	423	0.2%	0.3%	0.2%	0.3%	45.8%	62.8%	4.1%	5.7%	1.6%	2.2%	23.5%	32.3%	0.9%	1.3%	29.3%	40.2%	16.4%	22.6%
2008	424	0.3%	0.5%	0.2%	0.3%	37.0%	55.8%	4.2%	6.3%	1.3%	2.0%	22.9%	34.5%	0.8%	1.3%	30.3%	45.6%	15.3%	23.1%
2008	426	0.5%	0.8%	*	*	36.6%	54.7%	5.4%	8.1%	0.7%	1.0%	20.7%	31.0%	1.7%	2.6%	33.8%	50.5%	15.4%	23.0%
2008	427	0.3%	0.4%	*	*	42.2%	60.7%	4.5%	6.5%	0.7%	1.0%	22.0%	31.6%	0.7%	1.0%	31.3%	45.0%	15.3%	22.0%
2008	428	0.2%	0.3%	*	*	35.4%	49.3%	2.7%	3.7%	0.9%	1.2%	25.9%	36.1%	0.8%	1.0%	36.9%	51.4%	15.3%	21.4%
2008	429	0.7%	1.0%	*	*	32.7%	48.5%	4.5%	6.6%	0.4%	0.6%	24.9%	36.9%	2.4%	3.6%	32.7%	48.4%	14.2%	21.1%
2008	430	0.9%	1.4%	0.1%	0.1%	32.1%	47.7%	4.9%	7.4%	0.9%	1.3%	24.6%	36.6%	2.3%	3.4%	32.1%	47.7%	15.1%	22.5%
2008	431	0.2%	0.3%	0.1%	0.1%	35.7%	52.4%	3.3%	4.9%	0.8%	1.2%	24.5%	35.9%	2.2%	3.3%	31.9%	46.8%	12.3%	18.0%
2008	432	0.4%	0.6%	0.1%	0.2%	38.9%	55.8%	4.4%	6.4%	1.4%	2.0%	23.2%	33.3%	1.6%	2.3%	36.0%	51.6%	15.1%	21.6%
2008	435	0.4%	0.6%	*	*	39.9%	56.3%	5.3%	7.5%	1.2%	1.7%	23.8%	33.5%	1.0%	1.4%	35.7%	50.4%	14.4%	20.3%
2008	437	0.3%	0.4%	*	*	40.8%	59.4%	1.8%	2.7%	0.9%	1.2%	26.7%	38.9%	0.4%	0.6%	30.0%	43.7%	8.2%	11.9%
2008	438	*	*	*	*	39.7%	58.7%	1.6%	2.4%	1.0%	1.5%	27.1%	39.9%	0.7%	1.0%	28.7%	42.4%	12.2%	18.0%
2008	439	0.4%	0.6%	0.1%	0.1%	40.5%	59.4%	2.1%	3.1%	1.1%	1.6%	24.2%	35.6%	0.5%	0.8%	30.9%	45.4%	10.4%	15.2%
2008	440	0.4%	0.6%	0.1%	0.2%	40.4%	58.1%	2.7%	3.9%	1.6%	2.3%	24.6%	35.4%	0.9%	1.3%	30.0%	43.2%	14.0%	20.1%
2008	441	0.5%	0.7%	0.2%	0.2%	40.0%	58.3%	3.0%	4.3%	1.0%	1.5%	26.4%	38.5%	1.1%	1.6%	27.3%	39.8%	14.1%	20.6%
2008	442	0.5%	0.7%	0.5%	0.8%	45.4%	64.7%	1.6%	2.3%	1.2%	1.8%	24.6%	35.1%	0.5%	0.6%	30.8%	43.9%	11.2%	15.9%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2008	443	0.6%	0.8%	0.1%	0.2%	38.7%	55.2%	5.3%	7.6%	1.3%	1.8%	24.3%	34.7%	2.3%	3.2%	34.6%	49.4%	17.5%	25.0%
2008	444	0.5%	0.8%	*	*	37.5%	53.5%	5.1%	7.2%	1.1%	1.5%	25.8%	36.7%	1.4%	2.0%	35.4%	50.5%	16.3%	23.3%
2008	445	0.3%	0.4%	0.1%	0.2%	35.9%	53.2%	4.5%	6.7%	0.9%	1.4%	22.6%	33.5%	1.7%	2.5%	32.2%	47.7%	17.1%	25.4%
2008	446	*	*	*	*	37.0%	54.9%	1.9%	2.9%	0.4%	0.6%	24.6%	36.6%	0.9%	1.4%	33.5%	49.8%	14.2%	21.0%
2008	447	0.3%	0.4%	*	*	38.1%	54.9%	3.0%	4.3%	1.0%	1.5%	24.9%	36.0%	1.7%	2.5%	33.3%	48.0%	13.4%	19.4%
2008	448	0.2%	0.3%	*	*	36.7%	52.4%	2.1%	3.0%	1.8%	2.5%	27.1%	38.6%	0.2%	0.3%	34.1%	48.6%	14.2%	20.2%
2008	449	0.5%	0.7%	0.1%	0.1%	38.1%	53.4%	2.1%	2.9%	1.1%	1.5%	26.4%	37.0%	1.2%	1.6%	34.1%	47.9%	13.2%	18.5%
2008	450	0.8%	1.1%	*	*	36.0%	51.3%	1.3%	1.9%	0.7%	1.0%	28.3%	40.4%	1.0%	1.4%	34.8%	49.7%	10.6%	15.1%
2008	451	0.4%	0.5%	0.1%	0.1%	34.6%	51.5%	3.0%	4.5%	0.9%	1.4%	25.1%	37.3%	1.8%	2.7%	30.7%	45.7%	13.5%	20.2%
2008	452	0.4%	0.6%	*	*	41.7%	57.2%	1.6%	2.2%	0.9%	1.2%	24.4%	33.5%	1.6%	2.2%	38.7%	53.0%	15.4%	21.0%
2008	456	*	*	*	*	38.4%	53.5%	2.4%	3.4%	*	*	27.1%	37.8%	1.2%	1.7%	30.9%	43.1%	15.7%	21.9%
2008	457	*	*	*	*	48.4%	64.7%	5.4%	7.2%	1.1%	1.4%	23.3%	31.1%	0.9%	1.2%	29.1%	38.9%	17.2%	23.0%
2009	1	0.3%	0.4%	0.1%	0.1%	39.4%	57.7%	4.0%	5.8%	1.1%	1.7%	24.5%	35.9%	1.0%	1.4%	29.7%	43.5%	13.2%	19.3%
2009	2	0.4%	0.6%	0.2%	0.3%	37.2%	53.4%	5.5%	7.9%	0.9%	1.2%	26.8%	38.5%	1.2%	1.7%	33.6%	48.2%	12.3%	17.6%
2009	5	0.1%	0.2%	*	*	38.5%	57.0%	3.8%	5.6%	1.0%	1.5%	23.7%	35.0%	1.0%	1.5%	27.2%	40.3%	13.8%	20.4%
2009	6	0.3%	0.4%	0.1%	0.2%	41.4%	58.4%	4.7%	6.6%	1.0%	1.4%	25.8%	36.5%	1.1%	1.6%	29.8%	42.0%	14.2%	20.1%
2009	7	0.3%	0.4%	0.3%	0.4%	36.3%	54.1%	3.9%	5.8%	0.8%	1.2%	25.4%	37.9%	0.9%	1.3%	30.4%	45.4%	14.7%	21.9%
2009	9	0.3%	0.4%	*	*	40.3%	58.3%	2.6%	3.7%	0.6%	0.9%	26.8%	38.9%	1.4%	2.1%	32.2%	46.6%	14.9%	21.6%
2009	10	0.3%	0.5%	*	*	43.6%	61.1%	5.4%	7.6%	1.9%	2.7%	27.3%	38.2%	0.7%	0.9%	26.5%	37.1%	14.7%	20.6%
2009	11	0.3%	0.4%	*	*	37.1%	57.9%	4.0%	6.2%	1.5%	2.4%	20.2%	31.6%	0.9%	1.3%	25.6%	40.0%	12.7%	19.8%
2009	12	0.3%	0.5%	0.1%	0.2%	40.7%	61.3%	3.5%	5.3%	1.0%	1.5%	22.0%	33.2%	1.0%	1.6%	27.8%	41.9%	13.2%	19.9%
2009	14	*	*	*	*	34.1%	58.3%	4.3%	7.3%	1.9%	3.3%	15.9%	27.2%	1.3%	2.2%	26.6%	45.5%	10.3%	17.7%
2009	15	0.3%	0.5%	*	*	38.5%	60.8%	3.5%	5.5%	0.9%	1.5%	21.7%	34.3%	1.0%	1.6%	27.6%	43.6%	11.5%	18.2%
2009	16	0.5%	0.7%	0.2%	0.3%	37.1%	55.8%	3.4%	5.1%	0.8%	1.2%	23.5%	35.3%	1.2%	1.8%	30.7%	46.2%	13.3%	19.9%
2009	18	0.3%	0.5%	*	*	44.4%	60.4%	5.5%	7.5%	1.0%	1.3%	26.0%	35.3%	0.7%	1.0%	36.2%	49.3%	11.0%	15.0%
2009	19	0.3%	0.4%	0.1%	0.1%	38.8%	56.1%	4.0%	5.8%	0.7%	1.0%	23.4%	33.9%	1.3%	1.9%	33.4%	48.3%	12.0%	17.4%
2009	21	0.4%	0.5%	0.4%	0.5%	40.8%	60.0%	3.9%	5.7%	1.4%	2.1%	22.7%	33.4%	1.3%	1.9%	27.3%	40.1%	12.0%	17.7%
2009	22	0.4%	0.5%	*	*	34.5%	50.6%	3.4%	5.0%	0.7%	1.0%	25.6%	37.6%	1.2%	1.7%	33.2%	48.8%	10.7%	15.7%
2009	23	1.3%	2.1%	0.2%	0.3%	39.2%	65.2%	9.8%	16.3%	1.1%	1.8%	16.0%	26.6%	2.7%	4.4%	26.3%	43.8%	16.5%	27.4%
2009	25	0.4%	0.6%	0.1%	0.1%	42.1%	63.4%	4.9%	7.4%	0.7%	1.1%	21.3%	32.2%	1.7%	2.6%	29.0%	43.6%	23.0%	34.7%
2009	31	1.0%	1.6%	0.2%	0.3%	40.1%	62.2%	5.3%	8.3%	1.9%	2.9%	20.0%	31.1%	1.3%	2.1%	24.4%	38.0%	18.7%	29.0%
2009	33	0.6%	1.0%	*	*	38.2%	61.4%	5.3%	8.5%	0.5%	0.9%	19.1%	30.7%	1.8%	3.0%	26.6%	42.7%	14.2%	22.8%
2009	43	0.5%	0.8%	0.1%	0.2%	39.7%	59.8%	4.6%	6.9%	0.8%	1.3%	22.6%	34.1%	1.3%	2.0%	25.8%	39.0%	23.2%	35.0%
2009	56	0.8%	1.3%	0.1%	0.2%	35.7%	60.9%	8.4%	14.3%	0.8%	1.4%	18.9%	32.3%	3.9%	6.7%	27.1%	46.2%	16.6%	28.3%
2009	58	0.8%	1.2%	0.2%	0.3%	41.7%	62.8%	4.8%	7.3%	1.4%	2.1%	21.3%	32.1%	2.2%	3.4%	29.5%	44.4%	21.3%	32.0%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	62	0.7%	1.0%	*	*	44.8%	65.5%	4.1%	6.0%	0.9%	1.4%	21.3%	31.1%	1.1%	1.6%	28.3%	41.3%	15.8%	23.1%
2009	65	0.9%	1.5%	0.1%	0.1%	36.9%	60.7%	4.0%	6.5%	0.4%	0.7%	18.6%	30.6%	2.0%	3.2%	26.2%	43.1%	15.7%	25.8%
2009	69	1.0%	1.8%	0.2%	0.4%	37.2%	63.8%	5.4%	9.2%	1.3%	2.3%	17.4%	29.9%	1.2%	2.1%	23.8%	40.9%	14.0%	24.0%
2009	73	0.6%	0.9%	*	*	43.3%	65.7%	3.5%	5.3%	1.2%	1.9%	19.8%	30.1%	1.4%	2.1%	25.6%	38.9%	16.6%	25.2%
2009	77	0.6%	0.8%	0.2%	0.3%	42.0%	61.9%	6.1%	8.9%	1.2%	1.7%	21.4%	31.5%	1.6%	2.4%	29.1%	42.9%	18.9%	27.8%
2009	78	0.2%	0.3%	*	*	41.3%	61.4%	4.4%	6.6%	1.3%	1.9%	21.4%	31.8%	3.1%	4.6%	28.6%	42.5%	19.0%	28.3%
2009	79	0.6%	0.9%	0.2%	0.2%	38.4%	60.8%	5.4%	8.6%	0.8%	1.2%	22.7%	36.0%	1.5%	2.4%	30.4%	48.2%	16.2%	25.7%
2009	80	0.7%	1.0%	0.2%	0.3%	42.5%	64.3%	7.4%	11.2%	1.0%	1.6%	21.5%	32.5%	1.9%	2.9%	25.7%	38.9%	18.4%	27.8%
2009	81	1.5%	2.3%	0.1%	0.1%	39.5%	61.1%	5.4%	8.3%	0.8%	1.3%	16.6%	25.7%	1.6%	2.4%	32.0%	49.4%	14.2%	22.0%
2009	82	1.4%	2.2%	0.1%	0.1%	38.3%	62.2%	5.7%	9.2%	0.6%	0.9%	15.4%	25.0%	3.4%	5.4%	28.9%	47.0%	16.8%	27.3%
2009	83	0.3%	0.5%	0.3%	0.6%	40.4%	70.4%	4.7%	8.2%	1.3%	2.3%	15.5%	27.0%	1.3%	2.2%	23.2%	40.5%	11.2%	19.5%
2009	85	1.6%	2.6%	*	*	40.8%	66.9%	6.3%	10.3%	1.2%	2.0%	13.8%	22.6%	3.0%	4.9%	26.9%	44.1%	14.0%	23.0%
2009	86	0.6%	1.0%	0.2%	0.4%	41.5%	65.9%	7.7%	12.1%	1.8%	2.9%	17.4%	27.6%	2.7%	4.2%	24.4%	38.8%	19.5%	30.9%
2009	87	0.5%	0.8%	*	*	38.7%	61.8%	4.1%	6.6%	0.7%	1.2%	20.4%	32.6%	2.0%	3.2%	30.1%	48.1%	15.5%	24.8%
2009	89	0.8%	1.2%	*	*	41.8%	62.3%	4.2%	6.3%	1.4%	2.0%	20.2%	30.1%	1.3%	2.0%	28.8%	42.9%	14.6%	21.7%
2009	91	0.7%	1.0%	*	*	40.9%	59.6%	5.7%	8.3%	0.6%	0.8%	22.8%	33.2%	2.4%	3.5%	30.3%	44.2%	19.9%	29.1%
2009	96	0.5%	0.8%	0.1%	0.2%	42.6%	66.6%	6.7%	10.4%	0.8%	1.3%	18.5%	28.9%	2.8%	4.4%	25.4%	39.6%	17.8%	27.7%
2009	101	*	*	*	*	43.7%	63.2%	5.2%	7.6%	1.3%	1.8%	22.5%	32.5%	*	*	24.1%	34.9%	15.0%	21.6%
2009	102	0.4%	0.6%	0.2%	0.2%	44.4%	62.4%	4.7%	6.6%	1.0%	1.4%	25.5%	35.9%	0.8%	1.1%	29.4%	41.4%	13.4%	18.8%
2009	103	0.2%	0.3%	0.1%	0.2%	42.5%	60.4%	5.0%	7.2%	1.5%	2.1%	24.6%	35.0%	0.7%	1.1%	27.5%	39.1%	15.5%	22.0%
2009	104	*	*	*	*	47.2%	64.5%	6.4%	8.7%	1.0%	1.4%	23.3%	31.8%	1.1%	1.5%	28.6%	39.0%	14.9%	20.3%
2009	105	*	*	*	*	46.1%	63.3%	5.4%	7.5%	1.0%	1.3%	25.2%	34.7%	0.7%	0.9%	28.5%	39.1%	10.7%	14.7%
2009	106	0.5%	0.7%	*	*	47.0%	64.6%	4.1%	5.6%	1.1%	1.5%	24.0%	33.0%	0.8%	1.1%	31.8%	43.8%	14.7%	20.3%
2009	107	*	*	*	*	43.6%	61.1%	5.0%	7.0%	0.9%	1.3%	29.8%	41.8%	1.1%	1.5%	29.2%	40.9%	14.4%	20.2%
2009	109	0.3%	0.5%	*	*	34.6%	57.1%	6.7%	11.0%	0.7%	1.2%	18.3%	30.1%	1.3%	2.2%	25.5%	42.1%	15.9%	26.2%
2009	110	0.3%	0.4%	0.1%	0.1%	34.6%	52.1%	5.1%	7.7%	0.6%	0.9%	24.4%	36.8%	1.9%	2.9%	27.5%	41.5%	12.8%	19.2%
2009	111	0.3%	0.4%	0.1%	0.1%	32.3%	51.9%	5.2%	8.4%	0.7%	1.2%	22.6%	36.2%	1.3%	2.1%	26.3%	42.2%	12.1%	19.3%
2009	112	0.5%	0.9%	0.2%	0.3%	31.9%	52.6%	5.0%	8.3%	0.6%	1.0%	20.9%	34.4%	2.8%	4.6%	26.8%	44.2%	11.2%	18.5%
2009	113	0.3%	0.5%	0.1%	0.1%	33.5%	52.3%	4.8%	7.5%	0.6%	0.9%	24.0%	37.5%	2.0%	3.1%	28.4%	44.3%	10.7%	16.6%
2009	115	0.2%	0.4%	*	*	32.2%	56.0%	4.2%	7.3%	0.8%	1.4%	17.2%	29.9%	0.8%	1.3%	27.2%	47.3%	10.5%	18.3%
2009	116	0.3%	0.4%	*	*	31.5%	52.5%	5.3%	8.8%	0.8%	1.3%	21.7%	36.1%	1.3%	2.1%	25.9%	43.1%	11.0%	18.3%
2009	118	0.1%	0.3%	0.2%	0.4%	27.3%	52.9%	5.2%	10.1%	1.1%	2.1%	17.7%	34.3%	2.6%	5.0%	22.9%	44.3%	8.6%	16.7%
2009	119	0.2%	0.3%	0.3%	0.5%	36.4%	58.3%	6.4%	10.2%	1.3%	2.0%	18.5%	29.6%	2.7%	4.3%	27.3%	43.7%	11.9%	19.1%
2009	120	0.3%	0.4%	*	*	38.2%	57.6%	5.0%	7.6%	1.0%	1.5%	22.9%	34.6%	1.3%	2.0%	30.8%	46.6%	12.8%	19.3%
2009	122	0.2%	0.4%	*	*	32.5%	55.8%	4.7%	8.1%	0.8%	1.4%	19.8%	34.0%	1.1%	1.9%	28.8%	49.4%	9.6%	16.5%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	123	0.3%	0.4%	0.2%	0.2%	35.1%	52.9%	5.4%	8.1%	0.9%	1.4%	26.4%	39.9%	2.2%	3.4%	27.0%	40.7%	11.1%	16.8%
2009	124	*	*	*	*	34.8%	55.7%	4.9%	7.9%	1.4%	2.2%	23.0%	36.8%	1.3%	2.1%	29.2%	46.7%	11.8%	18.9%
2009	127	0.3%	0.5%	0.2%	0.3%	33.7%	53.6%	5.0%	7.9%	0.8%	1.3%	33.6%	53.5%	2.4%	3.8%	26.4%	42.0%	13.3%	21.2%
2009	129	0.2%	0.4%	0.1%	0.2%	35.0%	58.0%	5.7%	9.5%	1.1%	1.8%	17.8%	29.4%	1.1%	1.9%	30.0%	49.7%	10.6%	17.5%
2009	130	0.2%	0.3%	0.2%	0.3%	34.9%	55.9%	4.9%	7.9%	1.2%	1.9%	22.2%	35.5%	1.7%	2.8%	29.4%	47.2%	11.5%	18.4%
2009	131	0.4%	0.7%	0.2%	0.3%	33.4%	57.0%	6.0%	10.3%	1.3%	2.2%	20.0%	34.2%	1.2%	2.1%	26.9%	45.9%	9.0%	15.4%
2009	133	0.2%	0.4%	0.9%	1.3%	36.2%	54.3%	8.5%	12.7%	1.4%	2.1%	24.6%	37.0%	1.2%	1.8%	30.8%	46.2%	10.3%	15.5%
2009	134	0.2%	0.3%	0.3%	0.4%	39.1%	57.2%	5.7%	8.3%	1.2%	1.8%	24.8%	36.4%	0.8%	1.2%	27.5%	40.2%	13.1%	19.2%
2009	137	0.2%	0.4%	0.1%	0.2%	34.8%	59.7%	5.0%	8.5%	1.4%	2.4%	17.3%	29.7%	1.5%	2.5%	24.4%	41.8%	10.0%	17.2%
2009	139	0.5%	0.8%	*	*	33.7%	54.6%	5.2%	8.4%	0.9%	1.4%	22.0%	35.7%	1.6%	2.7%	25.7%	41.7%	15.9%	25.8%
2009	140	0.2%	0.2%	0.3%	0.4%	38.4%	55.2%	5.2%	7.4%	1.4%	2.1%	27.0%	38.8%	1.1%	1.6%	31.5%	45.4%	15.5%	22.3%
2009	141	0.3%	0.5%	0.2%	0.3%	34.4%	54.2%	5.2%	8.3%	0.9%	1.4%	23.9%	37.6%	1.0%	1.6%	28.8%	45.3%	14.2%	22.3%
2009	142	0.2%	0.3%	*	*	38.6%	53.8%	5.0%	7.0%	0.7%	1.0%	28.4%	39.7%	1.1%	1.6%	33.2%	46.3%	11.5%	16.0%
2009	144	0.3%	0.5%	0.1%	0.1%	37.6%	55.4%	5.1%	7.5%	0.9%	1.4%	24.8%	36.6%	1.4%	2.0%	30.1%	44.4%	12.0%	17.6%
2009	145	0.4%	0.6%	0.2%	0.2%	35.0%	51.3%	5.7%	8.3%	0.8%	1.2%	25.7%	37.6%	1.4%	2.0%	30.4%	44.5%	14.4%	21.1%
2009	146	0.8%	1.2%	*	*	35.1%	54.0%	4.7%	7.2%	0.9%	1.4%	23.3%	35.9%	1.1%	1.7%	29.2%	44.9%	12.8%	19.7%
2009	147	0.3%	0.5%	0.1%	0.2%	35.5%	52.5%	4.6%	6.8%	1.0%	1.5%	25.7%	38.0%	1.4%	2.1%	31.0%	45.9%	12.6%	18.6%
2009	148	0.2%	0.3%	0.2%	0.2%	40.8%	57.9%	6.5%	9.3%	1.3%	1.9%	23.7%	33.7%	1.1%	1.5%	32.3%	45.8%	14.0%	19.9%
2009	149	0.2%	0.3%	0.1%	0.1%	36.9%	54.1%	4.5%	6.7%	1.1%	1.7%	26.3%	38.6%	1.2%	1.8%	28.7%	42.0%	15.8%	23.1%
2009	150	0.8%	1.3%	0.2%	0.3%	33.5%	55.7%	8.1%	13.4%	0.7%	1.2%	15.1%	25.1%	3.4%	5.7%	26.1%	43.4%	16.7%	27.7%
2009	151	0.2%	0.3%	0.1%	0.2%	42.0%	59.3%	3.4%	4.8%	1.4%	2.0%	24.8%	35.1%	0.5%	0.8%	26.9%	38.0%	16.5%	23.3%
2009	152	*	*	*	*	55.4%	72.7%	3.2%	4.2%	4.4%	5.8%	19.4%	25.5%	0.5%	0.7%	19.7%	25.8%	15.7%	20.6%
2009	154	*	*	*	*	39.7%	56.2%	4.2%	5.9%	1.1%	1.6%	24.9%	35.3%	0.9%	1.2%	36.4%	51.5%	12.0%	16.9%
2009	155	0.5%	0.7%	0.1%	0.1%	34.9%	54.1%	5.1%	8.0%	0.9%	1.4%	22.9%	35.4%	2.2%	3.5%	31.6%	49.0%	9.9%	15.3%
2009	156	0.9%	1.4%	0.0%	0.0%	36.1%	56.6%	3.7%	5.7%	0.5%	0.7%	24.0%	37.6%	1.5%	2.4%	30.9%	48.3%	12.7%	19.8%
2009	158	0.3%	0.5%	0.2%	0.3%	38.0%	56.9%	5.1%	7.6%	0.8%	1.2%	21.7%	32.6%	2.4%	3.6%	32.2%	48.2%	11.8%	17.7%
2009	161	0.4%	0.7%	0.1%	0.1%	35.8%	56.6%	5.4%	8.5%	0.9%	1.4%	19.0%	30.1%	2.3%	3.6%	30.0%	47.5%	11.7%	18.5%
2009	163	0.3%	0.5%	*	*	37.3%	57.2%	7.0%	10.7%	1.2%	1.9%	20.6%	31.6%	1.8%	2.7%	30.8%	47.4%	11.1%	17.1%
2009	164	0.4%	0.6%	*	*	35.7%	54.0%	4.5%	6.7%	0.9%	1.4%	23.2%	35.1%	1.8%	2.7%	32.5%	49.2%	11.4%	17.2%
2009	166	0.4%	0.6%	0.1%	0.2%	37.4%	56.6%	5.6%	8.5%	0.9%	1.3%	21.3%	32.3%	1.8%	2.8%	32.5%	49.1%	13.0%	19.7%
2009	170	0.5%	0.7%	*	*	40.3%	56.3%	3.2%	4.5%	0.7%	1.0%	24.1%	33.7%	1.3%	1.8%	35.6%	49.9%	14.5%	20.3%
2009	171	0.3%	0.4%	0.2%	0.3%	40.9%	58.2%	3.3%	4.6%	1.0%	1.4%	24.2%	34.4%	1.2%	1.7%	31.8%	45.2%	14.3%	20.4%
2009	172	0.3%	0.4%	0.2%	0.3%	39.1%	55.1%	3.6%	5.1%	0.7%	1.0%	25.0%	35.2%	0.9%	1.2%	35.1%	49.4%	13.5%	19.0%
2009	173	0.2%	0.3%	0.2%	0.3%	39.4%	54.5%	3.5%	4.9%	0.8%	1.1%	27.9%	38.6%	1.1%	1.5%	33.0%	45.6%	12.2%	16.9%
2009	175	*	*	*	*	40.0%	55.7%	4.1%	5.7%	0.6%	0.8%	25.0%	34.7%	0.8%	1.1%	36.2%	50.3%	10.8%	15.0%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	179	0.2%	0.3%	0.2%	0.3%	38.2%	53.6%	4.3%	6.0%	1.0%	1.4%	27.0%	37.9%	1.2%	1.7%	32.1%	45.1%	13.1%	18.4%
2009	180	0.2%	0.3%	0.2%	0.3%	38.7%	54.0%	6.7%	9.4%	1.4%	1.9%	28.0%	39.2%	1.5%	2.1%	31.2%	43.7%	13.8%	19.4%
2009	181	0.2%	0.3%	*	*	36.0%	52.7%	3.9%	5.6%	0.5%	0.7%	26.9%	39.5%	1.9%	2.7%	30.5%	44.6%	10.4%	15.2%
2009	183	0.3%	0.5%	0.2%	0.3%	36.8%	52.4%	4.8%	6.8%	1.4%	1.9%	27.6%	39.3%	1.1%	1.6%	30.3%	43.2%	13.1%	18.7%
2009	184	0.4%	0.5%	0.3%	0.4%	40.8%	58.3%	3.8%	5.5%	1.3%	1.8%	25.9%	37.1%	0.8%	1.1%	32.3%	46.2%	10.5%	15.1%
2009	185	*	*	*	*	36.1%	51.6%	5.2%	7.4%	1.0%	1.4%	29.2%	41.7%	0.7%	1.0%	29.3%	41.8%	12.2%	17.5%
2009	186	0.9%	1.4%	*	*	36.1%	56.5%	5.0%	7.9%	0.8%	1.2%	22.2%	34.7%	1.5%	2.3%	30.5%	47.7%	9.4%	14.7%
2009	187	0.2%	0.3%	0.2%	0.2%	42.0%	58.9%	4.9%	6.9%	0.8%	1.1%	26.3%	36.8%	1.9%	2.6%	29.7%	41.6%	12.2%	17.0%
2009	188	0.4%	0.6%	*	*	39.2%	55.1%	5.3%	7.4%	1.1%	1.5%	26.6%	37.4%	2.7%	3.7%	29.6%	41.6%	11.1%	15.7%
2009	190	0.2%	0.3%	*	*	38.0%	54.0%	2.4%	3.4%	1.1%	1.5%	24.9%	35.4%	0.8%	1.1%	33.4%	47.5%	11.5%	16.3%
2009	191	0.3%	0.4%	0.2%	0.2%	38.3%	54.8%	3.9%	5.6%	0.9%	1.3%	24.7%	35.3%	0.8%	1.2%	34.8%	49.8%	14.0%	20.0%
2009	192	0.2%	0.3%	0.2%	0.2%	41.0%	58.0%	4.0%	5.7%	0.9%	1.3%	24.5%	34.7%	1.0%	1.4%	34.1%	48.2%	13.2%	18.7%
2009	193	*	*	*	*	32.5%	48.4%	3.3%	4.9%	0.9%	1.3%	25.6%	38.1%	1.4%	2.0%	30.3%	45.0%	14.3%	21.3%
2009	194	0.2%	0.3%	*	*	39.2%	55.7%	3.0%	4.2%	0.8%	1.2%	23.4%	33.2%	0.7%	1.0%	37.3%	52.9%	12.5%	17.8%
2009	195	*	*	0.5%	0.6%	39.4%	54.6%	5.2%	7.2%	2.1%	2.9%	25.2%	34.8%	0.6%	0.8%	34.1%	47.1%	10.2%	14.1%
2009	196	0.2%	0.3%	*	*	41.1%	56.8%	4.5%	6.3%	1.4%	1.9%	21.8%	30.1%	1.0%	1.3%	30.8%	42.5%	22.2%	30.6%
2009	197	*	*	*	*	38.1%	54.4%	3.2%	4.6%	1.6%	2.3%	25.7%	36.7%	1.1%	1.5%	33.3%	47.6%	12.1%	17.3%
2009	200	0.5%	0.7%	0.4%	0.5%	38.8%	56.1%	4.4%	6.4%	1.5%	2.2%	24.3%	35.1%	0.7%	1.0%	29.9%	43.4%	13.1%	19.0%
2009	201	0.2%	0.3%	0.5%	0.7%	40.5%	55.8%	4.5%	6.2%	1.8%	2.5%	27.2%	37.4%	1.4%	1.9%	28.7%	39.5%	14.3%	19.7%
2009	203	0.4%	0.6%	*	*	39.9%	58.0%	5.2%	7.5%	0.7%	1.0%	25.5%	37.1%	2.0%	2.9%	27.8%	40.5%	13.5%	19.7%
2009	204	0.4%	0.6%	0.2%	0.3%	42.5%	60.9%	6.2%	8.9%	1.3%	1.8%	25.1%	35.9%	1.5%	2.2%	32.5%	46.5%	13.2%	18.9%
2009	205	0.4%	0.6%	0.2%	0.3%	38.5%	56.4%	4.6%	6.8%	0.8%	1.2%	24.4%	35.8%	1.6%	2.3%	30.2%	44.3%	13.1%	19.2%
2009	207	*	*	0.8%	1.2%	37.6%	57.3%	6.9%	10.5%	2.7%	4.2%	21.5%	32.8%	2.5%	3.8%	24.2%	36.9%	13.3%	20.2%
2009	208	0.3%	0.5%	0.2%	0.2%	40.1%	56.8%	4.3%	6.1%	1.3%	1.8%	24.9%	35.3%	0.9%	1.3%	31.9%	45.2%	13.0%	18.4%
2009	209	0.3%	0.4%	0.2%	0.2%	36.2%	52.4%	5.4%	7.8%	0.7%	1.0%	28.2%	40.8%	1.1%	1.6%	32.9%	47.6%	12.6%	18.2%
2009	210	0.4%	0.5%	0.3%	0.5%	38.9%	54.9%	4.9%	7.0%	1.4%	1.9%	28.5%	40.2%	2.3%	3.3%	28.0%	39.5%	16.0%	22.6%
2009	212	0.5%	0.7%	*	*	42.0%	59.3%	5.0%	7.0%	0.9%	1.3%	23.9%	33.8%	3.0%	4.3%	34.8%	49.1%	17.2%	24.3%
2009	213	0.2%	0.3%	0.1%	0.2%	39.7%	57.6%	5.6%	8.1%	1.2%	1.8%	23.2%	33.6%	2.4%	3.5%	32.9%	47.7%	18.6%	26.9%
2009	214	0.3%	0.4%	*	*	41.8%	59.6%	6.6%	9.4%	1.0%	1.5%	25.9%	36.9%	0.9%	1.3%	33.4%	47.7%	11.5%	16.5%
2009	216	0.4%	0.6%	*	*	35.4%	53.0%	4.6%	6.9%	1.1%	1.7%	26.3%	39.3%	2.5%	3.8%	30.6%	45.7%	11.3%	16.9%
2009	217	0.3%	0.4%	0.2%	0.2%	38.7%	56.1%	6.0%	8.7%	1.7%	2.5%	26.1%	37.8%	2.0%	2.9%	30.1%	43.6%	16.8%	24.3%
2009	218	0.4%	0.6%	*	*	35.6%	53.5%	4.9%	7.3%	0.6%	0.9%	28.4%	42.6%	2.5%	3.8%	28.3%	42.5%	11.2%	16.9%
2009	219	0.3%	0.4%	*	*	38.8%	55.4%	5.6%	8.0%	0.5%	0.8%	27.0%	38.5%	1.3%	1.8%	29.3%	41.9%	14.8%	21.1%
2009	220	*	*	*	*	40.7%	59.9%	6.2%	9.1%	1.3%	1.9%	24.5%	36.1%	1.6%	2.4%	28.7%	42.2%	12.6%	18.5%
2009	221	0.3%	0.5%	0.1%	0.1%	40.5%	62.1%	3.4%	5.2%	0.9%	1.4%	21.3%	32.6%	0.6%	0.9%	28.7%	44.0%	10.4%	16.0%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	222	0.3%	0.4%	0.1%	0.1%	37.1%	56.1%	4.7%	7.1%	1.5%	2.2%	23.4%	35.3%	0.7%	1.0%	31.1%	47.0%	9.0%	13.5%
2009	223	0.3%	0.5%	0.1%	0.1%	33.3%	53.7%	4.7%	7.6%	0.8%	1.3%	21.6%	34.9%	1.4%	2.2%	29.4%	47.4%	10.3%	16.6%
2009	225	0.2%	0.4%	0.2%	0.2%	35.3%	52.5%	5.0%	7.5%	1.2%	1.7%	22.8%	33.8%	1.4%	2.1%	33.1%	49.1%	12.2%	18.1%
2009	226	0.4%	0.7%	*	*	35.5%	56.1%	5.5%	8.7%	0.5%	0.9%	21.9%	34.6%	2.2%	3.4%	29.5%	46.5%	12.4%	19.6%
2009	227	0.3%	0.5%	0.1%	0.2%	39.0%	59.8%	2.7%	4.1%	0.8%	1.2%	22.9%	35.2%	1.0%	1.6%	28.2%	43.2%	10.8%	16.6%
2009	230	0.3%	0.4%	0.1%	0.1%	38.3%	56.1%	2.5%	3.7%	0.8%	1.1%	26.3%	38.5%	0.8%	1.2%	29.6%	43.5%	14.8%	21.7%
2009	231	0.2%	0.3%	*	*	40.8%	61.5%	2.3%	3.5%	0.6%	1.0%	25.0%	37.6%	0.6%	0.8%	27.9%	42.0%	11.3%	17.0%
2009	232	0.3%	0.5%	0.1%	0.2%	35.6%	57.3%	3.3%	5.4%	0.7%	1.1%	23.1%	37.2%	1.2%	1.9%	27.8%	44.8%	8.6%	13.9%
2009	233	0.4%	0.7%	*	*	33.6%	60.7%	3.6%	6.5%	0.5%	0.9%	19.6%	35.4%	1.0%	1.9%	26.9%	48.6%	9.6%	17.4%
2009	234	0.3%	0.5%	0.1%	0.1%	30.2%	54.5%	3.1%	5.5%	0.4%	0.7%	21.9%	39.5%	1.3%	2.3%	25.1%	45.3%	8.0%	14.5%
2009	235	0.3%	0.5%	*	*	33.9%	56.5%	2.6%	4.3%	1.0%	1.7%	23.0%	38.4%	0.9%	1.5%	28.0%	46.7%	8.0%	13.3%
2009	236	0.3%	0.4%	0.2%	0.3%	38.5%	53.9%	3.0%	4.3%	1.1%	1.5%	28.7%	40.1%	0.8%	1.2%	28.5%	39.8%	14.8%	20.7%
2009	238	0.4%	0.6%	0.2%	0.2%	41.9%	57.0%	3.1%	4.2%	0.9%	1.2%	27.9%	37.9%	1.1%	1.4%	30.1%	41.0%	14.7%	20.0%
2009	239	0.2%	0.3%	0.1%	0.2%	41.3%	57.7%	4.7%	6.6%	1.0%	1.4%	26.6%	37.2%	0.9%	1.2%	31.0%	43.4%	14.4%	20.1%
2009	240	*	*	*	*	39.0%	56.3%	2.3%	3.4%	0.6%	0.9%	27.8%	40.1%	0.8%	1.2%	29.2%	42.2%	10.4%	15.1%
2009	242	*	*	0.3%	0.4%	36.9%	52.3%	2.8%	4.0%	1.0%	1.4%	29.6%	41.9%	0.7%	0.9%	26.7%	37.8%	14.0%	19.9%
2009	243	*	*	*	*	37.8%	57.3%	3.8%	5.7%	1.3%	2.0%	26.4%	40.0%	1.2%	1.8%	26.6%	40.3%	11.0%	16.6%
2009	244	0.7%	1.2%	*	*	32.0%	57.3%	3.7%	6.6%	0.8%	1.4%	20.0%	35.8%	1.4%	2.5%	23.8%	42.5%	8.0%	14.2%
2009	245	0.3%	0.6%	0.1%	0.2%	29.1%	56.0%	4.6%	8.9%	0.6%	1.2%	16.8%	32.4%	2.3%	4.4%	22.7%	43.6%	7.2%	13.9%
2009	246	0.3%	0.4%	0.2%	0.3%	37.8%	57.1%	2.7%	4.1%	1.4%	2.0%	24.0%	36.3%	0.9%	1.4%	30.6%	46.2%	10.2%	15.5%
2009	248	0.5%	0.7%	*	*	39.0%	54.3%	5.2%	7.2%	1.0%	1.4%	25.5%	35.5%	2.0%	2.8%	31.7%	44.1%	15.5%	21.5%
2009	249	0.2%	0.3%	0.4%	0.6%	41.6%	60.9%	5.0%	7.3%	2.1%	3.0%	23.1%	33.8%	1.2%	1.8%	27.5%	40.3%	12.4%	18.2%
2009	250	*	*	*	*	38.1%	56.3%	2.3%	3.4%	1.1%	1.6%	27.7%	41.0%	0.4%	0.6%	29.7%	43.9%	9.6%	14.1%
2009	251	0.1%	0.2%	0.1%	0.2%	39.8%	56.9%	2.7%	3.8%	1.3%	1.9%	26.2%	37.4%	0.6%	0.9%	31.0%	44.2%	11.5%	16.4%
2009	253	0.3%	0.4%	*	*	37.9%	54.1%	2.0%	2.8%	0.7%	1.1%	27.6%	39.4%	0.9%	1.3%	31.0%	44.3%	7.0%	10.0%
2009	254	*	*	*	*	41.9%	59.4%	4.4%	6.2%	1.1%	1.6%	22.9%	32.4%	1.4%	2.0%	29.4%	41.7%	12.9%	18.2%
2009	256	0.2%	0.3%	*	*	39.3%	55.6%	2.9%	4.1%	1.5%	2.1%	29.0%	41.0%	0.6%	0.9%	30.1%	42.6%	13.0%	18.4%
2009	257	*	*	*	*	40.3%	56.3%	4.8%	6.8%	1.3%	1.9%	25.6%	35.8%	1.5%	2.1%	29.5%	41.3%	15.1%	21.2%
2009	258	0.2%	0.3%	*	*	39.7%	54.1%	4.5%	6.1%	0.6%	0.8%	27.4%	37.3%	0.7%	1.0%	36.0%	49.1%	12.7%	17.3%
2009	259	0.2%	0.3%	*	*	38.7%	53.1%	4.7%	6.4%	1.0%	1.4%	28.9%	39.6%	1.3%	1.7%	32.4%	44.5%	14.3%	19.6%
2009	260	0.2%	0.3%	0.2%	0.3%	39.3%	52.2%	3.4%	4.6%	0.9%	1.2%	29.3%	38.9%	1.2%	1.5%	37.3%	49.6%	16.4%	21.8%
2009	261	*	*	*	*	41.4%	55.0%	5.9%	7.8%	1.1%	1.4%	27.1%	36.1%	1.7%	2.3%	31.6%	42.0%	15.7%	20.8%
2009	262	0.3%	0.4%	0.2%	0.2%	40.2%	54.6%	3.6%	4.9%	1.4%	1.9%	29.3%	39.9%	2.0%	2.7%	28.0%	38.2%	10.8%	14.6%
2009	263	0.7%	1.0%	0.3%	0.5%	40.6%	57.8%	5.7%	8.2%	1.3%	1.9%	25.8%	36.8%	1.1%	1.6%	31.3%	44.5%	14.0%	19.9%
2009	264	0.2%	0.3%	0.2%	0.3%	40.9%	60.1%	4.0%	5.9%	1.3%	1.9%	24.1%	35.4%	0.9%	1.3%	30.8%	45.3%	12.1%	17.8%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	267	0.2%	0.3%	0.3%	0.5%	39.6%	58.9%	4.5%	6.7%	1.7%	2.6%	23.8%	35.4%	1.1%	1.7%	29.4%	43.8%	15.1%	22.4%
2009	268	0.3%	0.4%	0.2%	0.3%	38.3%	56.5%	3.7%	5.5%	1.1%	1.6%	25.8%	38.0%	0.9%	1.4%	28.7%	42.4%	11.8%	17.4%
2009	270	0.4%	0.5%	0.3%	0.4%	44.4%	62.3%	4.0%	5.6%	1.8%	2.6%	25.2%	35.4%	0.9%	1.2%	30.7%	43.2%	13.6%	19.1%
2009	273	0.5%	0.7%	0.2%	0.3%	37.9%	55.3%	4.8%	7.0%	1.2%	1.8%	25.6%	37.5%	1.2%	1.8%	32.3%	47.2%	11.6%	17.0%
2009	274	0.2%	0.3%	0.1%	0.2%	45.6%	61.9%	3.9%	5.3%	1.9%	2.5%	23.7%	32.3%	0.6%	0.8%	28.5%	38.7%	16.0%	21.7%
2009	275	*	*	*	*	41.2%	58.5%	5.7%	8.2%	0.9%	1.3%	23.9%	33.9%	*	*	32.1%	45.5%	18.0%	25.6%
2009	276	0.2%	0.3%	0.2%	0.3%	43.1%	60.4%	3.6%	5.1%	1.9%	2.7%	23.9%	33.5%	0.6%	0.9%	27.5%	38.5%	13.8%	19.3%
2009	277	0.2%	0.3%	0.1%	0.1%	39.3%	55.2%	3.3%	4.7%	1.2%	1.7%	24.2%	34.0%	1.0%	1.4%	32.0%	45.0%	16.5%	23.1%
2009	278	0.2%	0.3%	0.1%	0.1%	39.9%	56.1%	4.2%	5.9%	1.0%	1.4%	24.2%	34.0%	1.0%	1.4%	32.1%	45.2%	15.8%	22.2%
2009	279	0.3%	0.5%	0.1%	0.2%	39.5%	61.9%	5.8%	9.1%	1.6%	2.4%	19.3%	30.2%	1.2%	1.9%	27.7%	43.4%	14.1%	22.2%
2009	280	0.4%	0.6%	*	*	44.2%	64.3%	4.8%	7.0%	1.2%	1.7%	20.8%	30.2%	0.9%	1.4%	29.1%	42.3%	14.4%	20.9%
2009	281	0.3%	0.5%	0.3%	0.4%	38.8%	58.7%	2.3%	3.4%	0.6%	0.9%	25.4%	38.4%	0.6%	0.9%	28.0%	42.3%	8.4%	12.7%
2009	282	0.3%	0.4%	0.1%	0.2%	37.5%	57.2%	3.8%	5.8%	1.5%	2.3%	22.9%	34.9%	1.1%	1.6%	28.7%	43.8%	10.9%	16.7%
2009	283	0.5%	0.9%	0.1%	0.2%	29.5%	51.2%	7.0%	12.2%	1.0%	1.7%	18.0%	31.3%	6.3%	11.0%	26.1%	45.2%	11.1%	19.2%
2009	284	0.8%	1.4%	0.1%	0.2%	32.6%	59.5%	8.7%	15.8%	0.6%	1.1%	14.6%	26.7%	4.2%	7.7%	26.0%	47.6%	13.2%	24.2%
2009	285	0.5%	0.9%	0.2%	0.3%	33.6%	57.3%	7.8%	13.3%	1.2%	2.0%	16.7%	28.5%	3.9%	6.6%	28.5%	48.5%	10.7%	18.3%
2009	288	0.8%	1.4%	0.1%	0.2%	32.8%	57.3%	8.2%	14.4%	1.0%	1.7%	16.8%	29.4%	6.1%	10.6%	26.8%	46.9%	10.7%	18.8%
2009	289	0.7%	1.1%	0.1%	0.2%	31.6%	55.5%	7.7%	13.4%	0.8%	1.5%	19.0%	33.4%	4.5%	7.9%	27.0%	47.3%	13.1%	23.0%
2009	291	0.5%	0.8%	*	*	34.2%	58.1%	6.7%	11.4%	0.5%	0.8%	18.1%	30.8%	3.1%	5.3%	30.0%	50.9%	12.9%	21.9%
2009	292	0.4%	0.8%	*	*	27.7%	54.5%	6.0%	11.9%	1.2%	2.4%	15.1%	29.7%	3.7%	7.2%	22.8%	45.0%	9.2%	18.1%
2009	293	0.2%	0.2%	0.2%	0.3%	42.4%	61.6%	3.6%	5.3%	1.1%	1.6%	24.6%	35.7%	0.7%	1.0%	30.7%	44.5%	15.3%	22.2%
2009	295	0.4%	0.6%	0.2%	0.3%	33.6%	52.4%	6.8%	10.6%	1.6%	2.4%	23.9%	37.3%	2.0%	3.1%	27.5%	42.9%	11.6%	18.0%
2009	296	0.3%	0.4%	0.2%	0.3%	35.3%	52.0%	7.7%	11.3%	1.8%	2.6%	24.0%	35.3%	4.3%	6.4%	29.4%	43.2%	15.4%	22.7%
2009	297	0.5%	0.8%	0.1%	0.1%	35.8%	59.2%	6.9%	11.5%	0.6%	1.1%	22.0%	36.4%	2.2%	3.6%	27.1%	44.7%	13.3%	21.9%
2009	299	0.3%	0.5%	0.1%	0.1%	39.8%	57.5%	6.1%	8.9%	1.6%	2.4%	27.0%	39.0%	1.3%	1.9%	29.0%	41.9%	14.3%	20.7%
2009	300	0.4%	0.7%	*	*	34.5%	50.9%	8.9%	13.2%	1.6%	2.3%	24.8%	36.6%	3.7%	5.5%	30.7%	45.4%	12.7%	18.7%
2009	301	0.7%	1.4%	0.1%	0.2%	27.3%	57.1%	7.6%	15.8%	0.8%	1.6%	13.8%	28.8%	2.5%	5.2%	24.0%	50.2%	9.1%	19.1%
2009	303	1.3%	2.6%	0.1%	0.2%	30.6%	58.6%	9.8%	18.7%	0.9%	1.6%	15.6%	29.8%	4.0%	7.7%	25.0%	47.8%	12.0%	22.9%
2009	304	0.5%	0.7%	0.2%	0.2%	37.9%	56.1%	5.5%	8.2%	1.0%	1.5%	25.6%	37.9%	1.4%	2.1%	29.0%	42.9%	12.4%	18.4%
2009	307	0.4%	0.6%	0.1%	0.2%	35.5%	51.3%	8.1%	11.7%	1.3%	1.9%	25.8%	37.4%	1.9%	2.8%	28.5%	41.2%	12.1%	17.5%
2009	308	0.5%	0.9%	0.1%	0.3%	30.6%	56.1%	7.6%	13.9%	1.0%	1.8%	16.2%	29.7%	2.2%	4.1%	25.1%	46.0%	10.7%	19.6%
2009	309	0.2%	0.3%	0.2%	0.3%	40.6%	58.1%	4.2%	6.1%	1.1%	1.6%	25.6%	36.6%	1.7%	2.5%	29.7%	42.6%	14.5%	20.7%
2009	311	0.2%	0.2%	0.2%	0.3%	39.4%	56.4%	4.6%	6.6%	1.4%	2.0%	25.5%	36.6%	1.4%	2.0%	30.8%	44.2%	14.0%	20.1%
2009	312	0.3%	0.4%	0.1%	0.1%	36.3%	52.0%	4.6%	6.6%	0.7%	1.0%	27.4%	39.2%	1.2%	1.7%	32.4%	46.3%	13.3%	19.0%
2009	313	0.2%	0.3%	0.2%	0.3%	36.6%	54.4%	5.7%	8.4%	0.9%	1.4%	25.1%	37.3%	0.8%	1.3%	32.3%	48.0%	14.2%	21.1%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	314	0.3%	0.4%	0.1%	0.2%	36.4%	50.9%	4.7%	6.6%	1.1%	1.6%	27.7%	38.7%	1.5%	2.0%	32.4%	45.3%	14.4%	20.1%
2009	315	0.2%	0.3%	0.2%	0.4%	40.3%	58.5%	3.2%	4.6%	1.2%	1.7%	22.9%	33.2%	0.8%	1.2%	32.7%	47.4%	15.6%	22.7%
2009	318	0.3%	0.5%	0.2%	0.3%	37.2%	53.3%	5.0%	7.2%	1.2%	1.8%	27.1%	38.9%	1.6%	2.3%	31.3%	44.9%	15.5%	22.3%
2009	319	0.2%	0.3%	0.2%	0.3%	36.7%	54.8%	6.1%	9.2%	1.9%	2.8%	24.6%	36.8%	2.4%	3.6%	27.0%	40.3%	13.2%	19.7%
2009	320	0.3%	0.4%	0.1%	0.2%	38.6%	56.4%	5.0%	7.2%	1.0%	1.4%	24.6%	36.0%	0.9%	1.3%	32.0%	46.7%	12.4%	18.2%
2009	321	*	*	*	*	36.2%	50.3%	3.9%	5.4%	1.0%	1.5%	27.8%	38.6%	0.4%	0.5%	33.1%	46.0%	11.2%	15.6%
2009	322	0.2%	0.3%	*	*	37.7%	53.0%	3.0%	4.2%	1.0%	1.5%	28.5%	40.1%	0.4%	0.6%	30.8%	43.4%	8.4%	11.8%
2009	323	*	*	*	*	41.1%	56.2%	3.9%	5.3%	1.1%	1.5%	28.3%	38.7%	0.3%	0.4%	31.2%	42.6%	10.2%	13.9%
2009	324	*	*	*	*	43.1%	59.7%	2.0%	2.8%	0.4%	0.6%	24.3%	33.7%	0.5%	0.7%	31.9%	44.2%	9.9%	13.7%
2009	325	0.3%	0.4%	*	*	34.8%	50.8%	5.6%	8.3%	0.7%	1.0%	28.1%	41.1%	2.1%	3.1%	28.1%	41.0%	13.7%	20.0%
2009	326	0.3%	0.4%	0.2%	0.2%	37.8%	53.8%	5.4%	7.7%	1.0%	1.5%	26.4%	37.5%	1.9%	2.7%	31.4%	44.7%	15.1%	21.5%
2009	327	0.3%	0.5%	0.2%	0.3%	37.2%	54.8%	4.8%	7.1%	1.0%	1.4%	26.9%	39.6%	1.4%	2.0%	29.1%	42.9%	12.7%	18.6%
2009	328	0.3%	0.4%	0.1%	0.1%	34.5%	51.7%	4.8%	7.1%	0.9%	1.3%	27.1%	40.7%	1.4%	2.0%	30.1%	45.1%	10.9%	16.4%
2009	329	0.6%	0.8%	0.2%	0.3%	38.6%	55.8%	6.7%	9.7%	1.6%	2.2%	25.7%	37.2%	1.4%	2.0%	31.3%	45.3%	15.2%	22.0%
2009	330	0.4%	0.7%	0.2%	0.3%	36.4%	53.7%	5.4%	8.0%	1.6%	2.3%	27.0%	39.8%	1.4%	2.0%	31.4%	46.3%	12.3%	18.2%
2009	331	0.3%	0.4%	*	*	39.6%	56.8%	5.2%	7.5%	1.6%	2.3%	27.6%	39.6%	1.8%	2.6%	32.2%	46.1%	12.9%	18.5%
2009	332	0.4%	0.6%	*	*	34.7%	53.4%	6.1%	9.4%	1.0%	1.6%	24.7%	38.1%	1.8%	2.7%	27.6%	42.6%	13.0%	20.0%
2009	334	0.2%	0.4%	0.1%	0.2%	35.3%	57.4%	4.7%	7.6%	1.2%	2.0%	22.9%	37.1%	1.2%	2.0%	27.8%	45.1%	10.2%	16.5%
2009	335	0.3%	0.5%	0.3%	0.5%	32.0%	49.8%	5.4%	8.3%	1.1%	1.8%	25.3%	39.3%	2.7%	4.2%	29.3%	45.6%	10.5%	16.3%
2009	336	*	*	*	*	38.9%	56.2%	9.1%	13.2%	0.8%	1.2%	23.1%	33.5%	1.6%	2.3%	27.3%	39.5%	20.1%	29.1%
2009	339	0.3%	0.5%	0.1%	0.1%	42.2%	59.9%	6.8%	9.7%	1.2%	1.7%	23.0%	32.7%	1.2%	1.7%	32.0%	45.4%	16.8%	23.8%
2009	340	0.3%	0.5%	0.2%	0.2%	39.7%	57.5%	5.2%	7.5%	1.2%	1.8%	24.8%	35.8%	1.4%	2.0%	29.0%	42.0%	16.6%	24.1%
2009	341	*	*	*	*	44.0%	64.2%	4.1%	6.0%	1.6%	2.3%	20.8%	30.3%	*	*	28.0%	40.8%	12.6%	18.3%
2009	342	0.3%	0.4%	*	*	39.7%	60.5%	2.1%	3.2%	0.7%	1.1%	22.9%	34.8%	0.6%	0.8%	29.5%	44.8%	10.1%	15.4%
2009	343	0.3%	0.4%	*	*	45.0%	66.3%	3.2%	4.7%	1.0%	1.5%	21.6%	31.8%	0.5%	0.7%	26.1%	38.4%	12.8%	18.8%
2009	344	0.3%	0.5%	0.1%	0.2%	42.9%	62.1%	2.2%	3.2%	1.2%	1.7%	25.4%	36.8%	0.7%	1.0%	29.8%	43.2%	10.0%	14.5%
2009	345	0.6%	0.8%	*	*	43.6%	63.8%	2.4%	3.6%	1.2%	1.8%	24.8%	36.3%	0.6%	0.8%	29.6%	43.3%	9.7%	14.2%
2009	346	0.5%	0.7%	0.1%	0.2%	34.6%	52.4%	7.5%	11.3%	0.9%	1.4%	22.2%	33.6%	4.0%	6.1%	30.7%	46.5%	11.3%	17.2%
2009	347	0.6%	0.8%	*	*	42.4%	59.3%	6.2%	8.6%	0.8%	1.1%	25.8%	36.0%	2.2%	3.0%	31.1%	43.4%	13.5%	18.8%
2009	350	0.4%	0.6%	0.2%	0.3%	38.6%	57.3%	4.7%	7.0%	0.8%	1.1%	23.5%	34.9%	2.0%	3.0%	31.2%	46.3%	12.2%	18.2%
2009	351	0.4%	0.6%	0.2%	0.3%	35.2%	51.8%	5.4%	7.9%	0.8%	1.2%	25.5%	37.5%	2.0%	3.0%	29.8%	43.7%	13.9%	20.5%
2009	352	0.5%	0.8%	0.1%	0.2%	35.9%	53.5%	4.9%	7.3%	1.0%	1.5%	23.2%	34.5%	1.6%	2.5%	33.2%	49.4%	13.1%	19.5%
2009	354	*	*	*	*	37.1%	53.1%	5.2%	7.4%	0.8%	1.1%	26.3%	37.6%	1.4%	2.0%	33.7%	48.3%	11.5%	16.4%
2009	355	0.5%	0.7%	*	*	36.1%	55.2%	4.0%	6.1%	0.9%	1.3%	20.9%	32.1%	1.6%	2.4%	32.1%	49.1%	12.7%	19.4%
2009	356	0.5%	0.9%	0.1%	0.2%	29.6%	50.7%	5.5%	9.4%	0.8%	1.3%	21.1%	36.2%	4.3%	7.4%	25.1%	43.1%	10.4%	17.8%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	357	0.5%	0.7%	0.2%	0.3%	32.5%	48.5%	6.1%	9.1%	1.0%	1.5%	25.6%	38.2%	4.9%	7.3%	29.1%	43.4%	10.9%	16.3%
2009	358	0.5%	0.7%	0.1%	0.2%	38.3%	55.9%	7.8%	11.3%	0.7%	1.0%	23.1%	33.6%	2.3%	3.4%	35.3%	51.4%	11.7%	17.1%
2009	359	0.4%	0.5%	0.4%	0.5%	38.1%	53.6%	5.8%	8.2%	1.4%	1.9%	26.7%	37.6%	2.7%	3.8%	31.3%	44.0%	14.3%	20.1%
2009	360	0.2%	0.3%	*	*	37.5%	54.9%	7.7%	11.3%	0.9%	1.3%	22.4%	32.8%	3.1%	4.5%	33.5%	49.1%	11.7%	17.1%
2009	362	1.2%	1.8%	0.2%	0.3%	32.7%	48.8%	7.1%	10.6%	1.1%	1.6%	23.1%	34.5%	5.6%	8.4%	30.7%	45.8%	10.9%	16.2%
2009	363	0.8%	1.1%	*	*	36.4%	53.7%	3.4%	5.1%	0.7%	1.0%	20.9%	30.9%	1.6%	2.4%	34.8%	51.4%	14.3%	21.1%
2009	364	0.4%	0.6%	0.1%	0.2%	33.1%	52.3%	3.1%	4.9%	0.7%	1.2%	21.7%	34.4%	1.4%	2.2%	31.3%	49.6%	10.6%	16.8%
2009	365	0.2%	0.3%	0.1%	0.2%	37.9%	56.5%	4.8%	7.1%	1.0%	1.5%	24.2%	36.0%	1.3%	1.9%	29.7%	44.3%	12.1%	18.0%
2009	366	0.2%	0.2%	0.2%	0.2%	36.6%	52.7%	5.5%	7.8%	1.0%	1.4%	26.3%	37.8%	2.5%	3.5%	28.2%	40.6%	14.8%	21.3%
2009	367	0.1%	0.2%	0.1%	0.2%	40.5%	55.2%	4.9%	6.7%	0.6%	0.9%	29.7%	40.5%	2.0%	2.8%	27.6%	37.7%	16.1%	22.0%
2009	368	0.2%	0.3%	0.1%	0.2%	37.0%	55.0%	4.7%	6.9%	0.9%	1.3%	24.0%	35.6%	1.3%	2.0%	30.2%	44.9%	13.6%	20.3%
2009	369	0.2%	0.2%	0.2%	0.3%	39.8%	55.4%	6.4%	9.0%	1.0%	1.3%	26.0%	36.1%	1.0%	1.3%	32.9%	45.7%	14.0%	19.5%
2009	370	*	*	*	*	41.5%	57.5%	4.1%	5.7%	0.7%	1.0%	25.2%	34.9%	1.1%	1.6%	28.9%	40.0%	16.7%	23.1%
2009	371	0.2%	0.2%	*	*	39.0%	55.0%	3.8%	5.4%	0.9%	1.2%	24.2%	34.1%	0.9%	1.3%	32.1%	45.2%	13.4%	18.9%
2009	373	0.2%	0.2%	0.2%	0.3%	38.4%	55.6%	4.6%	6.6%	2.0%	2.9%	25.8%	37.3%	2.3%	3.4%	29.9%	43.3%	11.3%	16.3%
2009	374	0.6%	0.8%	*	*	41.5%	58.3%	3.9%	5.5%	1.3%	1.8%	25.3%	35.5%	0.9%	1.2%	34.7%	48.7%	15.9%	22.4%
2009	375	0.2%	0.3%	*	*	40.6%	61.0%	3.4%	5.1%	0.9%	1.4%	24.3%	36.5%	0.7%	1.0%	29.7%	44.6%	11.7%	17.6%
2009	376	0.3%	0.5%	0.2%	0.3%	41.3%	60.1%	5.3%	7.7%	1.6%	2.3%	24.2%	35.3%	1.2%	1.7%	31.2%	45.5%	13.3%	19.4%
2009	377	0.3%	0.4%	0.1%	0.1%	41.3%	58.1%	5.6%	7.9%	1.8%	2.5%	27.0%	38.0%	1.4%	1.9%	31.1%	43.7%	13.1%	18.4%
2009	379	0.7%	0.9%	0.2%	0.2%	37.9%	53.0%	4.8%	6.7%	1.1%	1.5%	27.1%	37.9%	1.8%	2.5%	32.9%	46.0%	14.2%	19.8%
2009	380	0.4%	0.5%	0.1%	0.2%	40.3%	57.2%	4.3%	6.1%	1.3%	1.9%	26.3%	37.3%	1.9%	2.7%	30.6%	43.4%	13.1%	18.6%
2009	382	*	*	*	*	42.1%	60.0%	5.3%	7.6%	1.3%	1.8%	23.8%	33.9%	0.6%	0.8%	31.8%	45.3%	13.8%	19.7%
2009	383	0.7%	0.9%	*	*	41.7%	55.6%	4.6%	6.2%	0.9%	1.2%	27.4%	36.5%	1.9%	2.5%	32.4%	43.2%	17.1%	22.8%
2009	385	0.2%	0.4%	0.1%	0.1%	38.1%	55.3%	6.0%	8.7%	1.3%	1.8%	25.1%	36.4%	1.4%	2.1%	29.4%	42.8%	15.2%	22.1%
2009	386	0.2%	0.2%	0.1%	0.2%	36.3%	55.2%	6.4%	9.7%	1.8%	2.7%	23.0%	35.0%	4.2%	6.3%	24.1%	36.6%	12.4%	18.9%
2009	388	*	*	*	*	41.8%	60.8%	6.0%	8.7%	1.4%	2.1%	24.6%	35.8%	1.1%	1.6%	29.6%	43.1%	14.9%	21.7%
2009	390	0.2%	0.3%	0.2%	0.2%	36.1%	54.9%	5.4%	8.3%	1.4%	2.1%	26.8%	40.8%	1.4%	2.1%	27.3%	41.5%	12.5%	19.0%
2009	391	0.2%	0.3%	0.1%	0.1%	38.0%	55.6%	4.4%	6.5%	0.8%	1.1%	26.5%	38.7%	1.1%	1.6%	28.9%	42.3%	12.1%	17.7%
2009	393	0.5%	0.7%	0.1%	0.2%	41.3%	60.4%	6.3%	9.3%	0.6%	0.9%	24.0%	35.1%	1.1%	1.5%	29.0%	42.4%	14.8%	21.6%
2009	394	0.2%	0.3%	0.1%	0.2%	37.9%	55.6%	6.3%	9.2%	0.8%	1.1%	27.1%	39.7%	1.1%	1.7%	29.1%	42.7%	12.7%	18.6%
2009	396	0.4%	0.6%	0.3%	0.4%	39.3%	59.0%	7.2%	10.9%	1.2%	1.7%	25.9%	38.9%	1.9%	2.8%	31.0%	46.6%	14.7%	22.2%
2009	397	0.4%	0.7%	0.1%	0.1%	36.9%	57.0%	5.4%	8.3%	1.0%	1.6%	23.1%	35.7%	1.9%	3.0%	29.4%	45.4%	11.4%	17.6%
2009	399	0.4%	0.5%	*	*	40.0%	57.1%	4.1%	5.8%	1.4%	2.0%	28.1%	40.1%	0.8%	1.1%	32.4%	46.2%	11.4%	16.2%
2009	400	0.3%	0.4%	*	*	42.2%	59.9%	4.5%	6.5%	0.9%	1.3%	25.3%	35.9%	1.2%	1.7%	31.9%	45.3%	15.2%	21.6%
2009	402	0.5%	0.7%	0.3%	0.5%	39.0%	57.9%	9.9%	14.6%	1.5%	2.2%	25.3%	37.5%	4.2%	6.2%	32.8%	48.7%	17.0%	25.3%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	406	0.2%	0.3%	*	*	44.0%	60.4%	6.4%	8.8%	0.9%	1.3%	26.8%	36.8%	1.8%	2.5%	31.5%	43.3%	13.7%	18.8%
2009	411	*	*	*	*	39.5%	56.2%	5.8%	8.3%	1.0%	1.5%	27.0%	38.4%	1.2%	1.7%	35.4%	50.4%	11.4%	16.2%
2009	412	0.6%	0.9%	0.2%	0.2%	35.1%	53.3%	6.5%	9.9%	1.3%	1.9%	25.2%	38.2%	1.4%	2.1%	28.4%	43.0%	16.6%	25.2%
2009	413	*	*	*	*	39.4%	56.2%	5.0%	7.2%	0.8%	1.1%	29.4%	42.0%	0.7%	1.0%	30.8%	43.9%	10.5%	14.9%
2009	416	0.1%	0.1%	0.1%	0.1%	38.9%	57.0%	5.6%	8.2%	1.3%	1.9%	24.6%	36.0%	0.8%	1.2%	31.8%	46.6%	12.3%	18.1%
2009	417	0.4%	0.5%	*	*	39.2%	59.6%	6.1%	9.3%	0.7%	1.1%	21.4%	32.6%	1.9%	2.8%	25.5%	38.8%	16.4%	25.0%
2009	418	*	*	*	*	39.4%	55.2%	3.9%	5.5%	0.8%	1.1%	27.8%	38.9%	0.7%	1.0%	30.1%	42.2%	13.2%	18.5%
2009	420	*	*	*	*	38.2%	54.8%	3.8%	5.4%	1.0%	1.4%	26.8%	38.5%	2.1%	3.1%	28.3%	40.6%	16.2%	23.3%
2009	421	*	*	*	*	45.5%	62.2%	3.5%	4.8%	0.9%	1.3%	25.6%	35.1%	0.6%	0.8%	28.7%	39.3%	12.7%	17.4%
2009	422	*	*	*	*	46.8%	64.1%	7.2%	9.8%	0.9%	1.3%	25.4%	34.8%	0.4%	0.6%	26.5%	36.4%	16.1%	22.1%
2009	423	0.2%	0.3%	0.2%	0.3%	46.1%	63.1%	4.9%	6.7%	1.2%	1.7%	24.7%	33.8%	0.7%	1.0%	27.8%	38.1%	14.5%	19.8%
2009	424	0.3%	0.4%	0.2%	0.3%	38.6%	57.4%	5.1%	7.6%	1.2%	1.7%	24.0%	35.7%	0.7%	1.1%	28.6%	42.6%	13.9%	20.6%
2009	426	0.5%	0.8%	0.1%	0.1%	38.9%	57.4%	6.4%	9.5%	0.5%	0.8%	21.5%	31.7%	1.5%	2.2%	32.6%	48.0%	13.9%	20.5%
2009	427	0.3%	0.4%	*	*	42.2%	60.9%	5.5%	8.0%	0.5%	0.7%	22.0%	31.8%	0.6%	0.9%	30.1%	43.5%	13.2%	19.0%
2009	428	0.3%	0.4%	*	*	36.1%	51.0%	3.1%	4.3%	0.6%	0.8%	25.4%	35.9%	0.5%	0.8%	35.1%	49.6%	12.6%	17.7%
2009	429	0.7%	1.1%	*	*	34.1%	50.2%	5.7%	8.3%	0.4%	0.5%	25.3%	37.2%	1.9%	2.8%	30.6%	45.1%	13.2%	19.4%
2009	430	0.8%	1.2%	0.1%	0.1%	33.3%	49.3%	6.6%	9.8%	0.9%	1.4%	25.1%	37.1%	1.8%	2.7%	30.1%	44.6%	13.5%	20.0%
2009	431	0.2%	0.3%	0.1%	0.1%	36.7%	53.5%	4.2%	6.1%	0.7%	1.0%	24.8%	36.2%	2.0%	2.8%	30.6%	44.6%	10.9%	15.9%
2009	432	0.4%	0.6%	0.1%	0.1%	39.8%	57.4%	5.1%	7.4%	1.0%	1.4%	23.4%	33.7%	1.3%	1.9%	33.9%	49.0%	13.1%	18.9%
2009	435	0.4%	0.5%	*	*	41.3%	57.7%	6.6%	9.2%	1.0%	1.4%	24.8%	34.7%	0.7%	1.0%	33.9%	47.4%	12.9%	18.0%
2009	437	0.3%	0.5%	*	*	41.7%	60.2%	2.4%	3.5%	0.7%	1.0%	28.2%	40.7%	0.4%	0.5%	28.9%	41.7%	7.4%	10.7%
2009	438	*	*	*	*	41.3%	60.5%	2.0%	3.0%	0.8%	1.2%	27.9%	40.9%	0.4%	0.6%	26.5%	38.9%	11.0%	16.0%
2009	439	0.4%	0.6%	0.1%	0.1%	42.0%	60.8%	2.6%	3.7%	0.9%	1.3%	25.1%	36.4%	0.5%	0.7%	29.7%	43.1%	9.1%	13.3%
2009	440	0.4%	0.5%	0.1%	0.2%	41.8%	59.8%	3.1%	4.5%	1.2%	1.8%	25.6%	36.6%	0.8%	1.1%	28.3%	40.5%	12.0%	17.2%
2009	441	0.4%	0.5%	0.2%	0.3%	40.0%	58.0%	3.7%	5.4%	0.9%	1.3%	27.8%	40.3%	0.9%	1.3%	25.9%	37.5%	11.7%	17.0%
2009	442	0.3%	0.5%	0.3%	0.4%	45.0%	65.5%	1.5%	2.1%	1.1%	1.6%	25.4%	36.9%	0.4%	0.6%	28.3%	41.1%	9.9%	14.3%
2009	443	0.5%	0.8%	0.1%	0.2%	40.2%	57.5%	6.8%	9.7%	0.9%	1.3%	24.7%	35.4%	1.9%	2.7%	33.3%	47.6%	15.4%	22.1%
2009	444	0.5%	0.8%	*	*	39.3%	55.8%	5.6%	7.9%	0.8%	1.1%	26.4%	37.5%	1.2%	1.7%	33.9%	48.3%	14.7%	20.9%
2009	445	0.2%	0.3%	*	*	36.9%	54.5%	6.0%	8.9%	0.6%	1.0%	23.8%	35.2%	1.5%	2.2%	30.9%	45.5%	15.4%	22.8%
2009	446	*	*	*	*	38.5%	56.4%	2.9%	4.3%	0.4%	0.6%	24.7%	36.1%	0.9%	1.4%	31.5%	46.0%	12.4%	18.2%
2009	447	0.2%	0.3%	*	*	39.8%	56.8%	4.1%	5.8%	0.9%	1.3%	25.7%	36.7%	1.3%	1.8%	32.6%	46.5%	12.0%	17.1%
2009	448	0.3%	0.4%	*	*	35.9%	52.7%	2.5%	3.7%	1.5%	2.2%	26.6%	39.0%	*	*	31.8%	46.7%	12.0%	17.6%
2009	449	0.4%	0.6%	*	*	39.9%	55.5%	2.7%	3.8%	1.0%	1.4%	26.6%	37.0%	1.0%	1.4%	32.7%	45.5%	11.5%	16.0%
2009	450	0.7%	1.0%	*	*	37.1%	52.2%	2.0%	2.8%	0.6%	0.9%	29.3%	41.3%	0.8%	1.2%	33.8%	47.6%	9.9%	14.0%
2009	451	0.3%	0.4%	0.1%	0.1%	35.8%	52.9%	3.8%	5.6%	0.8%	1.2%	25.7%	38.0%	1.5%	2.3%	29.6%	43.8%	11.9%	17.7%

Diabetic ABD FFS Beneficiaries With an Order for an Antidiabetic Drug in Drug Class																			
Year	HRR	Alpha Glucosidase Inhibitors		Amylin Analogs		Biguanides		Dipeptidyl Peptidase-4 Inhibitors		Glucagon-like Peptide 1 Receptor Agonists		Insulins		Meglitinides		Sulfonylureas		Thiazolidinediones	
		Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order	Diabetic Population	Diabetic Population With At Least One Anti-diabetic Drug Order
2009	452	0.4%	0.6%	*	*	43.8%	59.0%	3.1%	4.2%	0.4%	0.6%	25.9%	34.9%	1.0%	1.4%	36.8%	49.6%	14.0%	18.9%
2009	456	0.5%	0.8%	*	*	39.9%	55.7%	2.8%	3.9%	*	*	27.4%	38.2%	0.9%	1.3%	29.5%	41.2%	13.9%	19.4%
2009	457	*	*	*	*	49.5%	65.8%	5.8%	7.8%	1.0%	1.3%	24.5%	32.6%	0.9%	1.1%	27.9%	37.1%	14.5%	19.3%